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Leber hereditary optic neuropathy (LHON) and autosomal-dominant optic atrophy (DOA) are the two
most common inherited optic neuropathies in the general population. Both disorders share striking
pathological similarities, marked by the selective loss of retinal ganglion cells (RGCs) and the early
involvement of the papillomacular bundle. Three mitochondrial DNA (mtDNA) point mutations;
m.3460G>A, m.11778G>A, and m.14484T>C account for over 90% of LHON cases, and in DOA, the
majority of affected families harbour mutations in the OPA1 gene, which codes for a mitochondrial inner
membrane protein. Optic nerve degeneration in LHON and DOA is therefore due to disturbed mito-
chondrial function and a predominantly complex I respiratory chain defect has been identiﬁed using
both in vitro and in vivo biochemical assays. However, the trigger for RGC loss is much more complex than
a simple bioenergetic crisis and other important disease mechanisms have emerged relating to mito-
chondrial network dynamics, mtDNA maintenance, axonal transport, and the involvement of the cyto-
skeleton in maintaining a differential mitochondrial gradient at sites such as the lamina cribosa. The
downstream consequences of these mitochondrial disturbances are likely to be inﬂuenced by the local
cellular milieu. The vulnerability of RGCs in LHON and DOA could derive not only from tissue-speciﬁc,
genetically-determined biological factors, but also from an increased susceptibility to exogenous inﬂu-
ences such as light exposure, smoking, and pharmacological agents with putative mitochondrial toxic
effects. Our concept of inherited mitochondrial optic neuropathies has evolved over the past decade,
with the observation that patients with LHON and DOA can manifest a much broader phenotypic
spectrum than pure optic nerve involvement. Interestingly, these phenotypes are sometimes clinically
indistinguishable from other neurodegenerative disorders such as Charcot-Marie-Tooth disease, hered-
itary spastic paraplegia, and multiple sclerosis, where mitochondrial dysfunction is also thought to be an
important pathophysiological player. A number of vertebrate and invertebrate disease models has
recently been established to circumvent the lack of human tissues, and these have already provided
considerable insight by allowing direct RGC experimentation. The ultimate goal is to translate these
research advances into clinical practice and new treatment strategies are currently being investigated to
improve the visual prognosis for patients with mitochondrial optic neuropathies.
 2010 Elsevier Ltd. Open access under CC BY license.Contents
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P. Yu-Wai-Man et al. / Progress in Retinal and Eye Research 30 (2011) 81e114 831. Introduction 2.2. StructureInherited optic neuropathies affect at least 1 in 10,000 individuals
and as a group, they represent an important cause of chronic visual
impairment (Man et al., 2003; Newman and Biousse, 2004; Schaefer
et al., 2008; Yu-Wai-Man et al., 2010a). Historically, these inherited
optic nerve disorders were classiﬁed according to their mode of
inheritance, and whether they were isolated or part of a more
complicated syndromal variant. The identiﬁcation of the underlying
genetic defects in a large number of these inherited optic neuropa-
thies now allows for a more accurate molecular classiﬁcation, which
has greatly beneﬁted diagnostic accuracy and genetic counselling.
The two classical prototypes are Leber hereditary optic neuropathy
(LHON) and autosomal-dominant optic atrophy (DOA), which are
both characterised by the preferential loss of retinal ganglion cells
(RGCs) (Carelli et al., 2009). LHON is due to primary mitochondrial
DNA (mtDNA)mutations, whereas themajority of patientswithDOA
harbour pathogenic mutations within the OPA1 gene, which codes
for a mitochondrial inner membrane protein (Yu-Wai-Man et al.,
2009b; Fraser et al., 2010). As the genetic basis for other inherited
optic neuropathies were uncovered, it became apparent that mito-
chondrial dysfunction is a recurrentmolecular themeunderlying the
loss of RGCs in these disorders. In this review, we will cover basic
aspects ofmitochondrial biology andgenetics, andhowdisruptionof
these critical biological systems contributes to optic nerve degen-
eration in different mitochondrial disease models.
2. The mitochondria
2.1. Evolutionary origin
Mitochondria are ubiquitous intracellular organelles and they
fulﬁl a fundamental role by providing most of the adenosine
triphosphate (ATP) requirements of eukaryotic cells (DiMauro and
Schon, 2003). The prevailing endosymbiotic hypothesis suggests
that mitochondria evolved from aerobic a-proteobacteria, which
were thengraduallyassimilated byprimitive glycolytic eubacteria in
a symbiotic relationship (Margulis, 1971; Gray et al., 1999). During
evolution, thea-proteobacteria gradually transferred themajorityof
their genetic material to the eubacteria’s nuclear chromosomes,
creating the prototypal eukaryotic cell (Gabaldon and Huynen,
2004). Phylogenetic comparison of mtDNA between modern
humans and other organisms, including Rickettsia prowazekii, an a-
proteobacterium, supports this common evolutionary origin for the
mitochondrial genome (Martin and Muller, 1998; Gray et al., 1999).Fig. 1. The mitochondrial respiratory chain and oxidative phosphorylMitochondria are tubular-shaped organelles bounded by an
outer and an inner membrane, and these delineate two distinct
compartments: an intermembrane space and an internal matrix
space (Frey and Mannella, 2000). The outer membrane allows
passive diffusion of low molecular weight molecules up to 10 kDa,
and this permeability is conferred by a family of channel-forming
proteins known as porins, or voltage dependent anion channels
(VDAC). The inner membrane is highly convoluted and these
multiple infoldings, known as cristae, greatly increase its effective
surface area (Perkins et al.,1997). Compared to the outermembrane,
the inner membrane is relatively impermeable except for speciﬁc
active transport channels, allowing an electrochemical gradient to
be established across this barrier. The innermembrane also contains
a number of highly specialised proteins, including the respiratory
chain complexes and members of the mitochondrial membrane
protease family. The mitochondrial matrix compartment contains
mtDNAmolecules packagedwithinnucleoid structures, and it is also
the site ofmultiplemetabolic pathways essential for normal cellular
function: the citric acid cycle, b-oxidation of fatty acids, steroid,
aminoacid, andpyrimidinebiosynthesis (RahaandRobinson, 2000).
2.3. Oxidative phosphorylation
The mitochondrial respiratory chain comprises four multi-
subunit polypeptide complexes (IeIV) which are embedded within
the innermitochondrialmembrane (Fig.1). The production of ATP is
tightly regulated and it is the end-product of a process known as
oxidative phosphorylation (OXPHOS). Acetyl-CoA, an intermediate
product of glycolysis and b-oxidation, is metabolised further by the
citric acid cycle to the reducing equivalents nicotinamide adenine
dinucleotide hydrogen (NADH) and ﬂavin adenine dinucleotide
hydrogen (FADH2) (DiMauro and Schon, 2003). NADH and FADH2
are then re-oxidised by donating electrons to complexes I and II
respectively. The energy released by the shuttling of these high
energy electrons along the respiratory chain complexes allows
protons to be pumped from the matrix compartment into the
intermembrane space. Two additional carriers, ubiquinone (Co-
enzymeQ10) and cytochrome c, also play critical roles in the efﬁcient
transfer of electrons through these successive oxidationereduction
reactions. The electrochemical gradient generated across the inner
mitochondrial membrane is then used by complex V (ATP synthase)
to catalyze the conversion of adenosine diphosphate (ADP) and
inorganic phosphate (Pi) to ATP (Yoshida et al., 2001).ation. Reproduced with permission from Nijtmans et al. (2004).
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Mitochondria are unique in having their own genome in the
form of a circular, double-stranded molecule 16,569 bp long
(Fig. 2) (Anderson et al., 1981; Andrews et al., 1999b). It is a high-
copy number genome with hundreds to thousands of mtDNA
molecules per cell, depending on their speciﬁc energy require-
ments. MtDNA replicates continuously and this process is inde-
pendent of nuclear genome replication, occurring in both mitotic
and post-mitotic cells. The mitochondrial genome codes for 2
ribosomal RNAs (12S and 16S rRNA), 22 transfer RNAs (tRNAs), and
13 polypeptide subunits of the respiratory chain complexes. The
majority of these genes is located on the H-strand, with only
MTND6 and eight tRNA genes found on the L-strand (Taylor and
Turnbull, 2005). MtDNA is a very compact molecule with over-
lapping gene regions devoid of introns, and a small 1.1 kb non-
coding region, known as the D-loop, which is involved in mtDNA
transcription and replication.
2.5. Mitochondrial haplogroups
The mitochondrial genome accumulates mutations at a signiﬁ-
cantly faster ratecompared tothenucleargenome,andseveral factors
contribute to this higher mutational rate: the absence of protective
histones, the lack of effective repair mechanisms, the high mtDNA
replication rate increasing the likelihood of errors, and the close
proximity of mtDNA molecules to the respiratory chain complexes
where they are exposed to high levels of reactive oxygen species
(ROS) (Howell et al.,1996; Jazinet al.,1998;RahaandRobinson,2000).
Themutational rate varies betweendifferentmtDNA regions, and it is
much fasterwithin the twohypervariable regions (HVR I and II) of the
D-loop where a mutation is estimated to occur every 30 maternal
generations (Parsons et al., 1997; Siguroardottir et al., 2000). MtDNA
is therefore highly polymorphic, and during human evolution,
a number of relatively benign mitochondrial sequence variants haveFig. 2. The human mitochondrial genome. Protein coding (yellow), rRNA (red), and
tRNA (purple) genes are depicted on the heavy (H-, outer) and light (L-, inner) strands.
The 22 tRNAs are indicated by their cognate amino acid letter code and the 2 rRNAs
by their sedimentation coefﬁcients (12S and 16S). The origins of mtDNA replication
and the direction of synthesis are denoted by OH for the H-strand, and OL for the L-
strand.become ﬁxed in different populations. As mtDNA is maternally
inherited, these polymorphisms have accumulated sequentially
along radiating female lineages, following the pattern of human
migration fromAfrica into the various continents some150,000years
ago (Cann, 2001). The human phylogenetic tree contains 18 major
mtDNA haplogroups, and these comprise a total of 497 haplogroup-
deﬁning polymorphic variants (Torroni and Wallace, 1994;
Herrnstadt et al., 2002). Individuals of European ancestry belong to
one of nine haplogroups: H, I, J, K, T, U, V,WandX,with haplogroupH
accounting for nearly half of all cases.2.6. Heteroplasmy and mutational threshold
There are about 10,000 mtDNA molecules per cell, with each
mitochondrion containing multiple copies. Two possible situations
can therefore arise, known as homoplasmy and heteroplasmy
(Lightowlers et al., 1997; Chinnery, 2002). In the heteroplasmic
state, two or more mtDNA variants are present at a speciﬁc
nucleotide position, and the same phenomenon can also occur for
mtDNA re-arrangements such as deletions. Most mtDNAmutations
are heteroplasmic, a feature which supports the concept of
a mutational threshold for pathogenicity (Chinnery et al., 2000;
Taylor and Turnbull, 2005). The relationship between mutational
load and respiratory chain activity has been extensively investi-
gated in different tissues, and the deleterious consequences of most
mtDNA mutations on OXPHOS usually become apparent when the
proportion of the mutant species exceeds 60e80% (Shoubridge
et al., 1990; Bua et al., 2006; Durham et al., 2007). There are
mutation- and tissue-speciﬁc variations in this biochemical
threshold (Corral-debrinski et al., 1992; Chinnery et al., 1999; Wang
et al., 2001; Nekhaeva et al., 2002), and although these couldFig. 3. Mitochondrial and nuclear-encoded subunits of the mitochondrial respiratory
chain complexes.
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associated with a particular mtDNA defect, the molecular mecha-
nisms are likely to be much more complex.
2.7. Nuclear-mitochondrial interactions
Mitochondriaonlyhave limitedautonomyand they relyheavilyon
the nuclear genome for themajority of their structural and functional
subunits (Fig. 3). Mitochondrial disorders can therefore arise
secondary to both primary mtDNA mutations and nuclear genetic
defects which disrupt mitochondrial-related proteins. In 2001, the
ﬁrst nuclear genes, POLG1 and PEO1, were identiﬁed among families
with autosomal-dominant chronic progressive external oph-
thalmoplegia (CPEO) associated with multiple mtDNA deletions
(Spelbrink et al., 2001; Van Goethem et al., 2001). Since then, the
number of genes causing nuclear mitochondrial disorders has
expanded continuously (Table 1), allowing signiﬁcant progress to be
made in elucidating the fundamental mechanisms that underpin
mitochondrial physiology in both normal and disease states. As
a result, we have gained a better understanding of the complex
interactions between subunits of the respiratory chain complexes,
and the crucial role played by accessory proteins in ensuring their
proper assembly and stability along the inner mitochondrial
membrane. These sometimes rare neurodegenerative and metabolic
disorders have also provided important insights into the molecular
components required for mtDNAmaintenance, and the translational
machinery that regulates intra-mitochondrial protein synthesis.Table 1
Nuclear mitochondrial disorders.
Mutations involving structural subunits of the mitochondrial respiratory chain
Leigh syndrome: with complex I deﬁciency e mutations in NDUFS1, NDUFS4, NDUFS7,
Cardiomyopathy and encephalopathy with complex I deﬁciency e mutations in NDFU
Optic atrophy and ataxia with complex II deﬁciencyemutations in SDHA
Hypokalaemia and lactic acidosis with complex III deﬁciency e mutations in UQCRB
Mutations involving assembly factors of the mitochondrial respiratory chain
Leigh syndromeemutations in SURF I and LRPPRC
Hepatopathy and ketoacidosis e mutations in SCO1
Cardiomyopathy and encephalopathy e mutations in SCO2
Leukodystrophy and renal tubulopathy e mutations in COX10
Hypertrophic cardiomyopathy e mutations in COX15
Encephalopathy, liver failure, and renal tubulopathy with complex III deﬁciency e mu
Encephalopathy with complex V deﬁciency e mutations in ATP12
Nuclear genetic disorders of intra-mitochondrial protein synthesis
Leigh syndrome, liver failure, and lactic acidosis e mutations in EFG1
Lactic acidosis, developmental failure, and dysmorphism e mutations in MRPS16
Myopathy and sideroblastic anaemia e mutations in PUS1
Leukodystrophy and polymicrogyria e mutations in EFTu
Encephalomyopathy and hypertrophic cardiomyopathy e mutations in EFTs
Oedema, hypotonia, cardiomyopathy, and tubulopathyemutations in MRPS22
Hypotonia, renal tubulopathy, and lactic acidosis e mutations in RRM2B
Nuclear genetic disorders of mitochondrial protein import
MohreTranebjaerg syndrome or deafness-dystonia-optic neuronopathy (DDON) syndr
Early-onset dilated cardiomyopathy with ataxia (DCMA) or 3-methylglutaconic acidur
Nuclear genetic disorders of mitochondrial DNA maintenance
Chronic progressive external ophthalmoplegia e mutations in POLG1, POLG2, PEO1, SLC
Mitochondrial neurogastrointestinal encephalomyopathy e mutations in TYMP
Alpers syndromeemutations in POLG1 and MPV17
Infantile myopathy and spinal muscular atrophy e mutations in TK2
Encephalomyopathy and liver failure e mutations in DGUOK
Hypotonia, movement disorder and/or Leigh syndrome with methylmalonic aciduria e
Optic atrophy, deafness, chronic progressive external ophthalmoplegia, myopathy, ata
Miscellaneous
Co-enzyme Q10 deﬁciency e mutations in PDSS2, APTX, COQ2, and ETFDH
Barth syndrome emutations in TAZ
Cardiomyopathy and lactic acidosis associated with mitochondrial phosphate carrier d
Alpers syndrome: epilepsy, cortical blindness, micronodular hepatic cirrhosis, episodic ps
neutropenia.Nuclear mitochondrial disorders represent an important group of
human diseases. They often pose signiﬁcant diagnostic challenges
related to their genetic and phenotypic heterogeneity, but they are
increasingly being recognised, helped by greater clinical awareness
and easier access to molecular genetic testing. A common feature
shared by all these disorders is impairedmtDNAmaintenance, which
can lead to a reduction in mtDNA copy number, the accumulation of
high levels of somatic mtDNA mutations, or both (Alberio et al.,
2007; Chinnery and Zeviani, 2008; Spinazzola and Zeviani, 2009).
The identiﬁcation of these quantitative and qualitative mtDNA
abnormalities in diagnostic specimens is therefore a key ﬁnding,
suggesting an underlying nuclear defect, and helping to direct
appropriate molecular investigations. MtDNA depletion is the path-
ological hallmark of several early-onset mitochondrial syndromes,
and the clinical prognosis is often poor, due to the marked bioen-
ergetic crisis caused by such a gross reduction in mtDNA copy
number (Spinazzola et al., 2009). Interestingly, the observed mtDNA
depletion can be highly tissue-speciﬁc, which partly explains the
variability in disease presentation and severity.
A mosaic pattern of cytochrome c oxidase (COX) deﬁcient ﬁbres
is frequently observed in muscle biopsies of patients with both
primary mtDNA and nuclear mitochondrial disorders, with some of
these ﬁbres exhibiting abnormal accumulation of mitochondria in
the subsarcolemmal space, giving the classical appearance of
“ragged-red ﬁbres” (RRFs) (Fig. 4). For nuclear genetic defects
involving POLG1 (Horvath et al., 2006; Tzoulis et al., 2006), POLG2
(Longley et al., 2006), PEO1 (Spelbrink et al., 2001), SLC25A4NDUFS8, NDUFV1; with complex II deﬁciency e mutations in SDHA
S2
tations in BCS1L
ome e mutations in TIMM8A (DDP)
ia, type Vemutations in DNAJC19
25A4, RRM2B, and OPA1)
mutations in SUCLA2 and SUCLG1
xia, and peripheral neuropathy e mutations in OPA1
eﬁciency e mutations in SLC25A3
ychomotor regression; Barth syndrome: cardiomyopathy, hypotonia, weakness, and
Fig. 4. Skeletal muscle sections illustrating the characteristic histochemical features of mitochondrial dysfunction: (A) Ragged-red muscle ﬁbre identiﬁed using the modiﬁed
Gomori trichome stain. The red component of the staining mixture is selectively sequestered by mitochondria, which have accumulated in the subsarcolemmal region, giving the
ﬁbre an irregular red outline, (B) Serial section of the same muscle ﬁbre after SDH staining. This is a more speciﬁc assay for detecting the subsarcolemmal accumulation of
mitochondria, SDH being a speciﬁc marker for complex II activity, (C) Abnormal COXeSDH histochemistry from a patient with chronic progressive external ophthalmoplegia (CPEO)
due to a single 5 kb mtDNA deletion, showing normal COX-positive (Brown) and energy deﬁcient, COX-negative (Blue) muscle ﬁbres.
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recently OPA1 (Amati-Bonneau et al., 2008; Hudson et al., 2008;
Stewart et al., 2008), the COX-defect is secondary to the accumu-
lation of multiple mtDNA deletions, which have clonally expanded
within individual cells to reach suprathreshold levels >70%. These
deleted mtDNA species can be detected in homogenate DNA
samples with Southern blot and long-range polymerase chain
reaction (PCR), or more accurately quantiﬁed at the single-ﬁbre
level using real-time PCR assays (He et al., 2002; Taylor et al., 2004;
Bua et al., 2006). AsmostmtDNA deletions involve critical tRNA and
protein-encoding genes, OXPHOS is adversely affected, and this
eventually leads to apoptotic cell loss and tissue dysfunction.
Mutations in POLG1 and TYMP have also been linked with the
accumulation of somatic mtDNA point mutations (Del Bo et al.,
2003; Nishigaki et al., 2003; Wanrooij et al., 2004). Although still
speculative and controversial, these point mutations couldFig. 5. The minimum prevalence of inherited opcompromise the replication machinery located within the D-Loop,
thereby contributing to the formation of mtDNA deletions. It is
fascinating that different mutations within the same gene can
result in such a varied spectrum of secondary mtDNA abnormali-
ties. The clariﬁcation of the secondary factors which dictate
whether depletion, deletions, or point mutations predominate will
provide crucial insights into the underlying disease mechanisms in
nuclear mitochondrial disorders (Chinnery and Zeviani, 2008).
3. Leber hereditary optic neuropathy
3.1. Epidemiology
The North of England has been relatively stable in terms of
migratory ﬂux, with a population of about three million, predom-
inantly white, inhabitants (Fig. 5). As a result of the nature oftic nerve disorders in the North of England.
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with unexplained visual failure and suspected inherited optic
neuropathies have been referred to the neuro-ophthalmology
(PYWM and PGG) and neurogenetics (PFC) services in Newcastle
upon Tyne for further assessment. This centralised referral pattern,
in addition to active contact tracing, allowed us to determine for the
ﬁrst time the prevalence of LHON in a deﬁned geographical region
(Man et al., 2003). We found a minimum estimate of 1 in 31,000,
and fairly comparable prevalence ﬁgures of 1 in 39,000 and 1 in
50,000 have since been reported in Dutch and Finnish population
studies, respectively (Spruijt et al., 2006; Puomila et al., 2007). In
Australia, the cause of visual impairment for about 2% of individuals
on the national blind registry was optic atrophy secondary to LHON
(Mackey and Buttery, 1992).
3.2. Primary mitochondrial DNA mutations
The majority of patients with LHON (90e95%) harbour one of
three primary mtDNA point mutations: m.3460G>A (Howell et al.,
1991a; Huoponen et al., 1991), m.11778G>A (Wallace et al., 1988),
andm.14484T>C (Johns et al., 1992; Mackey and Howell, 1992). The
m.11778G>A mutation was identiﬁed in 1988 by Wallace et al.
(1988), and it is of special historical signiﬁcance, being the ﬁrst
mtDNA substitution conﬁrmed to cause human disease. The most
prevalent LHONmutation in Northern Europe, Australia, and the Far
East is m.11778G>A (Mackey et al., 1996; Mashima et al., 1998; Yen
et al., 2002), but as a result of a founder event, m.14484T>C is the
most common mutation (87%) among French Canadians. A number
of other pathogenic mtDNA LHON variants have since been repor-
ted (Table 2), with some still awaiting full conﬁrmation for patho-
genicity, having been identiﬁed in only single families (Taylor et al.,Table 2
Pathogenic mtDNA LHON mutations.
Mutation Gene
Common m.3460G>A MTND1
m.11778G>A MTND4
m.14484T>C MTND6
Rare m.3376G>A MTND1
m.3635G>A
m.3697G>A
m.3700G>A
m.3733G>Aa
m.4025C>T
m.4160T>C
m.4171C>Aa
m.4640C>A MTND2
m.5244G>A
m.10237T>C MTND3
m.11696G>A MTND4
m.11253T>C
m.10663T>Ca MTND4L
m.12811T>C MTND5
m.12848C>T
m.13637A>G
m.13730G>A
m.14325T>C MTND6
m.14568C>T
m.14459G>Aa
m.14729G>A
m.14482C>G/Aa
m.14495A>Ga
m.14498C>T
m.14568C>Ta
m.14596A>T
m.9101T>C MTATP6
m.9804G>A MTCO3
m.14831G>A MTCYB
a These mtDNA mutations are deﬁnitely pathogenic. They have been conﬁrmed in 22003). The distribution of these rarermtDNA defects is not uniform,
and the MTND1 and MTND6 gene regions are thought to be
“mutational hotspots”, harbouring other LHON-causing mutations,
in addition tom.3460G>A andm.14484T>C (Chinnery et al., 2001b;
Valentino et al., 2004; Fraser et al., 2010). On close questioning, up
to 60% of affected individuals report other family members with
a pattern of early-onset visual failure, and a detailed family history
should always be sought in suspected inherited optic neuropathy
cases. De novo m.3460G>A and m.14484T>C mutations have been
reported in LHON, but these are rare (Biousse et al., 1997; Man et al.,
2003). Most presumed singleton cases are therefore probably due
to difﬁculties in tracing back a more extensive family history.
As a follow-on to our original epidemiological study, about 3000
umbilical cord blood samples from a local birth cohort in the North
of England were screened for speciﬁc mtDNA point mutations
(Elliott et al., 2008). Nine healthy neonates were found to harbour
one of the three primary LHON mutations, about 1 in every 350
births. In six of these neonates, the mutation was heteroplasmic,
and of these cases, four were present at mutational levels less than
70%. There is clearly a large pool of these primary LHON mutations
in the general population, and for heteroplasmic variants, the
“mitochondrial bottleneck” will introduce shift in mitochondrial
allele frequencies among future generations, directly inﬂuencing
the risk of disease expression. The “mitochondrial bottleneck” is
thought to be a protective mechanism which allows the rapid
removal of deleterious mtDNA mutations from the genetic pool
(Khrapko, 2008; Cree et al., 2009). The fertilised oocyte contains
over 100,000 mtDNA molecules and during the early stages of
development, there is a dramatic reduction inmtDNA copy number,
down to 200e2000 copies before mtDNA replication is re-initiated.
This decrease in the number of mitochondrial genomesReferences
(Howell et al., 1991a; Huoponen et al., 1991)
(Wallace et al., 1988)
(Johns et al., 1992; Mackey and Howell, 1992)
(Blakely et al., 2005)
(Brown et al., 2001)
(Spruijt et al., 2007)
(Fauser et al., 2002b)
(Valentino et al., 2004)
(Huoponen et al., 1993)
(Howell et al., 1991b)
(Kim et al., 2002)
(Brown et al., 2001)
(Brown et al., 1995)
(Horvath et al., 2002)
(De Vries et al., 1996)
(Leo-Kottler et al., 2002)
(Brown et al., 2002)
(Huoponen et al., 1993)
(Mayorov et al., 2005)
(Huoponen et al., 1993)
(Howell et al., 1993)
(Howell et al., 2003)
(Besch et al., 1999)
(Jun et al., 1994; Gropman et al., 2004; Tarnopolsky et al., 2004)
(Zhadanov et al., 2005)
(Howell and Mackey, 1998; Valentino et al., 2002)
(Chinnery et al., 2001b)
(Wissinger et al., 1997)
(Wissinger et al., 1997; Fauser et al., 2002a)
(De Vries et al., 1996)
(Lamminen et al., 1995)
(Johns and Neufeld, 1993; Howell et al., 2003)
(Fauser et al., 2002b)
independent LHON pedigrees and show segregation with affected disease status.
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effect and accounts for the rapid changes in heteroplasmy levels. A
pathogenic mtDNA variant would either be lost during trans-
mission to the next generation, or it would quickly reach supra-
threshold levels within an oocyte, increasing the likelihood of
developmental arrest and its elimination. Even if a mature oocyte
carrying a high proportion of the mutant species is successfully
fertilised and a live birth results, there is a high probability that the
affected individual’s fertility will be subnormal, which again serves
to limit the transmission of mtDNAmutations. This situation clearly
does not apply to LHON, as there is no evidence that mutational
carriers have reduced fertility, and the majority of individuals, both
affected and unaffected, are homoplasmic for the mtDNA mutation
(Section 3.4.1).
3.3. Clinical manifestations
3.3.1. Pre-symptomatic phase
In some asymptomatic LHON carriers, fundal abnormalities such
as telangiectatic vessels around the optic discs, and ﬂuctuating
levels of retinal nerve ﬁbre layer oedema have previously been
observed (Nikoskelainen et al.,1996; Savini et al., 2005; Quiros et al.,
2006). More detailed psychophysical testing can also uncover more
subtle features of optic nerve dysfunction in some individuals, with
loss of colour discrimination along the redegreen axis, minimal
central visual ﬁeld changes on automated static perimetry, reduced
contrast sensitivity, and subnormal visual electrophysiology
(Salomao et al., 2004; Sadun et al., 2006; Sacai et al., 2010).
3.3.2. Acute phase
Disease onset among LHON carriers is characterised by acute,
painless loss of central vision, which is bilateral in about 25% of
cases (Johns et al., 1993a; Nikoskelainen, 1994; Harding et al.,
1995a; Nikoskelainen et al., 1996). If unilateral, the fellow eye is
usually affected within six to eight weeks. There are rare cases of
unilateral optic neuropathy (Nikoskelainen et al., 1996; Sugisaka
et al., 2007), but these are the exceptions, second-eye involve-
ment in LHON occurring invariably within 1 year of disease onset.
The majority of carriers become symptomatic in the second and
third decades of life, and over 90% of carriers who will experience
visual failure will do so before the age of 50 years (Man et al., 2003;
Spruijt et al., 2006). However, visual deterioration can occur
anytime during the ﬁrst to the seventh decade of life and LHON
should be part of the differential diagnosis for all cases of bilateral,
simultaneous or sequential optic neuropathy, irrespective of age,
and especially in male patients (Shah et al., 2008; Yu-Wai-Man
et al., 2008; Decanini-Mancera et al., 2009; Giraudet et al., 2010).
Although one report identiﬁed females harbouring the
m.11778G>A mutation as having a slightly increased age of onset
compared to other groups (Harding et al., 1995b), gender and
mutational status are not thought to signiﬁcantly inﬂuence the
timing or initial severity of visual loss.
Visual loss worsens over a period of four to six week, and it is
severe, dropping to levels of 6/60 or worse, with a dense central or
centrocaecal scotoma, and marked impairment in colour vision.
Importantly, the pupillary light reﬂexes are thought to be relatively
preserved in affected LHON patients compared with the extent of
visual loss, and this canbeauseful clinical sign (Wakakura andYokoe,
1995; Kawasaki et al., 2010). In the acute stage, dilated fundal
examination can be particularly informative, classical LHON cases
exhibiting several distinct abnormalities such as vascular tortuosity
of the central retinal vessels, swelling of the retinal nerve ﬁbre layer,
and a circumpapillary telangiectatic microangiopathy (Fraser et al.,
2010). However, it must be stressed that in about 20% of LHON
cases, the optic disc looks entirely normal, and these patients aresometimes labelled as having functional visual loss (Nikoskelainen
et al., 1977; Harding et al., 1995a; Nikoskelainen et al., 1996).
3.3.3. Chronic phase
Within six weeks, optic nerve pallor becomes apparent, initially
more marked temporally due to early axonal loss within the pap-
illomacular bundle. Pathological cupping of the optic disc can occur
with more extensive loss of RGC axons, and it is not an uncommon
ﬁnding in longstanding LHON cases. If a patient is ﬁrst assessed at
this late stage, it can be difﬁcult to exclude compressive, inﬁltrative
or inﬂammatory causes of a bilateral optic neuropathy, especially
when there is no convincing maternal history of early-onset visual
failure. The results of molecular genetic testing in some diagnostic
laboratories can take up to 2 months, and in these cases, the
appropriate investigations, including neuroimaging of the anterior
visual pathways, should not be delayed in order to exclude the
possibility of reversible causes.
3.3.4. Visual prognosis
LHON causes signiﬁcant visual impairment and in the majority
of cases, visual recovery is minimal, the patient remaining within
the legal requirement for blind registration. In the ﬁrst year
following disease onset, visual ﬁelds can improve with the
appearance of small islands of vision (Mackey and Howell, 1992;
Stone et al., 1992; Nikoskelainen et al., 1996). These fenestrations
can help with scanning vision, especially if the central scotoma
becomes concurrently less dense. The likelihood of visual recovery
is greatest with the m.14484T>C mutation, and least with the
m.11778G>A mutation, the m.3460G>A mutation having an
intermediate visual prognosis (Harding et al., 1995a; Yu-Wai-Man
et al., 2009b; Fraser et al., 2010). To objectively document the
level of visual handicap experienced by LHON patients, we used the
well-validated Visual Function Index (VF-14) questionnaire in
a large cohort of 125 LHON pedigrees (Kirkman et al., 2009a). LHON
had a negative detrimental impact on most activities of daily living,
and quality of life, as assessed by the overall VF-14 score, was the
worst compared with other acquired and inherited ophthalmo-
logical disorders.
3.3.5. Extra-ocular LHON features
Although visual failure is the cardinal clinical feature, cardiac
arrhythmias and neurological abnormalities such as peripheral
neuropathy, myopathy, dystonia, and myoclonus have been repor-
ted to bemore common among LHON carriers compared to controls
(Bower et al., 1992; Nikoskelainen et al., 1994; Meire et al., 1995;
Nikoskelainen et al., 1995; Mashima et al., 1996; McFarland et al.,
2007; La Morgia et al., 2008). In a small number of families from
Holland, Australia and North America, the reported extra-ocular
features were particularly severe, with variable combinations of
psychiatric disturbances, spastic dystonia, ataxia, and juvenile
onset encephalopathy complicating the optic neuropathy. The
phenotypic severity of these so-called “LHON plus” syndromes has
been linked with speciﬁc mtDNA variants at m.4160T>C (Howell
et al., 1991b), m.11696A>G and/or m.14596T>A (De Vries et al.,
1996), and m.14459G>A (Jun et al., 1994; Gropman et al., 2004;
Tarnopolsky et al., 2004). Two mtDNA point mutations affecting
complex I activity, m.3376G>A and m.3697G>A, have also been
identiﬁed in individuals with overlap clinical features of LHON and
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like
episodes (MELAS) (Blakely et al., 2005; Spruijt et al., 2007).
Harding et al. (1992) originally described an intriguing associ-
ation between the m.11778G>A primary mutation among female
LHON carriers and demyelination. Following the onset of visual
loss, these patients developed clinical and neuroimaging features
indistinguishable from multiple sclerosis (MS), with characteristic
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imaging (MRI), and unmatched oligoclonal bands in their cere-
brospinal ﬂuid (Kellar-Wood et al., 1994; Jansen et al., 1996;
Vanopdenbosch et al., 2000). Since this ﬁrst description of Har-
ding’s disease, further evidence has emerged in LHON and other
mitochondrial disorders, which suggest that this association is
unlikely to be a chance occurrence (Kovacs et al., 2005; Jaros et al.,
2007; Carelli and Bellan, 2008; Verny et al., 2008; Yu-Wai-Man
et al., 2010b). LHON female carriers are twice more likely to
develop an MS-like illness compared with male carriers, and
although there is a preponderance for the m.11778G>A mutation,
this phenotype has also been observed with the m.3460G>A and
m.14484T>C primary mutations (Sapey et al., 2001). More robust
conﬁrmatory epidemiological studies are required, but demyelin-
ation has been estimated to affect up to 1 in 20 LHON carriers
(Palace, 2009), which is ﬁfty times higher than the prevalence ofMS
in the general population (Fox et al., 2004; Koch-Henriksen and
Sorensen, 2010). It has not yet been determined whether subclin-
ical white matter MRI changes are present in asymptomatic LHON
carriers or those who only manifest pure optic nerve involvement.
If present, these again would suggest more widespread central
nervous involvement in LHON, which becomes clinically manifest
in only a subgroup of at-risk individuals (Inglese et al., 2001).
Interestingly, the proton magnetic resonance spectroscopic (1H-
MRS) proﬁle of both affected and unaffected LHON carriers were
found to be abnormal compared to healthy controls, with reduced
creatine (Cr) and N-acetylaspartate (NAA) levels in normal-
appearing white matter regions, suggesting an underlying mito-
chondrial metabolic deﬁcit (Ostojic et al., 2009). A number of
pathophysiological mechanisms have been put forward linking RGC
loss, oligodendrocyte survival, and mitochondrial dysfunction in
patients with LHON and MS-like features (Section 8).
3.4. Incomplete penetrance and gender bias
Two key features of LHON still remain unexplained; the marked
incomplete penetrance and the signiﬁcant gender bias in disease
predisposition, with only 50% of male and 10% of female carriers
eventually losing vision in their lifetime. The primary LHON
mutation is a prerequisite, but secondary factors are clearly
modulating the risk of visual loss. Their identiﬁcation has proven
challenging, and the accumulated evidence favours a complex
disease model, with both genetic and environmental factors
interacting to precipitate optic nerve dysfunction (Carelli et al.,
2007b; Yu-Wai-Man et al., 2009b; Tonska et al., 2010).
3.4.1. Mitochondrial genetic factors
Among heteroplasmic LHON carriers, visual loss only occurs if
the mutational load exceeds 60%, the threshold required for trig-
gering a bioenergetic defect (Chinnery et al., 2001a). However,
incomplete penetrance is still observed among heteroplasmic
carriers harbouring suprathreshold mutational levels, and over 80%
of all LHON pedigrees are homoplasmic for the primary mtDNA
mutation (Smith et al., 1993; Harding et al., 1995b; Man et al., 2003).
Another possible mitochondrial modulating factor is the hap-
logroup background onwhich the LHONmutation is segregating. In
a meta-analysis of 159 Caucasian LHON pedigrees, there was
a signiﬁcantly increased risk of visual failurewhen them.11778G>A
and m.14484T>C mutations occurred on a haplogroup J back-
ground, whereas m.3460G>A carriers were more likely to experi-
ence visual loss if they belonged to haplogroup K (Hudson et al.,
2007b). A protective effect was conferred by haplogroup H, but
only among m.11778G>A mutational carriers. The mitochondrial
background also inﬂuenced the clinical expression of the
m.11778G>A mutation among mainland Chinese LHON carriers,with haplogroup M7b1’2 increasing the risk of disease conversion,
and haplogroup M8a having a protective effect (Ji et al., 2008).
MtDNA haplogroups are deﬁned by combinations of various poly-
morphic substitutions within the mitochondrial genome (Section
2.5). Some of these are non-synonymous, and they result in amino
acid changes within mitochondrially-encoded subunits of the
respiratory chain. Although it is convenient to view them as sepa-
rate entities (Fig. 1), mitochondrial respiratory chain complexes do
not exist in isolation, but they interact closely with one another
forming so-called supercomplexes (Dudkina et al., 2010). Although
speculative, these amino acid changes could induce subtle confor-
mational changes, which affect the assembly and stability of these
putative supercomplexes (Dudkina et al., 2005; Carelli et al., 2006;
Hudson et al., 2007b; Pello et al., 2008). In support of this hypoth-
esis, cybrid cell lines harbouring the m.11778G>A mutation had
a lower oxygen consumption and a longer doubling time on a hap-
logroup J background, compared with other mtDNA haplogroups
(Vergani et al., 1995). However, the link between speciﬁc mtDNA
haplogroups and the risk of visual failure in LHON is not entirely
clear-cut. A study of South-East Asian m.11778G>A LHON pedigrees
found no signiﬁcant association between speciﬁc mtDNA poly-
morphisms and the risk of developing overt optic nerve dysfunction
(Tharaphan et al., 2006). Similarly, using in vivo 31P-MRS
measurements, haplogroup J did not induce a more pronounced
mitochondrial biochemical defect in the brain and skeletal muscle
of affected m.11778G>A mutational carriers (Lodi et al., 2000).
3.4.2. Nuclear genetic factors
The marked male bias seen in LHON cannot be explained by
mitochondrial genetic factors. Based on an extensive analysis of 31
large pedigrees totalling more than 1200 individuals, Bu and Rotter
(1991, 1992) have proposed a two-locus model for visual failure in
LHON. The segregation pattern was consistent with a visual-loss
susceptibility gene on the X-chromosome, acting in synergy with
the primary mtDNA mutation to precipitate visual loss among at-
risk carriers. Male carriers have only one X-chromosome, and
unlike female carriers, they cannot compensate for the inheritance
of a putative X-linked visual-loss susceptibility allele (Oostra et al.,
1996; Pegoraro et al., 1996; Hudson et al., 2007a). Three studies
using microsatellite markers have now conﬁrmed signiﬁcant
linkage on the X-chromosome, with some of these candidate
regions showing areas of overlap (Figs. 6 and 7) (Hudson et al.,
2005; Shankar et al., 2008; Ji et al., 2010). The actual gene or
genes involved have yet to be identiﬁed, and more sophisticated
bioinformatic tools are currently being applied for candidate gene
analysis and to narrow down speciﬁc areas of interest. LHON could
be an even more complex disorder than originally considered and
the existence of autosomal nuclear modiﬁers remains a distinct
possibility. A recent genome-wide study of nine large m.11778G>A
Thai pedigrees found evidence of signiﬁcant linkage on areas of
chromosomes 3, 12, 13, and 18. Candidate gene regions were ana-
lysed with a tagging single nucleotide polymorphism (SNP)
methodology, and two SNPs, rs3749446 and rs1402000, located
within PARL (Presenilin-associated rhomboid-like) were associated
with a statistically increased risk of phenotypic expression among
LHON carriers (Phasukkijwatana et al., 2010). However, the asso-
ciation between these two PARL SNPs and visual loss was not
replicated in an independent cohort of Chinese m.11778G>A LHON
pedigrees (Zhang et al., 2010).
3.4.3. Hormonal factors
Although much attention has been focused on possible
secondary genetic modiﬁers in LHON, hormonal factors could also
inﬂuence phenotypic expression. This hypothesis has recently been
investigated by Giordano et al. (2010) using osteosarcoma-derived
Fig. 6. Summary of linkage studies investigating the existence of putative LHON nuclear modiﬁers on the X-chromosome. A nonparametric LOD score (NPL) >2 is indicative of
signiﬁcant linkage, and these chromosomal areas possibly harbour susceptibility loci which inﬂuence the risk of visual loss among LHON carriers. The different studies are colour
coded: red (Hudson et al., 2005), blue (Shankar et al., 2008), and black (Ji et al., 2010). Reproduced with permission from Ji et al. (2010).
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tions: m.3460G>A, m.11778G>A, and m.14484T>C. These mutant
cybrids exhibited elevated ROS levels, decreased mitochondrial
membrane potential, increased rates of apoptosis, and hyper-frag-
mented mitochondrial networks compared with controls. Inter-
estingly, treatment with 17b-oestradiol had a mitigating effect on
these pathological features. In addition, supplementation of these
LHON cybrids with 17b-oestradiol led to increased cellular levels of
the anti-oxidant enzyme superoxide dismutase (SOD) and to more
efﬁcient mitochondrial biogenesis. These results are very inter-
esting, providing another explanation for the protective effect of
female gender on LHON penetrance, and supporting the possible
therapeutic use of oestrogen-like compounds in this disorder.
3.4.4. Environmental factors
Two pairs of discordant monozygotic twins have been
described, where one sibling has remained visually unaffected on
long-term follow-up (Johns et al., 1993b; Biousse et al., 1997). TheseFig. 7. The complex interaction of genetic, hormonal, and environmental factors in the
pathophysiology of LHON.rare observations support an environmental component to the
pathophysiology of optic nerve dysfunction in LHON, and there is
increasing evidence in the literature supporting this hypothesis.
The role of smoking and alcohol in LHON has been studied in
a number of relatively small case-control studies, with contradic-
tory ﬁndings (Chalmers and Harding, 1996; Tsao et al., 1999; Sadun
et al., 2003; Newman, 2009). In one study, which included affected
and unaffected siblings from 80 LHON sibships, high alcohol and
tobacco consumption were not linked with an increased likelihood
of visual failure (Kerrison et al., 2000). To further clarify this
important issue, we conducted a multi-centre study of potential
triggers in LHON, comparing the environmental exposure between
196 affected and 206 unaffected carriers (Kirkman et al., 2009b).
Smoking was strongly associated with an increased risk of visual
loss, and interestingly, therewas a dose-response relationship, with
the risk of visual loss being much greater in heavy smokers
compared to light smokers. There was also a trend towards an
increased risk of visual failure among heavy drinkers, but this effect
was not as strong as smoking. Based on these results, LHON carriers
should be strongly advised not to smoke and to moderate their
alcohol intake, especially avoiding binge drinking episodes.
Although no functional studies were performed, smoking could
further impair mitochondrial OXPHOS, either through a direct
effect on complex I activity, or by reducing arterial oxygen
concentration (Gvozdjak et al., 1987; Vanjaarsveld et al., 1992; Yang
et al., 2007; Kirkman et al., 2009b; Newman, 2009). Several other
environmental triggers have been reported in LHON, including
head trauma, acute physical illness, psychological stress, occupa-
tional exposure to chemical toxins such as 2,5-hexanedione, anti-
retroviral drugs, and anti-tuberculous agents (Sadun et al., 2003;
Sanchez et al., 2006; Carelli et al., 2007a; Hudson et al., 2007b;
Kirkman et al., 2009b). Most of these reports are clinical descrip-
tions and they do not provide conclusive evidence for a causal
relationship. However, Ghelli et al. (2009) have shown that 2,5-
hexanedione had a mitochondrial toxic effect on LHON cybrids
harbouring the m.11778G>A and m.14484T>C primary mutations.
Of particular interest, an increased sensitivity to undergo apoptosis
was noted on the haplogroup J mtDNA background, further high-
lighting the possible synergistic interactions between environ-
mental and genetic risk factors.
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All the three primary LHON mutations involve complex I
subunits and their impact on mitochondrial OXPHOS has been
extensively investigated using a wide range of cell types and
biochemical assays. These in vitro studies have not always been
consistent regarding the extent of the respiratory chain defect in
LHON, but the overall evidence supports a predominant impair-
ment in complex I-driven ATP synthesis (Table 3). In vivo 31P-MRS
studies have also conﬁrmed an underlying biochemical defect in
LHON, with the m.11778G>A mutation resulting in the most
pronounced reduction in mitochondrial ATP synthesis, followed by
m.14484T>C, and m.3460G>A (Barbiroli et al., 1995; Lodi et al.,
1997, 2002). With the caveat that RGCs were not directly
assessed, an interesting observation from all these studies is that no
signiﬁcant difference in biochemical proﬁle has ever been clearly
demonstrated between affected and unaffected LHON carriers.
Oxidative stress leads to free radical production and ROS levels
were found to be signiﬁcantly increased in transmitochondrial
cybrids carrying one of the three primary LHON mutations (Wong
et al., 2002; Carelli et al., 2004b; Baracca et al., 2005; Floreani et al.,
2005). LHON patients also have reduced a-tocopherol/lipid ratios
and elevated 8-hydroxy-2-deoxygaunosine levels in their blood
leukocytes, both of these biomarkers being indicative of increased
ROS production (Klivenyi et al., 2001; Yen et al., 2004). LHON cybrids
have impaired EAAT1 (Excitatory amino acid transporter 1) activity,
which is highly relevant to RGC survival, as these transporters are
actively involved in the uptake of glutamate into Muller cells of the
inner retina (Beretta et al., 2004). The glutamate transport defect
could be partially reversed by supplementing these LHON cybrids
with antioxidants, supporting the use of these compounds in RGC
neuroprotection (Ghelli et al., 2008; Sala et al., 2008). Increased ROS
and glutamate excitotoxicity are potent inducers of apoptotic cell
death, and in LHON, this process is likely to be both Fas-dependent
and caspase-independent (Ghelli et al., 2003; Zanna et al., 2003).
4. Autosomal-dominant optic atrophy
4.1. Epidemiology
DOA affects at least 1 in 35,000 individuals in the North of
England, a ﬁgure which is comparable to LHON (Yu-Wai-Man et al.,
2010a). Based on the Danish Registry for Hereditary Eye Diseases,
the prevalence of this optic nerve disorder in Denmark has been
estimated at 1 in 12,000 (Toomes et al., 2001), a higher ﬁgurewhich
could reﬂect the methodological criteria used. This study was also
performed in the pre-molecular era and patients were included
based on a clinical diagnosis of DOA.
4.2. Clinical features
Visual loss in DOA is insidious, invariably starting in the ﬁrst
two decades of life, and with a mean age of onset of 6e10 years.Table 3
Biochemical Consequences of the Primary LHON mutations.
MtDNA Mutation In Vitroa
Complex I Activity (%) Respira
m.3460G>A 60e80 30e35
m.11778G>A 0e50 30e50
m.14484T>C 0e65 10e20
% Decrease relative to controls
a (Parker et al., 1989; Larsson et al., 1991; Majander et al., 1991; Degli Esposti et al., 1994
1995; Vergani et al., 1995; Hofhaus et al., 1996; Majander et al., 1996; Carelli et al., 199
b (Barbiroli et al., 1995; Cortelli et al., 1997; Lodi et al., 1997, 2000, 2002)Compared with LHON, it has a milder phenotype and up to 1 in 4
patients are visually asymptomatic, optic atrophy only being
detected through contact tracing of an affected proband (Kline and
Glaser, 1979; Hoyt, 1980). Mean visual acuities of 6/18e6/60 have
been reported in various case series, with visual acuities ranging
from 6/6 to the detection of hand movement (Kjer, 1959; Eliott
et al., 1993; Votruba et al., 1998b; Puomila et al., 2005; Cohn
et al., 2008). There is a marked inter- and intra-familial vari-
ability in the rate of disease progression, but a signiﬁcant
proportion of patients (50e75%) will experience further wors-
ening of their visual function in later life (Cohn et al., 2008; Yu-
Wai-Man et al., 2010a,c). Although the overall visual prognosis is
better compared with LHON, DOA still causes signiﬁcant visual
impairment with half of all patients failing the driving standards
and being registered legally blind (Kjer et al., 1996; Votruba et al.,
1998a; Cohn et al., 2007).
Most patients with DOA have a generalised dyschromatopsia
and only a minority (10%) has pure tritanopia, which used to be
considered a pathognomonic feature of this optic nerve disorder
(Berninger et al., 1991). Due to the primary involvement of the
papillomacular bundle, the most common visual defects are
central, centrocaecal, and paracentral scotomas, with sparing of the
peripheral ﬁeld (Votruba et al., 1998a; Yu-Wai-Man et al., 2010a,c).
Both magnocellular and parvocellular pathways seem to be simi-
larly affected in DOA. Similar to LHON, the retino-tectal ﬁbres
mediating the pupillary light reﬂex are relatively preserved, and
patients do not normally exhibit an afferent pupillary defect
(Bremner et al., 2001).
Optic disc pallor in DOA can be either diffuse, involving the
entire neuro-retinal rim, or it can show a characteristic temporal
wedge (Fig. 8). Pallor of the neuro-retinal rim can be subtle and in
one report, nearly a third of all affected patients had normal looking
optic discs on slit lamp biomicroscopy (Cohn et al., 2007). Based on
our own experience, measurement of retinal nerve ﬁbre layer
(RNFL) thickness with optical coherence tomography (OCT) can be
particularly helpful in equivocal cases, by conﬁrming pathological
RNFL thinning, especially in the temporal quadrant involving the
papillomacular bundle (Ito et al., 2007; Kim and Hwang, 2007;
Milea et al., 2010). Although not characteristic, other morpholog-
ical disc features have been reported in DOA; saucerisation of the
neuro-retinal rim, peripapillary atrophy, and enlarged cup-to-disc
ratios greater than 0.5, the latter often leading to an erroneous
diagnosis of normal tension glaucoma (Votruba et al., 1998a, 2003;
Fournier et al., 2001; Yu-Wai-Man et al., 2010a,c).
4.3. Mutational spectrum
The majority (50e60%) of patients with DOA harbour mutations
in the OPA1 gene (OMIM 165500), and over 200 pathogenic
mutations have been identiﬁed (eOPA1 database at http://lbbma.
univ-angers.fr/lbbma.php?id¼9, Accessed 31st of August 2010)
(Table 4). OPA1 consists of 30 exons spread over 100 kb of genomic
DNA and alternative splicing of exons 4, 4b and 5b results in eightIn Vivob
tory Rate (%) ATP Synthesis (%) 31P-MRS (%)
90 0e40
35 75
90 50
; Smith et al., 1994; Cock et al., 1995, 1998, 1999; Montagna et al., 1995; Oostra et al.,
7; Brown et al., 2000; Baracca et al., 2005)
Fig. 8. The optic disc appearance of a patient with a conﬁrmed pathogenic OPA1mutation showing pallor of the neuro-retinal rim, which is more marked temporally. The bottom panels illustrate the pattern of retinal nerve ﬁbre layer
(RNFL) thinning seen in patients with OPA1 mutations, with relative sparing of the nasal peripapillary quadrant. The RNFL proﬁle for each eye is superimposed on the normal distribution percentiles, and compared with each other
(Bottom left panel). Various measurement parameters are automatically generated by the analysis software including sectorial RNFL thickness for each individual quadrant and clock hour, and an overall value for the average RNFL
thickness (Bottom middle panel). The normal distribution indices are colour-coded: (i) red <1%, (ii) yellow 1e5%, (iii) green 5e95%, and (iv) white >95% (Bottom right panel).
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Table 4
Primary inherited optic nerve disorders e Pattern of inheritance, reported loci, and causative genes.
Inheritance Locus Gene OMIM Phenotypes References
AD 3q28-q29 OPA1 165500 Isolated optic atrophy and syndromal
forms of dominant optic atrophy (DOAþ)
(Delettre et al., 2000;
Alexander et al., 2000;
Yu-Wai-Man et al., 2010b)
19q13.2-q13.3 OPA3 165300 Optic atrophy and premature cataracts
(ADOAC)
(Garcin et al., 1961;
Reynier et al., 2004)
18q12.2-q12.3 OPA4
(Unknown)
605293 Optic atrophy (Kerrison et al., 1999)
22q12.1-q13.1 OPA5
(Unknown)
610708 Optic atrophy (Barbet et al., 2005)
16q21-q22 OPA8
(Unknown)
e Optic atrophy and sensorineural deafness (Carelli et al., 2007c)
AR 19q13.2-q13.3 OPA3 606580 3-methylglutaconic aciduria type III
(Costeff syndrome)
(Anikster et al., 2001)
8q21-q22 OPA6
(Unknown)
258500 Optic atrophy (Barbet et al., 2003)
11q14.1-q21 OPA7
(TMEM126A)
612989 Optic atrophy (Hanein et al., 2009)
XL Xp11.4-p11.21 OPA2
(Unknown)
311050 Optic atrophy (Assink et al., 1997;
Katz et al., 2006)
Mitochondrial e e 53500 Leber hereditary optic neuropathy
and overlap mitochondrial syndromes
Table 1
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2006; Lenaers et al., 2009). OPA1 mutations cluster in the GTPase
domain (Exons 8e15) and dynamin central region (Exons 16e23),
with single base-pair substitutions (69%) representing the most
common mutational subtype, followed by deletions (26%), and
insertions (5%) (Ferre et al., 2005, 2009). OPA1 testing is usually
performed with PCR-based sequencing protocols, and although
cost and access are important practical issues, about 10e20% of
patients who are found to be negative using these screening
methods will harbour large-scale OPA1 re-arrangements
(Fuhrmann et al., 2009; Yu-Wai-Man et al., 2010a). The majority of
OPA1 mutations result in premature termination codons, with
truncated mRNAs which are unstable and mostly degraded by
protective cellular mechanisms (Pesch et al., 2001; Schimpf et al.,
2006; Zanna et al., 2008). The reduction in OPA1 protein level is
a major disease mechanism in DOA, and the importance of hap-
loinsufﬁciency is further emphasised by rare families with micro-
deletions which span the entire OPA1 coding region (Marchbank
et al., 2002; Fuhrmann et al., 2009). However, about 30% of
patients with DOA harbour missense OPA1 mutations, and those
located within the catalytic GTPase domain are more likely to exert
a dominant-negative effect (Section 4.4) (Amati-Bonneau et al.,
2008; Ferraris et al., 2008; Hudson et al., 2008; Yu-Wai-Man
et al., 2010b).
Other genetic loci have been identiﬁed in families with DOA
phenotypes (Table 4), but of these, only the causative gene for OPA3
has been characterised. OPA3 mutations were ﬁrst identiﬁed in
Iraqi Jewish families with Type III 3-methylglutaconic aciduria
(Costeff syndrome); an autosomal recessive neurodegenerative
disorder characterised by optic atrophy, progressive neuro-
degeneration, increased urinary levels of 3-methylglutaconic acid,
and elevated plasma 3-methylglutaric acid levels (Costeff et al.,
1989; Anikster et al., 2001). Pathogenic mutations were subse-
quently found in two independent French families segregating both
optic atrophy and premature cataract in an autosomal-dominant
mode of inheritance (ADOAC) (Reynier et al., 2004). However, OPA3
mutations are likely to be extremely rare, especially in isolated
optic atrophy cases. We did not identify any pathogenic OPA3
variants in two large case series of OPA1-negative individuals, even
with the use of a comparative genomic hybridization (CGH) assay to
screen for large-scale OPA3 re-arrangements (Yu-Wai-Man et al.,
2010a,c).4.4. Expanding clinical phenotypes
Even in the pre-molecular era, a number of pedigrees with
DOA were described where optic neuropathy occurred in parallel
with other clinical features such as sensorineural deafness and
CPEO (Kjer, 1956, 1959; Kline and Glaser, 1979; Hoyt, 1980; Meire
et al., 1985). OPA1 mutations have been conﬁrmed as the caus-
ative genetic defects in these syndromal forms of DOA, but until
recently, these were thought to be rare manifestations among
isolated families (Amati-Bonneau et al., 2003, 2005; Shimizu
et al., 2003; Payne et al., 2004; Liguori, 2008). In our North of
England inherited optic neuropathy cohort, DOAþ phenotypes
were observed in 1 in 6 OPA1 carriers, which clearly indicate that
these syndromal variants affect a signiﬁcant patient subgroup
(Yu-Wai-Man et al., 2010a). We then conducted a multi-centre
study of 104 patients manifesting DOAþ to deﬁne the phenotypic
spectrum and natural history of these additional neurological
complications (Yu-Wai-Man et al., 2010b). Bilateral sensorineural
deafness beginning in late childhood and early adulthood was
the most frequently observed extra-ocular manifestation,
affecting nearly two-thirds of all cases. Other prominent clinical
features then developed from the third decade of life onwards;
ataxia, myopathy, peripheral neuropathy and CPEO. Unexpect-
edly, OPA1 mutations were also identiﬁed in families previously
labelled as having autosomal-dominant hereditary spastic para-
plegia (HSP), and in individuals with visual failure complicated
by a multiple sclerosis-like illness. Of note, there was a two- to
three-fold increased risk of developing multi-system neurolog-
ical disease with missense OPA1 mutations located within the
GTPase domain, suggesting deleterious gain-of-function mecha-
nisms. Although these syndromal DOAþ variants show signiﬁ-
cant phenotypic variability even within the same family,
a consistent ﬁnding is a worse visual prognosis among this
patient subgroup. These observations are of major pathophysio-
logical importance, highlighting the widespread deleterious
consequences of OPA1 mutations, not only for RGCs, but also for
other neuronal populations, skeletal muscle, and extra-ocular
muscle (Spinazzi et al., 2008; Zeviani, 2008; Mackey and
Trounce, 2010). A key feature of these OPA1 mutations is the
induction of secondary mtDNA deletions, and their possible roles
in triggering multi-system cellular dysfunction are currently
being investigated (Yu-Wai-Man et al., 2010d).
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OPA1 is highly expressed within the RGC layer, but it is a ubiq-
uitous protein, and abundant levels have also been identiﬁed in
photoreceptors, and other non-ocular tissues such as the inner ear
and the brain (Aijaz et al., 2004; Pesch et al., 2004; Bette et al.,
2005; Kamei et al., 2005; Akepati, 2008). OPA1 belongs to a large
family of mechanoenzymes, which is characterised by a highly
conserved, dynamin GTPase domain (Davies and Votruba, 2006;
Lenaers et al., 2009). OPA1 is a transmembrane protein
embedded within the mitochondrial inner membrane, and it
mediates several interrelated cellular functions. One important
aspect relates to its pro-fusion properties and unsurprisingly, the
pathological hallmark of OPA1mutations is mitochondrial network
fragmentation, the isolated mitochondria becoming dysmorphic,
with aberrant balloon-like enlargements, disorganised cristae, and
paracrystalline inclusion bodies (Kamei et al., 2005; Olichon et al.,
2007; Amati-Bonneau et al., 2008; Chevrollier et al., 2008; Zanna
et al., 2008). GTP hydrolysis activates membrane tubulation and
this GTPase activity is thought to be enhanced following interaction
of OPA1 with inner membrane phospholipids such as cardiolipin
(Ban et al., 2010). Cytochrome c molecules are normally seques-
tered within the tight cristae junctions, and as they leach out into
the cytosol, the apoptotic cascade is potentiated contributing to cell
death and tissue dysfunction (Cipolat et al., 2006; Frezza et al.,
2006; Suen et al., 2008). OPA1 also regulates OXPHOS by interact-
ing directly with the respiratory chain complexes, controlling their
delicate assembly, and facilitating the efﬁcient shuttling of elec-
trons between complexes (Zanna et al., 2008). Fibroblasts har-
bouring OPA1 mutations have reduced mitochondrial membrane
potentials and ATP synthesis was found to be signiﬁcantly impaired
(Amati-Bonneau et al., 2005; Chevrollier et al., 2008), secondary to
a predominantly complex I defect (Zanna et al., 2008). With the use
of in vivo phosphorus magnetic resonance spectroscopy (31P-MRS),
these biochemical defects have also been demonstrated in the calf
muscles of patients harbouring OPA1 mutations (Lodi et al., 2004;
Yu-Wai-Man et al., 2010f). Interestingly, it is now apparent that
OPA1 plays a critical role in maintaining the integrity of the mito-
chondrial genome. High levels of COX-negative ﬁbres have been
identiﬁed in skeletal muscle biopsies from patients with DOAþ
phenotypes, and this has been conclusively linked to the accumu-
lation of multiple mtDNA deletions (Stewart et al., 2008; Yu-Wai-
Man et al., 2010b,d).
OPA3 has a mitochondrial targeting domain, and it was thought
to localise to the mitochondrial inner membrane (Anikster et al.,
2001; Ho et al., 2008; Huizing et al., 2010). However, a recent
study challenged this view, suggesting instead that OPA3 is an
integral component of the mitochondrial outer membrane, with its
C-terminus exposed to the cytosol (Ryu et al., 2010). Mitochondrial
fragmentation was induced both with mutant forms of the protein,
and following overexpression of the wild-type protein, indicating
an important pro-ﬁssion role for OPA3 (Ryu et al., 2010). The cells
studied had an increased sensitivity to various pro-apoptotic
stimuli, a phenomenon which was also observed in ﬁbroblasts
collected from an affected patient belonging to one of the French
ADOAC families (Reynier et al., 2004).
5. Other mitochondrial optic neuropathies
5.1. Charcot-Marie-Tooth disease
Charcot-Marie-Tooth (CMT) disease is a heterogeneous group of
inherited peripheral neuropathies, and as a group they are one of
the most common inherited human disorders, affecting at least 1 in
2500 individuals (Zuchner and Vance, 2006; Pareyson andMarchesi, 2009). Both motor and sensory nerves are affected
resulting in distal limb weakness, sensory loss, decreased deep
tendon reﬂexes, and foot deformities. A speciﬁc CMT subtype,
hereditarymotor and sensory neuropathy type VI (HMSN-VI, OMIM
601152), is caused by MFN2 mutations (1p36.2) (Zuchner et al.,
2004). In addition to early onset, severe peripheral neuropathy,
affected individuals develop progressive optic nerve dysfunction
starting in later childhood (Zuchner et al., 2006). Visual acuity
usually deteriorates to levels of 6/60 or worse, but a subset of
patients with HMSN-VI can experience sometimes dramatic visual
recovery in later life. MFN1 and MFN2 are mitochondrial outer
membrane proteins with dynamin GTPase domains, and they share
a remarkable degree of structural and functional complementarity
with OPA1 (Cartoni and Martinou, 2009; Chen and Chan, 2009).
These three proteins interact closely with each other to coordinate
the various steps involved in mitochondrial membrane fusion.
MFN2 is also thought to exert a direct inﬂuence on mitochondrial
biogenesis by regulating the expression of nuclear-encoded respi-
ratory chain subunits (Pich et al., 2005). Consistent with this
hypothesis, ﬁbroblasts from patients harbouring MFN2 mutations
exhibit a mitochondrial coupling defect, with impaired membrane
potential and reduced OXPHOS capacity (Loiseau et al., 2007).
5.2. Hereditary spastic paraplegia
The clinical hallmark of HSP is slowly progressive lower limb
spasticity and weakness. Its prevalence has been estimated at 3e10
per 100,000 in Europe, and the age of onset varies according to the
causative genetic defect (Salinas et al., 2008). HSP is classiﬁed into
pure and complicated forms, depending on whether additional
clinical features are present besides spastic paraplegia, such as optic
atrophy, ataxia, peripheral neuropathy, extrapyramidal deﬁcits, and
cognitive decline (Harding, 1983). HSP is genetically heterogeneous
with 41 mapped loci. So far, 17 genes have been identiﬁed,
providing valuable insights into the various pathogenetic mecha-
nisms which trigger axonal degeneration along the corticospinal
tracts (Shy et al., 2002; Reid, 2003; Salinas et al., 2008).
OPA1 is cleaved by mitochondrial proteases following import
into the mitochondrial intermembrane space, and these post-
translational maturational steps are critical, generating long (L) and
short (S) forms of the protein (Pellegrini and Scorrano, 2007;
Lenaers et al., 2009; Martinelli and Rugarli, 2010). On their own,
the L and S forms of OPA1 have little functional activity, but when
co-expressed, they complement each other, triggering mitochon-
drial network fusion. One of these key mitochondrial proteases is
paraplegin, which is encoded by SPG7 (16q24.3). Mutations in SPG7
have been identiﬁed in an autosomal recessive form of HSP, and in
some patients, bilateral optic neuropathy is a prominent clinical
feature further complicating the neurological phenotype (HSP-7,
OMIM 607259) (Casari et al., 1998). Muscle biopsies from two
severely affected individuals with HSP-7 showed classical histo-
chemical changes of mitochondrial dysfunction with ragged-red
ﬁbres and COX-negative ﬁbres. Transmission electron microscopy
conﬁrmed an accumulation of abnormal mitochondria containing
paracrystalline inclusion bodies. Biochemical studies performed on
cultured myoblasts harbouring SPG7 mutations have revealed
a reduction in citrate synthase-corrected complex I activity, again
suggesting that impaired OXPHOS plays an important role in the
pathogenesis of HSP, and by extension the optic neuropathy
observed in a subgroup of patients (Wilkinson et al., 2004).
5.3. Friedreich ataxia
Friedreich ataxia (FRDA) is an autosomal recessive disorder
caused by pathological GAA trinucleotide repeat expansions in the
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encoded protein frataxin is directed to the mitochondrial inner
membrane and it is involved in the assembly of ironesulphur clus-
ters, which are critical components of themitochondrial respiratory
chain complexes (Rouault and Tong, 2005; Stemmler et al., 2010).
FXN mutations therefore impair OXPHOS and they also result in
abnormal accumulation of intra-mitochondrial iron, which even-
tually reaches toxic levels (Rotig et al., 1997, 1998). Because frataxin
has anti-oxidant properties, cellular defences against ROS are
impaired in FRDA, and this likely further exacerbates neuronal loss
(Rustin et al., 1999; Rotig et al., 2002; Schmucker and Puccio, 2010).
Patients with FRDA usually become symptomatic in the second
decade of life, with progressive gait ataxia, loss of the deep tendon
reﬂexes, dysarthria, distal limb weakness, pes cavus, scoliosis, and
arrhythmias secondary to hypertrophic cardiomyopathy (Durr
et al., 1996). In a recent study of 26 patients with genetically-
conﬁrmed FRDA, all patients had evidence of optic nerve dysfunc-
tion, although only ﬁve were visually symptomatic (Fortuna et al.,
2009). The optic neuropathy differed from that observed in LHON
and DOA, with a diffuse and progressive pattern of RNFL loss, and
no preferential involvement of the papillomacular bundle. Inter-
estingly, the pathological process in FRDA extended to the post-
geniculate optic radiations, and the involvement of the anterior and
posterior visual pathways seemed to proceed independently of
each other. Altogether, these ﬁndings suggest that FXN mutations
probably cause RGC loss via other disease mechanisms compared
with OPA1 and the primary mtDNA LHON mutations.
5.4. Autosomal recessive non-syndromal optic atrophy
Autosomal recessive optic neuropathies are rare and the visual
phenotype is usually overshadowed by other more prominent
neurodegenerative features. Using homozygosity mapping, Hanein
et al. (2009) identiﬁed mutations in TMEM126A (11q14.1-q21,
OMIM 612989) in a large, inbred, Algerian family segregating pure
optic atrophy. TMEM126A is conserved in higher eukaryotes and it
encodes a transmembranemitochondrial protein, which is found at
high levels within the RGC layer and optic nerve head. The exact
localisation and function of this protein remain to be clariﬁed, but
TMEM126A mutations do not cause mitochondrial network frag-
mentation or mtDNA depletion. A novel nonsense TMEM126A
mutation has since been reported where affected family members
had subclinical auditory neuropathy in addition to progressive
visual failure. The clinical phenotype associated with TMEM126A
mutations could therefore expand further as more families with
syndromal optic atrophy are screened for this particular gene
(Meyer et al., 2010).
5.5. Mitochondrial protein-import disorders
MohreTranebjaerg syndrome or deafness-dystonia-optic neu-
ronopathy (DDON) syndrome is caused by loss-of-function muta-
tions in the TIMM8A gene (Xq22, OMIM 300356) (Tranebjaerg et al.,
1997). The clinical phenotype includes prelingual or postlingual
sensorineural deafness, dystonia and ataxia in late childhood,
visual failure with optic atrophy from the age of 20 years, and
cognitive decline with psychiatric disturbances before the age of 50
years (Tranebjaerg et al., 1997; Tranebjaerg, 2003). Electrophysio-
logical studies indicate that the visual loss in DDON is secondary to
RGC loss, and the visual prognosis is poor, with most patients
registered legally blind by the age of 40 years (Tranebjaerg et al.,
1995, 2001; Ponjavic et al., 1996; Ujike et al., 2001). TIMM8A
assembles as a 70 kDa hetero-oligomeric complex in the mito-
chondrial intermembrane space, and in conjunction with TIMM13,
another mitochondrial membrane translocase, this complexfacilitates the import and insertion of inner membrane proteins
(MacKenzie and Payne, 2007). COX-negative ﬁbres were not
present in muscle biopsy specimens from affected patients and
there was no alteration in mitochondrial network morphology
(Binder et al., 2003; Blesa et al., 2007). However, therewas evidence
of an underlying mitochondrial biochemical defect, with reduced
complex IeIV enzymatic activities.
Dilated cardiomyopathy with ataxia (DCMA) or 3-methyl-
glutaconic aciduria, type V (OMIM 610198) is an autosomal reces-
sive disorder found in the Dariusleut Hutterite population of
Canada and the Northern United States. The clinical phenotype is
characterised by growth failure, severe, early-onset cardiomyop-
athy, and a cerebellar syndromewith ataxia. Optic atrophy has been
reported in some patients with DCMA, although it is not a cardinal
feature of this syndrome (Davey et al., 2006). Homozygous muta-
tions in the DNAJC19 gene (3q26.33) have recently been identiﬁed
in these inbred families, a GeC transversion within the splice
acceptor site of intron 3 (Davey et al., 2006). The DNAJC19 protein
localises to the mitochondrial compartment and although its
subcellular localisation requires further investigation, it is thought
to be the human orthologue of the yeast Tim14 protein (Mokranjac
et al., 2006). Tim14 is an integral mitochondrial inner membrane
protein and together with other mitochondrial translocases, it
actively participates in protein import into the mitochondrial
matrix compartment. Both DDON and DCMA are therefore due to
defective mitochondrial protein-import systems, and it is fasci-
nating that in both disorders optic nerve involvement is observed,
albeit as part of a more widespread multi-systemic degeneration
(MacKenzie and Payne, 2007).5.6. Mitochondrial encephalomyopathies
Optic neuropathy can also develop in the following classical
mitochondrial syndromes, although it is usually a secondary
feature, overshadowed by other more prominent neurological and
ocular manifestations: MELAS, myoclonic epilepsy and ragged-red
ﬁbres (MERRF), CPEO, KSS, maternally inherited Leigh syndrome
(MILS), and mitochondrial neurogastrointestinal encephalomyop-
athy (MNGIE) (Gronlund et al., 2010).5.7. Overlapping phenotypes
The concept of mitochondrial optic neuropathies has greatly
expanded over the years and this trend is set to continue as new
genes with mitochondrial-related functions are identiﬁed in other
inherited optic nerve disorders. What is truly remarkable is the
overlapping phenotypes seen with this group of disorders, for
example among OPA1 carriers, some patients develop neurological
features indistinguishable from HSP, others develop a pattern of
peripheral neuropathy with a similar disease course to CMT, and
others still will develop a prominent cerebellar syndrome
consistent with FRDA. These shared clinical features also apply to
the optic nerve phenotype, as seen with LHON and DOA, the two
most common inherited optic neuropathies diagnosed in the
general population. As described in earlier sections, LHON and
DOA have distinct clinical presentations which usually allow for
their easy differentiation, but with the greater availability of
genetic testing, it is now clear that a degree of phenotypic overlap
exists. Although unusual, some patients with genetically-
conﬁrmed OPA1 mutations have been described with acute and
even reversible visual loss (Cornille et al., 2008; Nochez et al.,
2009), and a subgroup of LHON patients can present with
a slowly progressive optic neuropathy, more suggestive of DOA
(Barboni et al., 2006).
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6.1. Smoking, alcohol, and nutritional deprivation
Individuals with excessive alcohol and tobacco intake can
develop a bilateral optic neuropathy, with slowly progressive visual
loss, dyschromatopsia, and centrocaecal scotomas (Rizzo and
Lessell, 1993; Lessell, 1998). This entity is sometimes referred to as
“tobacco-alcohol amblyopia”, but there is persisting debate
regarding its actual aetiology (Grzybowski, 2007; Grzybowski and
Holder, 2010). It is possible that alcohol and tobacco per se are not
themain or only causative factors, with other confounding variables
such as nutritional deprivation contributing to the observed RGC-
toxic effect. An epidemic of optic neuropathy was observed in Cuba
in the early 1990s at a time of deteriorating socioeconomic condi-
tions within this country (Sadun et al., 1994; Bern et al., 1995). This
outbreak of optic neuropathy has been linked with chronic malnu-
trition combined with high levels of tobacco and cassava
consumption. Cassava contains naturally-occurring cyanogenic
glucosides and the occurrence of cyanide poisoning has been well
described, especially during periods of famine. In terms of disease
mechanisms, it is interesting that primary mtDNA LHONmutations
have been detected in patients labelled as having “tobacco-alcohol
amblyopia” (Cullom et al., 1993; Purohit and Tomsak, 1997). More-
over, smoking has recently been identiﬁed as a strong risk factor for
visual loss among LHON mutational carriers, with heavy smokers
having a higher risk than light smokers (Kirkman et al., 2009b).
However, it should be noted that during the Cuban optic neuropathy
outbreak, there was no evidence of increased disease penetrance in
a large Cuban m.11778G>A family (Newman et al., 1994).
6.2. Chloramphenicol
With the advent of safe, broad spectrum antibiotics, systemic
chloramphenicol is now rarely used for treating severe, dissemi-
nated infections. However, until the late 1970s, it was frequently
used in the management of patients with cystic ﬁbrosis, and a rare
but serious complicationnoted in this groupof patientswasbilateral
optic neuropathy (Godel et al., 1980; Yunis, 1989; Venegas-Francke
et al., 2000). Post-mortem studies performed on patients who died
shortly afterwards showed complete loss of RGCs within the
distribution of the papillomacular bundle, with relative sparing of
the nasal and peripheral retina (Cogan et al., 1973). There was no
evidence of inﬂammationwithin the optic nerve but therewasmild
gliosis and demyelination in both the pre- and post-laminar
segments. Transmission electron microscopy of haemopoetic cells
collected from patients with chloramphenicol-induced bone
marrow suppression revealed swollenmitochondriawith disrupted
cristae architecture, in addition to abnormal intra-mitochondrial
iron deposits (Smith et al., 1970; Yunis and Smith, 1970; Skinnider
and Ghadially, 1976). These ﬁndings strongly suggest that the
pathological changes in chloramphenicol optic neuropathy are due
to a similar mitochondrial toxic effect. Chloramphenicol is a power-
ful inhibitor of both bacterial and mitochondrial ribosomal protein
synthesis, resulting in mitochondrial stress and a marked reduction
in cellular ATP biosynthesis (Bhat et al., 1981; Li et al., 2010).
6.3. Linezolid
Linezolid is an oxazolidinone antibiotic that is increasingly
being used to treat drug-resistant, gram positive organisms such as
methicillin-resistant Staphylococcus aureus (MRSA) and vancomy-
cin-resistant Enterococcus (VRE) (De Vriese et al., 2006). Overall, it is
a safe antibiotic agent when used for up to 28 days, with only minor
side effects reported in large Phase III clinical trials. However, about20 cases of linezolid-associated optic neuropathy (LION) have been
reported in the literature, and a common feature of this rare
association seems to be an extended duration of treatment (5e50
months) (McKinley and Foroozan, 2005; Saijo et al., 2005; Rucker
et al., 2006; Javaheri et al., 2007). Patients present with typical
features of a bilateral optic neuropathy and at ﬁrst presentation,
visual acuities ranging from 6/9 to counting ﬁngers have been
reported. Early in the course of the disease, optic disc swelling and
marked thickening of the RNFL have also been documented, the
latter indicating axonal RGC swelling and strikingly reminiscent of
the pathological process in acute LHON. Unlike linezolid-induced
peripheral neuropathy which is irreversible, full visual recovery is
possible following discontinutation of linezolid therapy. It is
therefore crucial for clinicians to be aware of this possibly devas-
tating complication among patients receiving linezolid treatment
beyond the 28-day safe limit. Intriguingly, mitochondrial dysfunc-
tion seems to be central to the pathophysiology of LION, and
a number of hypotheses have been proposed based upon the
mechanism of action of linezolid. The antibacterial effect of line-
zolid is due to inhibition of bacterial protein synthesis, with the
activemoiety binding to the 23S rRNA of the 50S ribosomal subunit,
thereby preventing the formation of the 70S RNA initiation
complex (Javaheri et al., 2007). Mammalian ribosomes lack the 50S
component and they are therefore not affected by linezolid.
Although speculative, it is possible that mitochondrial ribosomes
are susceptible to the sustained effect of long-term linezolid
because of their closer evolutionary similarities to bacterial ribo-
somes. Consistent with this mechanism, mitochondrial respiratory
chain activity was signiﬁcantly depressed in a range of tissues;
muscle, liver, and kidney, biopsied from a patient who developed
optic neuropathy, encephalopathy, skeletal myopathy, lactic
acidosis, and renal failure after a 4-month course of linezolid (De
Vriese et al., 2006). This ﬁnding was further substantiated in an
experimental rat model, with linezolid inducing a dose- and time-
dependent decrease in the activity of complex I, and to a lesser
extent that of complex IV (De Vriese et al., 2006).
6.4. Erythromycin
Luca et al. (2004) reported on a 23-year-oldmalewho developed
bilateral optic neuropathy following treatment with erythromycin.
His visual acuity was severely reduced to counting ﬁngers in both
eyes and bilateral diffuse optic nerve pallor was observed, more
marked temporally. A homoplasmic m.11778G>A mutation was
identiﬁed, and to investigate a possible link between erythromycin
and the onset of visual failure in this LHON carrier, cybrid osteo-
sarcoma cells were established harbouring the patient’s mtDNA.
When cultured in media containing erythromycin, a marked
impairment in mitochondrial protein synthesis was noted and this
was a dose-dependent effect. Similar to linezolid, erythromycin
binds to the 23S rRNA molecule of the 50S ribosomal subunit
blocking the exit of the growing polypeptide chain (Thomas and
Wilkie, 1968; Tok and Bi, 2003). Erythromycin and, by extension,
other macrolide antibiotics are therefore potential mitochondrial
toxins and their use should be avoided in patients with mitochon-
drial genetic disorders, especially if other alternatives are available.
6.5. Ethambutol
Ethambutol is an important ﬁrst-line drug used for treating
tuberculosis and 2e6% of patients receiving this anti-mycobacterial
drug will develop optic neuropathy, a serious side effect which is
duration- and dose-dependent (Melamud et al., 2003; Lee et al.,
2008). Optic nerve involvement is rare with treatment duration
of less than 2 months, and although visual function can improve
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versible (Kim and Hwang, 2009). Several studies have conﬁrmed
a direct, toxic effect of ethambutol on RGC survival, and various
pathophysiological mechanisms have been proposed including
glutamate excitotoxicity, zinc-mediated lysosomal membrane per-
meabilisation, and disruption of mitochondrial complex IV activity
through a copper-chelating action (Heng et al., 1999; Chung et al.,
2009). Dotti et al. (1998) were the ﬁrst to describe the onset of
bilateral, subacute visual loss in a LHON m.11778G>A carrier, 8
months following the initiation of treatment for pulmonary
tuberculosis. Since then, other case reports of ethambutol-induced
optic neuropathy among LHON carriers have been reported, sug-
gesting a synergistic deleterious effect of this anti-mycobacterial
drug on the background of a pre-existing pathogenic mtDNA
mutation (De Marinis, 2001; Hwang et al., 2003; Ikeda et al., 2006;
Pradhan et al., 2010; Seo et al., 2010). Against this argument, the
m.11778G>A mutation did not further enhance ethambutol cyto-
toxicity in NT2/D1 teratoma-derived cybrids, but this could simply
reﬂect a tissue-speciﬁc effect, the latter being more pronounced in
RGCs (Pommer et al., 2008).
The link between ethambutol therapy and inherited mito-
chondrial optic neuropathies was further highlighted by Guillet
et al. (2010). They unexpectedly identiﬁed a pathogenic OPA1
mutation in a male patient who developed bilateral, sudden,
central visual loss 3 months after starting treatment for primary
tuberculosis on a standard regimen of ehthambutol, isoniazid, and
rifampicin. His visual acuity was severely affected, with caecocen-
tral scotomas, and no visual recovery was noted following with-
drawal of ethambutol. The acute presentation observed in this case
is somewhat atypical for DOA and functional studies performed on
cultured ﬁbroblasts supported a role for ethambutol in precipi-
tating an accelerated loss of RGCs. Compared with control ﬁbro-
blasts similarly treated with ethambutol, a more marked
biochemical uncoupling defect was observed, with loss of mito-
chondrial membrane potential, mitochondrial fragmentation,
disturbed calcium homeostasis, and the accumulation of abnormal
intracellular vacuoles (Guillet et al., 2010).
6.6. Antiretroviral drugs
There are suggestive reports of visual loss being triggered
among LHON carriers following the initiation of highly active
antiretroviral therapy (HAART) for newly diagnosed HIV infections
(Shaikh et al., 2001; Mackey et al., 2003). These HIV patients were
all male and harboured either the m.11778G>A or the m.14484T>C
primary mtDNA mutations. The possible mechanisms have focused
mainly on a particular class of antitretrovirals, the nucleoside
analogue reverse transcriptase inhibitors (NRTIs), which can induce
mitochondrial toxicity. NRTIs can inhibit mitochondrial polymerase
gamma (POLG), a key component of the mtDNA replication
machinery (Samuels, 2006; Scruggs and Naylor, 2008). A well
reported side effect of NRTI therapy is mtDNA depletion, the
resulting biochemical defect leading to lactic acidosis, hepatotox-
icity, cardiomyopathy, generalised myopathy, and peripheral
neuropathy (Cote et al., 2002; Frerichs et al., 2002; Maagaard et al.,
2006). Fascinatingly, HAART has also been linked with the devel-
opment of a CPEO phenotype in a limited number of HIV patients,
with a gradual onset of ophthalmoplegia and ptosis (Pfeffer et al.,
2009). One attractive hypothesis is that patients harbouring
speciﬁc SNPs within POLG are at a higher risk of developing mito-
chondrial toxicity to NRTIs, with the HIV virus itself having an
additive detrimental effect, further exacerbating mitochondrial
dysfunction (Nolan and Mallal, 2004; Maagaard et al., 2006;
Samuels, 2006). The mitochondrial protein proﬁle of treatment-
native HIV patients and those receiving HAART therapy haverecently been investigated in blood leukocytes using a proteomic-
based approach. Both groups of patients showed downregulated
levels of prohibitins, important mitochondrial enzymes closely
involved in OXPHOS and the maintenance of the mitochondrial
network (Artal-Sanz and Tavernarakis, 2009; Ciccosanti et al.,
2010). Additional studies are needed to determine whether ﬁbro-
blasts from HIV patients, on or off HAART therapy, show any
evidence of mitochondrial network fragmentation. Given the
emerging links between HIV, HAART therapy, and mitochondrial
dysfunction, it is not unreasonable to speculate that LHON carriers
would be at an increased risk of visual loss in this particular
context, and should therefore be adequately counselled should they
require treatment with antiretrovirals.
7. Glaucoma
7.1. Normal tension glaucoma
Primary open angle glaucoma (POAG) affects over 60 million
people worldwide and it is the second most common cause of legal
blindness in developed countries (Bunce and Wormald, 2006;
Quigley and Broman, 2006). RGCs are lost at an accelerated rate
compared with normal ageing, resulting in pathological disc
cupping and visual ﬁeld defects. POAG is a complex disease and
several genetic susceptibility loci have been identiﬁed in pop-
ulations from different ethnic backgrounds (Libby et al., 2005;
Wiggs, 2007; Ray and Mookherjee, 2009). The major risk factor
for POAG is elevated intraocular pressure (IOP), but in about a third
of patients, IOPs never exceed the statistical normal threshold of
21 mmHg (Boland and Quigley, 2007). Although lowering IOP can
reduce visual ﬁeld progression in normal tension glaucoma (NTG),
additional IOP-independent risk factors are considered to be more
important in the pathophysiology of NTG than in high tension
glaucoma (HTG) (Alward et al., 1998; Schulzer et al., 1998; Cheng
et al., 2009). The pattern of RGC loss in these two disease
subgroups has been extensively investigated, and in most studies,
NTG patients tended to have steeper, more focal ﬁeld defects, which
were located closer to ﬁxation compared with HTG patients (Araie
et al., 1997; Ahrlich et al., 2010). It is therefore not surprising that
patients with DOA are often misdiagnosed as having NTG, espe-
cially if there is no family history of early-onset visual loss (Trobe
et al., 1980; Fournier et al., 2001). Furthermore, disc pallor in DOA
can be quite subtle, involving only the temporal segment, and about
half of all patients have excavated discs, with cup-to-disc ratios
greater than 0.5 (Votruba et al., 1998a, 2003). Some investigators
have even argued, rather provocatively, that NTG is in actual fact an
inherited optic neuropathy representing a forme fruste of DOA
(Buono et al., 2002).
7.2. OPA1 polymorphisms
OPA1 was an obvious candidate disease-susceptibility gene in
glaucoma and we recently carried out a systematic screen of the
entire coding region using a well-characterised POAG cohort from
the North of England (Yu-Wai-Man et al., 2010e). No pathogenic
sequence variants were identiﬁed ruling out OPA1 as a monogenic
risk determinant for this disorder. Instead, we found a statistically
signiﬁcant association between two speciﬁc intronic OPA1 SNPs,
IVS8þ4c>t and IVS8þ32t>c, and the risk of developing NTG but
not HTG. Three other studies have found a similar association
between these two OPA1 SNPs and NTG, supporting a possible role
of the OPA1 protein in modulating disease susceptibility to glau-
coma (Aung et al., 2002; Powell et al., 2003; Mabuchi et al., 2007).
However, these ﬁndings have not been replicated in other pop-
ulations, and functional studies are needed to clarify the
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increase the risk of developing NTG (Sato et al., 2003; Woo et al.,
2004; Kumaramanickavel et al., 2005; Yao et al., 2006; Wolf et al.,
2009).
7.3. OPTN mutations
Mutations in four genes have been identiﬁed in families with
POAG: optineurin (OPTN, OMIM 602432), myocilin (MYOC, OMIM
610652), CYP1B1 (OMIM 601771), and WDR36 (OMIM 609669).
OPTN mutations are present in about 17% of families with auto-
somal-dominant NTG (Rezaie et al., 2002), but overall they are
relatively rare, accounting for less than 2% of sporadic cases
(Weisschuh et al., 2005; Hauser et al., 2006; Sripriya et al., 2006).
These studies, including the original report of OPTN mutations in
NTG, also suggest that the p.M98K OPTN variant could be an
important disease risk factor, being present in 10e15% of glaucoma
subjects comparedwith only 2e4% of normal controls. In one study,
the p.M98K variant was not found to be associated with DOA and
LHON, and it did not inﬂuence the severity or risk of visual loss
(Craig et al., 2006).
Intriguingly, OPTN mutations have also recently been identiﬁed
in Japanese individuals from consanguineous marriages and with
a familial form of amyotrophic lateral sclerosis (ALS) (Maruyama
et al., 2010). OPTN is a multifaceted protein and one of its impor-
tant functions is to protect cells against high levels of oxidative
stress by regulating the activation of NF-kB, an important compo-
nent of the extrinsic apoptotic pathway (De Marco et al., 2006; Zhu
et al., 2007; Chalasani et al., 2008). NF-kB is also found in both the
cytosol and mitochondrial compartments and its upregulation
inhibits cytochrome c oxidase and cytochrome bmRNA, disrupting
the structural integrity of the mitochondrial respiratory chain and
adversely affecting ATP synthesis (Chalasani et al., 2007). Further-
more, OPTN co-localises to the Golgi apparatus and it probably
plays an important role in membrane trafﬁcking and vesicular
transport (del Toro et al., 2009). The neuropathology in ALS is
characterised by the degeneration of upper and lower motor neu-
rones, and it is intriguing that OPTN mutations seem to have
a predilection for long neuronal populations, including RGCs, with
mitochondrial dysfunction being one of the likely pathogenetic
mechanisms (Shi et al., 2010).
8. Demyelination, optic neuritis, and multiple sclerosis
MS is an inﬂammatory demyelinating disease of the central
nervous system and as the disease progresses, extensive axonal loss
is observed in the brain and spinal cord (Frohman et al., 2005;
Balcer, 2006). The prevalence of MS varies worldwide and in pop-
ulations of Northern European extraction, the average quoted
ﬁgure is 1 in 1000 (Fox et al., 2004; Koch-Henriksen and Sorensen,
2010). Up to half of all patients with MS will experience an episode
of optic neuritis, and in 15e20% of cases, it is the ﬁrst manifestation
of an underlying demyelinative disorder (Arnold, 2005; Balcer,
2006). Optic neuritis classically presents acutely, with loss of
central vision, marked dyschromatopsia, and pain on eye move-
ment. Spontaneous visual recovery usually occurs two to three
weeks after the ﬁrst onset of symptoms and it is nearly complete
within the next four weeks. The overall visual prognosis is very
good and 1 year after an attack of optic neuritis, more than 90% of
patients have recovered their premorbid level of visual acuity (Beck
et al., 1993). However, in longitudinal studies of MS patients,
including those without a previous history of optic neuritis,
progressive RNFL thinning was noted on OCT, clearly indicating
a chronic process of subclinical RGC loss (Frohman et al., 2008;
Zaveri et al., 2008; Talman et al., 2010).Female LHON carriers are twice more likely to develop an MS-
like illness than male carriers, despite the fact that the risk of visual
loss is ﬁve times higher among males (Section 3.3.5). We propose
two main hypotheses to account for this association. It is possible
that subclinical disease in at-risk LHON carriers results in immu-
nogenic mitochondrial peptides being exposed, which trigger or
potentiate an autoimmune cascade against oligodendrocytes
(Loveland et al., 1990; Chalmers et al., 1995). Conversely, the
autoimmune process could be the primary pathological factor and
the deleterious consequences for oligodendrocytes are magniﬁed
by the presence of an underlying mtDNA defect, the latter putting
additional stress on mitochondrial oxidative metabolism (Mahad
et al., 2007; Mahad et al., 2009). The optic neuropathy in LHON
patients who develop an MS-like illness is invariably severe with
poor visual recovery and as such behaves differently from the
natural history of acute demyelinative optic neuritis. Presumably,
RGC axonal loss in these LHON-MS patients is ampliﬁed by
dysfunctional oligodendrocytes leading to demyelination or failure
of remyelination (Sapey et al., 2001; Mao and Reddy, 2010).
The link between mitochondrial dysfunction and MS is not
limited to the primary mtDNA LHON mutations. We recently
reported the occurrence of a more disseminated demyelinative
process in two independent DOA families with genetically-
conﬁrmed OPA1 mutations. Compound heterozygous POLG1
mutations have also been recently identiﬁed in a 4-year-old child
with presumed acute disseminated encephalomyelitis (ADEM)
(Harris et al., 2010), and in two patients in their thirties presenting
initially with unilateral optic neuritis, which subsequently evolved
into clinically-deﬁnite MS with classical white matter MRI abnor-
malities and unmatched CSF oligoclonal bands (Echaniz-Laguna
et al., 2010). In both adult MS cases, muscle biopsy revealed
numerous COX-negative ﬁbres, with prominent RRFs and multiple
mtDNA deletions on long-range PCR analysis.
9. Optic nerve head morphology and disease susceptibility
Unaffected LHON carriers have larger optic disc areas compared
with affected carriers and normal controls. Among affected LHON
carriers, visual recovery was associated with larger vertical but not
horizontal disc diameters, and there was a trend towards a better
visual outcome with larger optic disc areas (Ramos et al., 2009).
About 10% of LHON carriers experience visual loss before the age of
10 years, and in these childhood cases, two patterns of visual loss
havebeendescribed; anacutepresentation similar to theone seen in
adults, and a milder variant with a slowly progressive course
(Barboni et al., 2006). Compared to the slowly progressive group,
children with acute LHON had worse visual acuities, thinner peri-
papillary RNFL thickness, and signiﬁcantly smaller optic disc areas.
The results from these two studies therefore suggest a possible link
between optic disc anatomy and the phenotypic expression of the
primary mtDNA LHON mutations. Similar to anterior ischaemic
optic neuropathy (AION), a small crowded optic disc could predis-
pose LHON carriers to a higher risk of visual loss (Hayreh 2009a,b).
Transient and segmental RNFL swelling have been observed in
asymptomatic LHON carriers (Nikoskelainen et al., 1996, 1977), and
with theadventofOCT imaging, thickeningof the temporalRNFLhas
been documentedmore objectively, conﬁrming these earlier clinical
observations (Barboni et al., 2005, 2009; Savini et al., 2005; Seo et al.,
2009). The swelling of these RGC axons is secondary to axoplasmic
stasis and it reﬂects the compromised bioenergetic state within
theseneurones,whichare struggling tomaintain energy-dependent
cytoskeletal transport mechanisms (Section 10.3). If the optic nerve
axons are congenitally packed within a relatively conﬁned space,
under the right circumstances, a compartment syndrome could
result, further impeding axonal transport. As the ﬁne capillary
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surrounding tissue oedema, the resulting ischaemia could set up
avicious cycle,which eventually precipitates the onset of visual loss.
The concept of a “disc-at-risk” is also attractive in that it could
explain the role of environmental factors such as heavy smoking in
increasing the risk of disease conversion among LHON carriers.
Long-term heavy smokers are more likely to have atherosclerotic
vascular changes and these could further exacerbate a local hypoxic
insult at the optic nerve head.
In one study, OPA1 carriers had signiﬁcantly smaller optic disc
areas compared with normal controls (Barboni et al., 2010), and
although speculative, these ﬁndings were ascribed to the role
played byOPA1 in early embryonic development (Section 11.3.2). By
accentuating developmental apoptosis, OPA1 mutations could
result in a greater loss of RGCs and therefore a correspondingly
smaller optic nerve head. In support of this hypothesis, OPA1
carriers have thinner peripapillary RNFL measurements than
controls at all age groups, and extrapolating the data, it is likely that
these patients had lower RGC counts at birth (Fig. 9) (Milea et al.,
2010). If OPA1 does exert a developmental inﬂuence on optic
nerve head morphology, this could have important implications for
other ocular disorders such as NTG and optic nerve hypoplasia. One
could speculate that speciﬁc combinations of OPA1 variants could
have a subtle effect on the biomechanical characteristics of the
lamina cribosa, which is the principal site of IOP-related damage to
RGC axons (Burgoyne et al., 2005; Sigal and Ethier, 2009; Sigal et al.,
2010). The mechanical effect of IOP on load-bearing connective
tissues is accentuated at the lamina cribosa, and this will vary
depending on the unique susceptibility conferred by an individual’s
optic nerve head conﬁguration. In individuals with high-risk OPA1
genotypes and relatively weak optic nerve head biomechanics,
axonal damage could occur at relatively low IOPs, increasing the
risk of developing NTG. The aetiology of optic nerve hypoplasia is
poorly deﬁned and in 20% of cases, this abnormality occurs in
isolation, without more widespread cerebral malformations or
hypothalamic dysfunction (Borchert and Garcia-Filion, 2008). It
would therefore be of great interest to screen for OPA1 in a cohort of
patients with isolated optic nerve hypoplasia to determinewhether
some patients harbour pathogenic mutations, or whether there is
any association with speciﬁc polymorphic sequence variants.Fig. 9. Age-related decrease in average RNFL thickness, consistent with progressive
retinal ganglion cell loss among OPA1 mutational carriers (n ¼ 40). Spearman rank
correlation coefﬁcient ¼ 0.2419, P ¼ 0.0307 (PWYM, unpublished data).10. Greater vulnerability of retinal ganglion cells
10.1. Anatomical considerations
Both OPA1 and the primary LHON mutations result in a mito-
chondrial biochemical defect, but the same situation applies to
other cell types such as photoreceptors and substantia nigra neu-
rones, which have similar, if not higher, oxidative requirements
than RGCs. What other factors therefore contribute to this greater
vulnerability of RGCs in mitochondrial optic neuropathies? The
optic nerve has some rather peculiar anatomical constraints which
could inﬂuence the pathological consequences of these genetic
defects. One such feature is the fact that RGC axons only acquire
a myelin sheath beyond the lamina cribosa. In the pre-laminar
region, the generation and propagation of action potentials are
therefore less efﬁcient and require greater energetic input (Carelli
et al., 2004a; Morgan, 2004). To investigate this further, we per-
formed a series of histological studies of human optic nerves, ﬁrst
staining them for mitochondrial COX and succinate dehydrogenase
(SDH) enzyme activities (Andrews et al., 1999a; Bristow et al.,
2002). As we expected, the pre-laminar, unmyelinated optic
nerve demonstrated much more intense COX staining compared
with the post-laminar, myelinated segment, clearly indicating
a differential concentration of mitochondria across the lamina cri-
bosa (Fig. 10). The increased mitochondrial content within the
unmyelinated RGC axons was associated with a high density of
voltage gated sodium channels, reﬂecting the greater energy
requirements for nerve conduction in the absence of myelination
(Fig. 11) (Barron et al., 2004). The pre-laminar segment of the optic
nerve could therefore be viewed as a vulnerable metabolic
“chokepoint”, magnifying the consequences of any impairment in
mitochondrial OXPHOS, however subtle. Another important point
to consider is that parvocellular RGCs within the papillomacular
bundle have relatively small cross-sectional areas, which could put
them at an even greater physiological disadvantage in terms of
their mitochondrial reserve, compared with the larger magnocel-
lular RGCs (Sadun et al., 2000).
Another cranial nerve marked by such a dramatic transition
between unmeylinated and myelinated segments is the cochlear
nerve. Nearly two-thirds of all patients with DOAþ phenotypes
develop sensorineural deafness (Yu-Wai-Man et al., 2010b). It is
therefore very revealing that in two family members with optic
atrophy and hearing loss due to a pathogenic OPA1mutation, audi-
tory investigations localised thedefect to the terminal unmyelinated
portions of cochlear nerve (Huang et al., 2009). Transtympanic
electrocochleography revealed sub-threshold, abnormally-pro-
longed negative potentials within the unmyelinated auditory nerve
terminals suggesting a failure to generate action potentials at the
ﬁrst node of Ranvier.
10.2. Mitochondrial network dynamics
The mitochondrial network is in a constant state of ﬂux and it
relies on a delicate balance between fusional and ﬁssional forces.
Disruption of mitochondrial fusion can have dramatic conse-
quences on cell survival as clearly illustrated by OPA1 and MFN2
mutations. The role of mitochondrial network dynamics in main-
taining cellular homeostatis was conﬁrmed further when
a heterozygous, dominant-negative, DLP1 mutation was identiﬁed
in a female infant with a complex neurodegenerative phenotype
characterised by microcephaly, abnormal brain development, optic
atrophy, and disturbed metabolic function (Waterham et al., 2007).
Themitochondrial network in the patient’s cultured ﬁbroblasts was
elongated, forming tangled tubular structures, which were clum-
ped around the nucleus. DLP1 codes for DRP1, a pro-ﬁssion,
Fig. 10. Optic nerve sections stained for myelin and mitochondrial COX activity: (A)
Sudan black staining revealing the presence of myelin posterior to the lamina cribosa,
(B) marked differential COX activity in the pre- and post-lamina cribosa segments,
with intense COX staining in transverse sections taken from the pre-laminar region (C),
and signiﬁcantly lower levels of COX activity in the pos-tlaminar region (D). Repro-
duced with permission from Andrews et al. (1999a).
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a dominant-negative loss of function, resulting in unopposed
mitochondrial fusion. A dysfunctional mitochondrial network can
obviously impact on other cellular processes such as axonal trans-
port, but as such, it still does not explain the selective vulnerability
of RGCs. Some important clues were uncovered by Kamei et al.
(2005), who transfected cultured rat RGCs and cerebellar granule
cells (CGCs) with short interfering RNAs (siRNAs) against Opa1
transcripts. RGCs were much more susceptible to these Opa1-
blocking siRNAs and they exhibited a greater degree of mitochon-
drial fragmentation compared with CGCs, reﬂecting the predomi-
nant optic nerve phenotype seen in patients with DOA.
10.3. Mitochondrialecytoskeletal interactions
Mitochondria do not exist in isolation and an intricate cyto-
skeletal system is essential for their proper localisation to areas of
increased energetic demands (Fig. 12) (Das et al., 2010). These
mitochondrialecytoskeletal interactions apply not only to the
lamina cribosa, but also to other sites requiring the maintenance of
a differential mitochondrial gradient such as the nodes of Ranvier.
Axonal transport along the relatively long RGC axons is mainlydependent on the microtubule tracks, which are powered by the
energy-dependent dynein and kinesin family of motor proteins
(Yaffe et al., 2003; Boldogh and Pon, 2007). Conceptually, abnormal
axonal transport could therefore be disrupted by two processes,
either a mitochondrial biochemical defect or a primary problem
with the assembly andmaintenance of themicrotubule network, as
seen in the HSP group of disorders (Salinas et al., 2008). The
distinction is somewhat artiﬁcial in that one will precipitate the
other, setting up a vicious circle leading to axonal swelling due to
axoplasmic stasis, and ultimately axonal degeneration marked by
theonset andprogressionof clinical symptoms (Morﬁni et al., 2009).
10.4. Light and mitochondrial toxicity
RGCs are constantly being exposed to light in the 400e760 nm
wavelength spectra, the cornea and the lens effectively blocking
ultraviolet light below 400 nm. The blue component of visible light
has the shortest wavelength and in studies of the retinal pigment
epithelium and photoreceptors, it had the greatest potential for
inducing cellular ROS production. Photoreceptors are partially
shielded by macular lutein and zeoxanthin pigments (Chen et al.,
2001; Landrum and Bone, 2001), whereas mitochondria within
the pre-laminar, unmyelinated RGC axons are directly exposed to
light and do not have the beneﬁt of these protective mechanisms. It
is therefore possible that chronic light exposure could tip the
balance in RGCs already compromised by a genetically-determined
mitochondrial respiratory chain defect. This hypothesis has been
partially tested in RGC-5 cell lines exposed to incremental light
intensities, and cultured in both normal media and conditions of
serum deprivation (Lascaratos et al., 2007; Osborne et al., 2008).
Light exposure resulted in the generation of a signiﬁcant amount of
ROS in these RGC-5 cells, an effect which was intensity-dependent
and exacerbated in conditions of nutritional deprivation. This light-
induced elevation in ROS levels affected cellular viability by sup-
pressing the expression of RGC-speciﬁc mRNAs and triggering the
apoptotic cascade. Additional studies are therefore warranted to
investigate the consequences of light exposure on RGC survival in
mitochondrial optic nerve disorders, and for that purpose, both
patient cell lines and existing animal models could be used
(Lascaratos et al., 2007; Osborne et al., 2008).
10.5. Melanopsin retinal ganglion cells
Much attention has focused on the selective vulnerability of
RGCs in mitochondrial optic neuropathies. However, immunohis-
tochemical analysis of post-mortem eyes from patients with LHON
and DOA has revealed relative sparing of a speciﬁc subpopulation of
melanopsin-containing RGCs (La Morgia et al., 2010). These mela-
nopsin RGCs constitute only about 1% of the total RGC population,
but they subserve an important evolutionary role, regulating the
body’s circadian rhythm as part of the retino-hypothalamic tract.
The relative sparing of these melanopsin RGCs in LHON and DOA
also explain to a certain extent the normally preserved pupillary
light reﬂexes in these two disorders. The inherent resistance of
melanopsin RGCs to mitochondrial dysfunction is tantalising and it
could reveal key protective mechanisms that could be applied to
neuroprotection of the larger pool of susceptible RGCs.
11. Experimental disease models
11.1. Drosophila dOpa1 mutants
Yarosh et al. (2008) have recently established a Drosophila
model harbouring a speciﬁc dOpa1 mutation (CG8479), and the
ocular phenotypes associated with heterozygous and homozygous
Fig. 11. Histology, mitochondrial histochemistry and immunohistochemistry (IHC) performed on serial longitudinal optic nerve sections: (A) haematoxylin and eosin, (B) Van
Gieson preparation for connective tissue ﬁbres (Red), with the arrow pointing towards the lamina cribosa, (C) Weigert iron haematoxylin preparation for myelin (Dark blue), (D) COX
activity, with a darker stain (Brown) evident in the unmyelinated pre-lamina cribosa segment of the optic nerve, (E) IHC for COX subunit IV revealing a pattern consistent with the
level of mitochondrial enzyme activity, (F ) IHC for Nav 1.1 showing a greater concentration of these speciﬁc voltage gated Naþ channels in the pre-laminar region, (G) IHC for Nav 1.2
demonstrating a uniformly pale labelling pattern in both pre- and post-lamina cribosa areas, (H) IHC for Nav 1.6 with a strong staining reaction observed in the unmyelinated pre-
laminar optic nerve, and (I) control optic nerve section with the primary antibody omitted. Reproduced with permission from Barron et al. (2004).
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a rough and glossy eye phenotype due to the loss of hexagonal
lattice cells, and decreased lens and pigment deposition. The dOpa1
mutation caused an increase in ROS levels and mitochondrial
fragmentation, which damaged both cone and pigment cells. In
a series of elegant experiments, these investigators were then able
to demonstrate that the rough and glossy eye phenotype could be
partially reversed by dietary supplementation with SOD-1 and
vitamin E, and by genetic overexpression of human SOD1. Hetero-
zygous adult ﬂies did not exhibit any ocular abnormalities, but
similar to the homozygous mutants, they also demonstrated
elevated ROS levels and a greater susceptibility to oxidative stress.
The heteterozygous drosophila carriers showed irregular and dys-
morphic mitochondria in their muscle, and they had a signiﬁcantly
shortened lifespan, which was only partially restored by anti-
oxidant treatment (Shahrestani et al., 2009; Tang et al., 2009).
11.2. Zebraﬁsh opa3 mutants
High levels of opa3 mRNA transcripts are present in the central
nervous system of zebraﬁsh (Danio rerio), including the optic nerve
and retinal layers. Zebraﬁsh embryos were therefore engineeredharbouring a 5.2 kb retroviral DNA insertion immediately down-
stream of the mitochondrial leader signal, which disrupts the opa3
reading frame and results in a premature termination codon (Pei
et al., 2010). Five-days-old homozygous mutant embryos (opa3ZM/
ZM) had increased MGA levels, recapitulating the biochemical
signature of patients with Costeff syndrome (Section 4.3). A
signiﬁcant loss of RGCs together with a reduction in optic nerve
diameter was also observed on histological analysis of 1-year-old
opa3ZM/ZM zebraﬁsh mutants, conﬁrming the role of opa3 in
preserving RGC function. In addition, these homozygous mutants
demonstrated extra-ocular deﬁcits with dramatic alterations in
swimming behaviour secondary to ataxia, loss of buoyancy control,
and hypokinesia.
11.3. Current murine models
11.3.1. LHON
There is still no animal model where the primary LHON muta-
tions have been successfully introduced into the mitochondrial
genome. In spite of these technical difﬁculties, four experimental
techniques have been developed which can replicate the optic
nerve degeneration seen in LHON: (i) intravitreal injection of
Fig. 12. The importance of the cytoskeleton in maintaining the differential concen-
tration of mitochondria in the pre- and post-lamina cribosa segments of the optic
nerve. The left panel shows a longitudinal section of a human optic nerve stained
sequentially for COX and SDH. The pre-lamina, unmyelinated segment has a much
darker COX staining consistent with the higher concentration of mitochondria. The
right panel is a schematic representation of the cytoskeletalemitochondrial interac-
tions which facilitate the transport, distribution, and localisation of mitochondria to
different areas of the optic nerve.
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stereotactic injection of biodegradable rotenone-loaded micro-
spheres into the optical layer of the superior colliculus (Marella
et al., 2010), (iii) downregulation of nuclear-encoded complex I
subunits (e.g. NFUFA1) with speciﬁc mRNA-degrading ribozymes
(Qi et al., 2003), and (iv) allotopic expression of mutant subunits
(e.g. MTND4) which are then imported into the mitochondria (Qi
et al., 2007b; Ellouze et al., 2008). These disease models will be
indispensable when testing the feasibility of gene therapy in LHON,
and different strategies are currently being pursued (Section 12.4).
11.3.2. Opa1
Two DOA mouse models have been developed which harbour
pathogenic mutations in exon 8 (c.1051C>T) and intron 10
(c.1065þ5g>a) of the Opa1 gene (Alavi et al., 2007; Davies et al.,
2007). These mutations are truncative in nature and they result in
a 50% reduction in the overall expression of theOpa1protein. In both
models, homozygous mutant mice (Opa1/) died in utero during
embryogenesis, highlighting the central role played by the Opa1
protein inearlydevelopment.HeterozygousOpa1þ/mice faithfully
replicated the human phenotype exhibiting a slowly progressive
optic neuropathy and demonstrating objective reduction in visual
function on psychophysical testing. Visual evoked potential (VEP)
measurements showed signiﬁcantly reduced amplitudes, but no
change in latencies, supporting an ascending progress of degenera-
tion from the soma towards the axon (Heiduschka et al., 2010).
Histological and retrograde labelling experiments conﬁrmed
a gradual loss of RGCs and an associated thinning of the retinal nerve
ﬁbre layer. The surviving optic nerve axons had an abnormal
morphology with swelling, distorted shapes, irregular areas of
demyelination and myelin aggregates. These features of optic nerve
degeneration were seen as early as 9 months, but they were much
more visible by 24 months. Loss of dendritic arborisation was
observed for on- but not off-centre RGCs, these early features of
neuronal dysfunction preceding the onset of axonal loss (Williams
et al., 2010). An increased number of autophagosomes was also
noted in the RGC layer of heterozygous Opa1þ/mice at later time
points, probably due to the accumulation of dysfunctionalmitochondria (White et al., 2009). Mitochondria within these axons
showed disorganised cristae structures on transmission electron
microscopy and cultured ﬁbroblasts showed increased mitochon-
drial network fragmentation. To further investigate the extent of
mitochondrial dysfunction, we carried out additional histochemical
andmolecular genetic studies onboth theseDOAmousemodels (Yu-
Wai-Man et al., 2009a). COX deﬁciency and multiple mtDNA dele-
tions were not detected in sketelal muscle and the RGC layer of
heterozygous mutant mice, implicating other Opa1-related disease
mechanisms in precipitating optic nerve degeneration.
A third Opa1 mouse model is currently being characterised
harbouring a heterozygous c.2708-2711delTTAG mutation in
exon27. Heterozygous mutant mice are showing signs of optic
nerve degeneration from the age of 6 months, with subnormal
VEPs, and abnormal mitochondrial distribution, especially in the
lamina cribosa region (Dr Guy Lenaers, Montpellier, personal
communication). All these Opa1 mouse models only manifest pure
optic atrophy, and it will be important to create a DOAþ mouse
model in order to dissect the mechanisms which contribute to
multi-system organ involvement.
The role played by Opa1 in early mouse embryogenesis was
recently conﬁrmed in the lilR3mutantmousewhere a proportion of
embryos was noted to die at midgestation (E11.5) displaying
growth retardation, exencephaly, and abnormal patterning along
the anterioreposterior axis (Moore et al., 2010). Using a meiotic
mapping strategy, Moore et al. (2010) uncovered the genetic basis
for this embryonic lethality by identifying a homozygous splice site
mutationwithin intron 19 of the Opa1 gene, which results in a 6-bp
intronic sequence insertion. As a result of this Opa1 mutation, the
mutant Opa1 protein is mislocalised, remaining within the cytosol
instead of being properly translocated to the mitochondrial inner
membrane.
11.3.3. Opa3
An Opa3 mouse model carrying a c.365T>C (p.L122P) muta-
tion has been reported (Davies et al., 2008). Heterozygous
Opa3þ/ mice were not compromised, whereas homozygous
Opa3/ mice developed multi-system organ failure with
cachexia, dilated cardiomyopathy, extrapyramidal features, and
a reduced lifespan of less than 4 months. These mice had severely
impaired visual function, and although all the retinal layers were
affected, cell loss was much more prominent within the RGC
layer, further reinforcing the selective vulnerability of this
speciﬁc cell type.
11.3.4. Glaucoma
A series of papers has been reported by the Weinreb group
exploring the relationships between Opa1 and IOP-mediated RGC
loss in murine glaucoma models (Ju et al., 2008a,b, 2009a,b, 2010).
Several interesting observationsweremade: (i) increased IOPs led to
apoptotic RGC loss, which was preceded by mitochondrial network
fragmentation, and marked Opa1 and cytochrome c release into the
cytosol, (ii) the IOP effect was mediated by glutamate receptor acti-
vation,which could be blocked by theN-methyl-D-aspartate (NMDA)
glutamate receptor antagonist memantine, and (iii) overexpression
of Opa1 with an adenovirus-associated virus (AAV) vector was
protective against RGC death in glaucomatous optic neuropathy.
11.4. In vivo imaging of retinal ganglion cells
Analysis of ﬁxed retinal whole mount preparations is time-
consuming and rather limited given that the animal in question
needs to be sacriﬁced. A better understanding of the complex
pathological mechanisms underlying inherited optic neuropathies
will therefore require more sophisticated in vivo techniques for
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long-term serial monitoring of various cellular processes. Apoptosis
has been implicated in all mitochondrial optic neuropathies and
a non-invasive system which allows RGC death to be visualised
directly would be a major research tool. Glaucoma investigators are
working on different experimental paradigms, which include (i)
retrograde labelling of RGCs, with tracer injection at the superior
colliculus (Kobbert et al., 2000; Gray et al., 2008), (ii) transduction of
RGCs following intravitreal injection of a recombinant AAV vector
carrying GFP (Folliot et al., 2003), and (iii) DARC (Detection of
apoptosing retinal cells) with intravitreal injection of ﬂuorescently-
labelled annexin 5, which binds to exposed phosphatidylserine in
early stages of apoptosis (Cordeiro et al., 2004; Guo and Cordeiro,
2008).
All these apoptosis-imaging techniques are invasive and they
require repeated injections, with the possibility of introducing non-
disease-related artefacts. To overcome these technical issues,
various groups have generated transgenic mice which express
a ﬂuorescent marker such as GFP, under a speciﬁc RCG promoter
such as Thy-1 (Walsh and Quigley, 2008; Leung and Weinreb,
2009). Although further improvement in transfection efﬁciency is
needed, RGCs which are successfully transfected can be visualised
using a standard confocal scanning laser ophthalmoscope (CSLO),
with the mouse anaesthesised on an appropriately adapted
microscope stage. Using this protocol, extremely detailed RGC
images can be obtained including cell body morphology and the
extent of dendritic arborisation. Furthermore, coupled with the
intravitreal injections of tracer agents, time-lapsed sequences
would allow axonal transport to be quantiﬁed both in the pre- and
post-laminar segments of the optic nerve. The application of these
new imaging modalities to both existing and future animal models
of mitochondrial optic neuropathies will be a major breakthrough,
allowing for example early subclinical RGC abnormalities to be
detected, and the therapeutic potential of putative neuroprotective
agents to be assessed at a more functional level.
12. Treatment strategies for inherited optic neuropathies
12.1. Genetic counselling
Male carriers harbouring mtDNA point mutations can be reas-
sured that their children are not at risk of inheriting their genetic
defect. Female carriers will transmit the mutation to all their
offspring, but if the mutation is heteroplasmic, it is not possible to
reliably predict the mutational level that will be transmitted. As
discussed earlier, signiﬁcant variations in heteroplasmy levels can
occur as a result of the mitochondrial genetic bottleneck. The use of
amniocentesis or chorionic villus sampling for prenatal testing is
therefore limited in this situation, as the mutational load detected
in amniocytes and chorionic villus cells could differ from other
foetal tissues, especially those at greater risk from a speciﬁc mtDNA
point mutation such as RGCs (Brown et al., 2006). Although it is not
possible to accurately predict whether a LHON carrier will even-
tually lose vision, individuals can be counselled based on the two
major identiﬁable risk factors in this disorder, age and gender. Male
carriers have about a 50% lifetime risk of visual failure compared
with only 10% for female carriers, andmost patients will experience
visual loss in their late teens and twenties. The probability of
becoming affected decreases subsequently and disease conversion
in LHON is rare over the age of 50 years. The risks of transmission
for nuclear mitochondrial disorders follow the laws of Mendelian
inheritance, but if a speciﬁc nuclear defect has not been identiﬁed,
only an approximate risk can be provided based on the family
history. As a result of the marked inter- and intra-familial pheno-
typic variability seenwith both pure and syndromal inherited opticneuropathies, genetic counselling for patients and their families
remains a challenging area of practice.
12.2. Supportive measures
The treatment options for patients with inherited optic
neuropathies are currently limited (Chinnery et al., 2006).
However, there are several practical steps that can be taken as part
of a multi-disciplinary team to improve a patient’s quality of life,
and minimise long-term morbidity (Yu-Wai-Man et al., 2009b;
Fraser et al., 2010). Depending on their needs, these patients
should be provided with access to facilities such as low visual aids
and occupational therapy, and clinicians can help with ﬁnancial
assistance through their local social services. It is also important to
aggressively manage related medical problems such as diabetes
and epilepsy, and clinicians need to be vigilant to the development
of new complications such as cardiomyopathy and sensorineural
deafness, which could be amenable to therapeutic intervention.
Patients with mitochondrial disorders should be strongly advised
not to smoke and to minimise their alcohol intake, not only as
a general health measure, but smoking, and to a lesser extent
excessive alcohol intake, have been linked with an increased risk of
visual loss among LHON carriers (Kirkman et al., 2009b). Patients
with CPEO often get signiﬁcant beneﬁt from simple conservative
measures such as ptosis props or Fresnel prisms for symptomatic
ocular misalignment (Richardson et al., 2005). In some cases,
strabismus and ptosis surgery are indicated but these should be
performed by experienced surgeons (Shorr et al., 1987; Ahn et al.,
2008), because of the increased risk of complications such as
corneal exposure secondary to poor orbicularis oculi function and
impaired Bell’s phenomenon (Daut et al., 2000).
12.3. Neuroprotection
On the basis of limited, mostly anecdotal evidence, various
combinations of pharmacological agents have been used to treat
patients with mitochondrial disorders including multi-vitamin
supplements, co-enzyme Q10 (CoQ10) and its derivatives, and
putative free radical scavengers (Horvath et al., 2008; Tarnopolsky,
2008; Schon et al., 2010). There is relatively more clinical data on
the use of CoQ10, which has shown a clear beneﬁt for patients with
primary CoQ10 deﬁciency. In one randomised, double-blind,
crossover study of 16 patients with mitochondrial cytopathies,
a combination of CoQ10 with creatine monohydrate and a-lipoic
acid, reduced the levels of resting plasma lactate and oxidative
stress markers (Rodriguez et al., 2007).
Idebenone is a synthetic analogue of CoQ10, and it is currently
being investigated as a treatment option for LHON and other
neurodegenerative disorders such as FRDA. Idebenone is able to
operate under low oxygen tension and it is thought to have anti-
oxidant properties, in addition to optimising ATP production by the
respiratory chain complexes (Tonon and Lodi, 2008; Sacconi et al.,
2010). Initial reports of idebenone therapy in FRDA showed prom-
ising results with an improvement in both cardiac and neurological
status (Rustin et al., 2004; Di Prospero et al., 2007). However,
preliminary data released from two recently completed rando-
mised controlled trials have proven rather disappointing, with no
signiﬁcant difference in primary cardiac and neurological endpoints
between the idebenone-treated and placebo groups. (http://www.
santhera.com/index.php?docid¼212&vid¼&lang¼en&newsdate¼
201005&newsid¼1417424&newslang¼en, Accessed 1st of Dece-
mber 2010). In a retrospective study of 28 affected LHON patients,
half of whom received a combination of idebenone, vitamin B2, and
vitamin C for at least 1 year, the treated group showed a faster rate
of visual recovery (Mashima et al., 2000). However, in amore recent
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prevent second-eye involvement in two m.11778G>A LHON
carriers treated after the onset of unilateral visual loss, and both
patients showed no improvement in visual function (Barnils et al.,
2007). The beneﬁts of idebenone in LHON therefore remain
unclear, but being a safe drug, it is often recommended by clinicians
or self-prescribed by patients. In collaborationwith clinical partners
in Germany and Canada, we recently completed a double-blind
randomised placebo-controlled trial of idebenone in LHON. The
preliminary results suggest a beneﬁcial effect, especially among
patients with recent disease onset, and relatively good remaining
visual acuity in the second eye to become affected. (http://www.
santhera.com/index.php?docid¼212&vid¼&lang¼enamp;newsdate
¼201006&newsid¼1424223&newslang¼en, Accessed 1st of
December 2010). If these initial ﬁndings are conﬁrmed, idebenone
could also be considered as a neuroprotective agent for other
mitochondrial optic neuropathies such as DOA, although long-term
follow-up will be required given the relatively slower rate of RGC
loss in this disorder.
Brimonidine is a topical a-2 agonist used in the management of
glaucoma for its IOP-lowering properties. In addition, studies based
onmodels of opticnerve ischaemiahavesuggested thatbrimonidine
could have an anti-apoptotic effect, mitigating RGC loss (Wheeler
et al., 2003). On this basis, topical brimonidine has been tested as
prophylactic agent for second-eye involvement in an open-labelled
studyof 9 patientswithunilateral acute vision fromLHON(Newman
et al., 2005). Brimonidine failed to prevent fellow eye involvement
and there was no evidence of improved visual beneﬁt following the
onset of visual loss. In the long term, neuroprotection for LHON
remains anattractive treatmentoptiongiven theeasyaccessibilityof
ocular tissues to various forms ofmanipulation. Various agents have
been shown to have RGC-neuroprotective properties in other
models of optic nerve degeneration such as memantine, valproic
acid (Biermann et al., 2010), prostaglandin J2 (PGJ2) (Touitou et al.,
2010), and SIRT-1 activators (Shindler et al., 2007). It is not incon-
ceivable an effective agent will soon become available in clinical
practice, which could be safely delivered intravitreally, providing an
instantaneous local protective effect.
12.4. Gene therapy
Classical gene therapy is proving very challenging for primary
mitochondrial disorders, because the tools required for successful
gene transfer into the mitochondrial genome is still not available
(DiMauro and Mancuso, 2007; Kyriakouli et al., 2008; DiMauro and
Rustin, 2009). The mitochondrial inner membrane represents
a signiﬁcant physical barrier that needs to be overcomed, and given
the large number of mitochondria per cell, a highly efﬁcient vector
will be required to achieve an adequate level of transfection. To
bypass these difﬁculties, allotopic strategies have been developed
where the gene of interest is transfected into the nuclear genome,
usually with an AAV vector (Manfredi et al., 2002; Qi et al., 2007a).
The protein product has a mitochondrial targeting sequence and as
a result, it gets imported into themitochondrial compartment, either
replacing the missing protein or complementing the dysfunctional
mutant protein.
In both in vitro and in vivo experimental LHON models, RGC loss
was dramatically reduced by transfecting themwith an AAV vector
containing the human SOD2 gene (Qi et al., 2004, 2007a). The
increased expression of the superoxide dismutase enzyme is
thought to improve RGC survival by minimising free radical
damage, and decreasing the cell’s susceptiblity to apoptosis. Allo-
topic rescue, with the replacement of the defective mitochondrial
complex subunit, is another attractive option for gene therapy in
LHON. Proof-of-principle for this approach has been demonstratedin a rat model expressing a defective ND4 gene containing the
m.11778A>G primary LHONmutation (Ellouze et al., 2008). The loss
of visual function in these rats was reversed by transfecting RGCs
with the wild-type ND4 gene, using an in vivo electroporation
technique instead of an AAV vector. The transgene became stably
integrated within the nuclear genome and the level of expression
achieved was sufﬁcient for successful RGC neuroprotection. These
early studies of allotopic rescue in LHON are promising, but the
results need to be replicated in larger animals, and long-term safety
data is essential before human clinical trials can be contemplated
(Friedmann, 2000; Miller, 2008). The same caveats will apply to
proposed gene therapy strategies for nuclear mitochondrial disor-
ders. Issues of safety and efﬁcacy are especially relevant given the
signiﬁcant concerns that have been raised recently about the
limitations of allotopic rescue in the treatment of primary mtDNA
disorders (Figueroa-Martinez et al., 2010; Perales-Clemente et al.,
2010). As yet, there is no conclusive experimental evidence that
allotopically-expressed mitochondrial subunits can be properly
integrated into fully-assembled OXPHOS complexes. Mitochond-
rially-encoded complex I subunits are also highly hydrophobic and
if a proportion of these polypeptides is not imported, they could
have deleterious consequences by physically aggregating into the
cytosol or triggering an inappropriate immune response.
12.5. Preventing transmission of pathogenic mutations
Following successful fertilisation, two distinct structures can be
observed within the fertilised oocyte, known as the male and
female pronuclei (Brown et al., 2006). Given the lack of treatment
for mitochondrial disorders, pronuclear transfer is currently being
investigated as a method to prevent the transmission of mtDNA
mutations in human embryos (Tachibana et al., 2009; Craven et al.,
2010). This strategy involves the replacement of the entire mito-
chondrial population, by transferring karyoplast containing the
pronuclei from a donor zygote to an enucleated recipient zygote. In
a landmark study using abnormally-fertilised human zygotes,
Craven et al. (2010) have shown that pronuclear transfer resulted in
minimal carry-over of donor zygote mtDNA, and it was compatible
with successful progression to the blastocyst stage. Preimplanta-
tion genetic diagnosis for nuclear defects is well established and it
does not involve the same degree of complexity faced with mtDNA
mutations.
13. Future directions
The past decade has seen signiﬁcant advances in the way both
clinicians and basic scientists approach inherited optic neuropa-
thies. With greater access to molecular genetic testing, the pheno-
typic spectrum of classical optic nerve disorders such as LHON and
DOA has expanded to encompass a much wider range of clinical
features, some overlappingwith other neurodegenerative disorders
such as CMT, HSP, and even MS. Mitochondrial optic neuropathies
could therefore be used as models to understand key pathophysi-
ological aspects of these complex disorders, the optic nerve being
relatively accessible and amenable to direct measurements with
non-invasive imaging modalities. A fundamental change in our
understanding is the realisation that in a signiﬁcant number of
genetically-determined optic nerve disorders, including glaucoma,
mitochondrial dysfunction is likely to be part of a ﬁnal common
pathway mediating RGC loss. However, there are still more ques-
tions than answers e What combination of secondary factors will
eventually prove to be the basis for the marked incomplete pene-
trance and male bias in LHON? What disease mechanisms explain
multi-system tissue involvement in OPA1 carriers with DOAþ
phenotypes, when other family members harbouring the same
P. Yu-Wai-Man et al. / Progress in Retinal and Eye Research 30 (2011) 81e114 105mutation only have pure optic nerve involvement? Conversely, why
is it that only some patientswithMFN2 and SPG7mutations develop
visual failure and optic atrophy? With rapid advances in genetic
technology, bioinformatics, and molecular biology, the next decade
will be an exciting time in this area of research. We are hopeful that
these future breakthroughs will translate into much-needed,
effective treatment strategies for LHON, DOA, and other mito-
chondrial optic neuropathies.
Conﬂicts of interest
None of the authors have any ﬁnancial interests to disclose.
Acknowledgements
This work was supported by a Medical Research Council (MRC,
UK) Clinical Research Fellowship in Neuro-Ophthalmology to
PYWM (G0701386). PFC is a Wellcome Trust Senior Fellow in
Clinical Science and an NIHR Senior Investigator. PFC also receives
funding from Parkinson’s UK, the Association Française contre les
Myopathies, the Medical Research Council Translational Muscle
Centre, and the UK NIHR Biomedical Research Centre in Ageing and
Age-related Disease.
References
Ahn, J., Kim, N.J., Choung, H.K., Hwang, S.W., Sung, M., Lee, M.J., et al., 2008. Frontalis
sling operation using silicone rod for the correction of ptosis in chronic progres-
sive external ophthalmoplegia. British Journal of Ophthalmology 92,1685e1688.
Ahrlich, K.G., De Moraes, C.G.V., Teng, C.C., Prata, T.S., Tello, C., Ritch, R., et al., 2010.
Visual ﬁeld progression differences between normal-tension and exfoliative
high-tension glaucoma. Investigative Ophthalmology & Visual Science 51,
1458e1463.
Aijaz, S., Erskine, L., Jeffery, G., Bhattacharya, S.S., Votruba, M., 2004. Developmental
expression proﬁle of the optic atrophy gene product: OPA1 is not localized
exclusively in the mammalian retinal ganglion cell layer. Investigative
Ophthalmology & Visual Science 45, 1667e1673.
Akepati, V.R., 2008. Characterization of OPA1 isoforms isolated from mouse tissues.
Journal of Neurochemistry 106, 372e383.
Alavi, M.V., Bette, S., Schimpf, S., Schuettauf, F., Schraermeyer, U., Wehrl, H.F., et al.,
2007. A splice site mutation in the murine Opa1 gene features pathology of
autosomal dominant optic atrophy. Brain 130, 1029e1042.
Alberio, S., Mineri, R., Tiranti, V., Zeviani, M., 2007. Depletion of mtDNA: syndromes
and genes. Mitochondrion 7, 6e12.
Alexander, C., Votruba,M., Pesch,U.E.A., Thiselton,D.L.,Mayer, S.,Moore,A., et al., 2000.
OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant
optic atrophy linked to chromosome 3q28. Nature Genetics 26, 211e215.
Alward, W.L., Feldman, F., Cashwell, L.F., Wilensky, J., Geijssen, H.C., Greeve, E., et al.,
1998. The effectiveness of intraocular pressure reduction in the treatment of
normal-tension glaucoma. American Journal of Ophthalmology 126, 498e505.
Amati-Bonneau, P., Guichet, A., Olichon, A., Chevrollier, A., Viala, F., Miot, S., et al.,
2005. OPA1 R445H mutation in optic atrophy associated with sensorineural
deafness. Annals of Neurology 58, 958e963.
Amati-Bonneau, P., Odent, S., Derrien, C., Pasquier, L., Malthiery, Y., Reynier, P., et al.,
2003. The association of autosomal dominant optic atrophy and moderate
deafness may be due to the R445H mutation in the OPA1 gene. American
Journal of Ophthalmology 136, 1170e1171.
Amati-Bonneau, P., Valentino, M.L., Reynier, P., Gallardo, M.E., Bornstein, B.,
Boissiere, A., et al., 2008. OPA1 mutations induce mitochondrial DNA instability
and optic atrophy plus phenotypes. Brain 131, 338e351.
Anderson, S., Bankier, A.T., Barrell, B.G., de Bruijn, M.H., Coulson, A.R., Drouin, J., et
al., 1981. Sequence and organization of the human mitochondrial genome.
Nature 290, 457e465.
Andrews, R.M., Grifﬁths, P.G., Johnson, M.A., Turnbull, D.M., 1999a. Histochemical
localisation of mitochondrial enzyme activity in human optic nerve and retina.
British Journal of Ophthalmology 83, 231e235.
Andrews, R.M., Kubacka, I., Chinnery, P.F., Lightowlers, R.N., Turnbull, D.M.,
Howell, N., 1999b. Reanalysis and revision of the Cambridge reference sequence
for human mitochondrial DNA. Nature Genetics 23, 147.
Anikster, Y., Kleta, R., Shaag, A., Gahl, W.A., Elpeleg, O., 2001. Type III 3-methyl-
glutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy
syndrome): identiﬁcation of the OPA3 gene and its founder mutation in Iraqi
Jews. American Journal of Human Genetics 69, 1218e1224.
Araie, M., Kitazawa, M., Koseki, N., 1997. Intraocular pressure and central visual ﬁeld
of normal tension glaucoma. British Journal of Ophthalmology 81, 852e856.
Arnold, A.C., 2005. Evolving management of optic neuritis and multiple sclerosis.
American Journal of Ophthalmology 139, 1101e1108.Artal-Sanz, M., Tavernarakis, N., 2009. Prohibitin and mitochondrial biology. Trends
in Endocrinology and Metabolism 20, 394e401.
Assink, J.J.M., Tijmes, N.T., ten Brink, J.B., Oostra, R.J., Riemslag, F.C., deJong, P., et al.,
1997. A gene for X-linked optic atrophy is closely linked to the Xp11.4-Xp11.2
region of the X chromosome. American Journal of Human Genetics 61, 934e939.
Aung, T., Ocaka, L., Ebenezer, N.D., Morris, A.G., Krawczak, M., Thiselton, D.L., et al.,
2002. A major marker for normal tension glaucoma: association with poly-
morphisms in the OPA1 gene. Human Genetics 110, 52e56.
Balcer, L.J., 2006. Optic neuritis. New England Journal of Medicine 354, 1273e1280.
Ban, T., Heymann, J.A.W., Song, Z.Y., Hinshaw, J.E., Chan, D.C., 2010. OPA1 disease
alleles causing dominant optic atrophy have defects in cardiolipin-stimulated
GTP hydrolysis and membrane tubulation. Human Molecular Genetics 19,
2113e2122.
Baracca, A., Solaini, G., Sgarbi, G., Lenaz, G., Baruzzi, A., Schapira, A.H., et al., 2005.
Severe impairment of complex I-driven adenosine triphosphate synthesis in
leber hereditary optic neuropathy cybrids. Archives of Neurology 62, 730e736
[see comment].
Barbet, F., Gerber, S., Hakiki, S., Perrault, I., Hanein, S., Ducroq, D., et al., 2003. A ﬁrst
locus for isolated autosomal recessive optic atrophy (ROA1) maps to chromo-
some 8q. European Journal of Human Genetics 11, 966e971.
Barbet, F., Hakiki, S., Orssaud, C., Gerber, S., Perrault, I., Hanein, S., et al., 2005.
A third locus for dominant optic atrophy on chromosome 22q. Journal of
Medical Genetics, 42.
Barbiroli, B., Montagna, P., Cortelli, P., Iotti, S., Lodi, R., Barboni, P., et al., 1995.
Defective brain and muscle energy-metabolism shown by in-vivo P-31
magnetic-resonance spectroscopy in nonaffected carriers of 11778-mtDNA
mutation. Neurology 45, 1364e1369.
Barboni, P., Carbonelli, M., Savini, G., Foscarini, B., Parisi, V., Valentino, M.L., et al.,
2010. OPA1 mutations associated with dominant optic atrophy inﬂuence optic
nerve head size. Ophthalmology 117, 1547e1553.
Barboni, P., Carbonelli, M., Savini, G., Ramos, C.D., Carta, A., Berezovsky, A., et al.,
2009. Natural history of Leber’s hereditary optic neuropathy: longitudinal
analysis of the retinal nerve ﬁber layer by optical coherence tomography.
Ophthalmology.
Barboni, P., Savini, G., Valentino, M.L., La Morgia, C., Bellusci, C., De Negri, A.M., et al.,
2006. Leber’s hereditary optic neuropathy with childhood onset. Investigative
Ophthalmology & Visual Science 47, 5303e5309.
Barboni, P., Savini, G., Valentino, M.L., Montagna, P., Cortelli, P., De Negri, A.M., et al.,
2005. Retinal nerve ﬁber layer evaluation by optical coherence tomography in
Leber’s hereditary optic neuropathy. Ophthalmology 112, 120e126.
Barnils, N., Mesa, E., Munoz, S., Ferrer-Artola, A., Arruga, J., 2007. Response to ide-
benone and multivitamin therapy in Leber’s hereditary optic neuropathy.
Archivos de la Sociedad Española de Oftalmología 82, 377e380.
Barron, M.J., Grifﬁths, P., Turnbull, D.M., Bates, D., Nichols, P., 2004. The distributions
of mitochondria and sodium channels reﬂect the speciﬁc energy requirements
and conduction properties of the human optic nerve head. British Journal of
Ophthalmology 88, 286e290.
Beck, R.W., Cleary, P.A., Trobe, J.D., Kaufman, D.I., Kupersmith, M.J., Paty, D.W., et al.,
1993. The effect of corticosteroids for acute optic neuritis on the subsequent
development of multiple-sclerosis. New England Journal of Medicine 329,
1764e1769.
Beretta, S., Mattavelli, L., Sala, G., Tremolizzo, L., Schapira, A.H.V., Martinuzzi, A., et al.,
2004. Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate
transport in cybrid cell lines. Brain 127, 2183e2192.
Bern, C., Philen, R.M., Fredman, D., Bowman, B.A., Newman, N.J., Gerr, F., et al., 1995.
Epidemic optic neuropathy in cuba e clinical characterization and risk-factors.
New England Journal of Medicine 333, 1176e1182.
Berninger, T.A., Jaeger, W., Krastel, H., 1991. Electrophysiology and color perimetry in
dominant infantile optic atrophy. British Journal of Ophthalmology 75, 49e52.
Besch, D., Leo-Kottler, B., Zrenner, E., Wissinger, B., 1999. Leber’s hereditary optic
neuropathy: clinical and molecular genetic ﬁndings in a patient with a new
mutation in the ND6 gene. Graefes Archive for Clinical & Experimental
Ophthalmology 237, 745e752.
Bette, S., Schlaszus, H., Wissinger, B., Meyermann, R., Mittelbronn, M., 2005. OPA1,
associated with autosomal dominant optic atrophy, is widely expressed in the
human brain. Acta Neuropathologica 109, 393e399.
Bhat, N.K., Niranjan, B.G., Avadhani, N.G., 1981. The complexity of mitochondrial
translation products in mammalian-cells. Biochemical and Biophysical Research
Communications 103, 621e628.
Biermann, J., Grieshaber, P., Goebel, U., Martin, G., Thanos, S., Di Giovanni, S., et al.,
2010. Valproic acid-mediated neuroprotection and regeneration in injured
retinal ganglion cells. Investigative Ophthalmology & Visual Science
51, 526e534.
Binder, J., Hofmann, S., Kreisel, S., Wohrle, J.C., Bazner, H., Krauss, J.K., et al., 2003.
Clinical and molecular ﬁndings in a patient with a novel mutation in the
deafness-dystonia peptide (DDP1) gene. Brain 126, 1814e1820.
Biousse, V., Brown, M.D., Newman, N.J., Allen, J.C., Rosenfeld, J., Meola, G., et al.,
1997. De novo 14484 mitochondrial DNA mutation in monozygotic twins
discordant for Leber’s hereditary optic neuropathy. Neurology 49, 1136e1138.
Blakely, E.L., de Silva, R., King, A., Schwarzer, V., Harrower, T., Dawidek, G., et al.,
2005. LHON/MELAS overlap syndrome associated with a mitochondrial MTND1
gene mutation. European Journal of Human Genetics 13, 623e627.
Blesa, J.R., Solano, A., Briones, P., Prieto-Ruiz, J.A., Hernandez-Yago, J., Coria, F., 2007.
Molecular genetics of a patient with MohreTranebjaerg syndrome due to a new
mutation in the DDPI gene. Neuromolecular Medicine 9, 285e291.
P. Yu-Wai-Man et al. / Progress in Retinal and Eye Research 30 (2011) 81e114106Boland, M.V., Quigley, H.A., 2007. Risk factors and open-angle glaucoma: classiﬁ-
cation and application. Journal of Glaucoma 16, 406e418.
Boldogh, I.R., Pon, L.A., 2007. Mitochondria on the move. Trends in Cell Biology
17, 502e510.
Borchert, M., Garcia-Filion, P., 2008. The syndrome of optic nerve hypoplasia.
Current Neurology and Neuroscience Reports 8, 395e403.
Bower, S.P., Hawley, I., Mackey, D.A., 1992. Cardiac arrhythmia and Leber’s heredi-
tary optic neuropathy. Lancet 339, 1427e1428 [letter].
Bremner, F.D., Tomlin, E.A., Shallo-Hoffmann, J., Votruba, M., Smith, S.E., 2001. The
pupil in dominant optic atrophy. Investigative Ophthalmology & Visual Science
42, 675e678.
Bristow, E.A., Grifﬁths, P.G., Andrews, R.M., Johnson, M.A., Turnbull, D.M., 2002. The
distribution of mitochondrial activity in relation to optic nerve structure.
Archives of Ophthalmology 120, 791e796.
Brown,D.T., Herbert,M., Lamb,V.K., Chinnery, P.F., Taylor, R.W., Lightowlers, R.N., et al.,
2006. Transmission of mitochondrial DNA disorders: possibilities for the future.
Lancet 368, 87e89.
Brown, M.D., Starikovskaya, E., Derbeneva, O., Hosseini, S., Allen, J.C.,
Mikhailovskaya, I.E., et al., 2002. The role of mtDNA background in disease
expression: a new primary LHON mutation associated with Western Eurasian
haplogroup. Journal of Human Genetics 110, 130e138.
Brown, M.D., Torroni, A., Reckord, C.L., Wallace, D.C., 1995. Phylogenetic analysis of
Leber’s hereditary optic neuropathy mitochondrial DNA’s indicates multiple
independent occurrences of the common mutations. Human Mutation 6,
311e325.
Brown, M.D., Trounce, I.A., Jun, A.S., Allen, J.C., Wallace, D.C., 2000. Functional
analysis of lymphoblast and cybrid mitochondria containing the 3460, 11778, or
14484 Leber’s hereditary optic neuropathy mitochondrial DNA mutation.
Journal of Biological Chemistry 275, 39831e39836.
Brown,M.D., Zhadanov, S., Allen, J.C., Hosseini, S., Newman, N.J., Atamonov, V.V., et al.,
2001. Novel mtDNA mutations and oxidative phosphorylation dysfunction in
Russian LHON families. Human Genetics 109, 33e39.
Bu, X., Rotter, J.I., 1992. Leber hereditary optic neuropathy: estimation of number of
embryonic precursor cells and disease threshold in heterozygous affected
females at the X-linked locus. Clinical Genetics 42, 143e148.
Bu, X.D., Rotter, J.I., 1991. X chromosome-linked and mitochondrial gene control of
Leber hereditary optic neuropathy: evidence from segregation analysis for
dependence on X chromosome inactivation. Proceedings of the National
Academy of Sciences of the United States of America 88, 8198e8202.
Bua, E., Johnson, J., Herbst, A., Delong, B., McKenzie, D., Salamat, S., et al., 2006.
Mitochondrial DNA-deletion mutations accumulate intracellularly to detri-
mental levels in aged human skeletal muscle ﬁbers. American Journal of Human
Genetics 79, 469e480.
Bunce, C., Wormald, R., 2006. Leading causes of certiﬁcation for blindness and
partial sight in England & Wales. BMC Public Health 6, 58.
Buono, L.M., Foroozan, R., Sergott, R.C., Savino, P.J., 2002. Is normal tension glau-
coma actually an unrecognized hereditary optic neuropathy? New evidence
from genetic analysis. Current Opinion in Ophthalmology 13, 362e370.
Burgoyne, C.F., Downs, J.C., Bellezza, A.J., Suh, J.K.F., Hart, R.T., 2005. The optic nerve
head as a biomechanical structure: a new paradigm for understanding the role
of IOP-related stress and strain in the pathophysiology of glaucomatous optic
nerve head damage. Progress in Retinal and Eye Research 24, 39e73.
Campuzano,V.,Montermini, L.,Molto,M.D., Pianese, L., Cossee,M., Cavalcanti, F., et al.,
1996. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA
triplet repeat expansion. Science 271, 1423e1427.
Cann, R.L., 2001. Genetic clues to dispersal in human populations: retracing the past
from the present. Science 291, 1742e1748.
Carelli, V., Achilli, A., Valentino, M.L., Rengo, C., Semino, O., Pala, M., et al., 2006.
Haplogroup effects and recombination of mitochondrial DNA: novel clues from
the analysis of Leber hereditary optic neuropathy pedigrees. American Journal
of Human Genetics 78, 564e574.
Carelli, V., Bellan, M., 2008. Myelin, mitochondria, and autoimmunity e what’s the
connection? Neurology 70, 1075e1076.
Carelli, V., Franceschini, F., Venturi, S., Barboni, P., Savini, G., Barbieri, G., et al.,
2007a. Grand rounds: could occupational exposure to n-hexane and other
solvents precipitate visual failure in Leber hereditary optic neuropathy? Envi-
ronmental Health Perspectives 115, 113e115.
Carelli, V., Ghelli, A., Ratta, M., Bacchilega, E., Sangiorgi, S., Mancini, R., et al., 1997.
Leber’s hereditary optic neuropathy: biochemical effect of 11778/ND4 and
3460/ND1 mutations and correlation with the mitochondrial genotype.
Neurology 48, 1623e1632.
Carelli, V., La Morgia, C., Iommarini, L., Carroccia, R., Mattiazzi, M., Sangiorgi, S., et al.,
2007b. Mitochondrial optic neuropathies: how two genomes may kill the same
cell type? Bioscience Reports 27, 173e184.
Carelli, V., La Morgia, C., Valentino, M.L., Barboni, P., Ross-Cisneros, F.N., Sadun, A.A.,
2009. Retinal ganglion cell neurodegeneration in mitochondrial inherited
disorders. Biochimica et Biophysica Acta-Bioenergetics 1787, 518e528.
Carelli, V., Ross-Cisneros, F.N., Sadun, A.A., 2004a. Mitochondrial dysfunction as
a cause of optic neuropathies. Progress in Retinal and Eye Research 23, 53e89.
Carelli, V., Rugolo, M., Sgarbi, G., Ghelli, A., Zanna, C., Baracca, A., et al., 2004b.
Bioenergetics shapes cellular death pathways in Leber’s hereditary optic
neuropathy: a model of mitochondrial neurodegeneration. Biochimica et Bio-
physica Acta-Bioenergetics 1658, 172e179.
Carelli, V., Schimpf, S., Valentino, M.L., Fuhrmann, N., Papke, M., Schaich, S., et al.,
2007c. Dominant optic atrophy (DOA) and sensorineural hearing loss: clinical,biochemical, spectroscopic and molecular genetic study of a large Italian
pedigree linked to a new locus an chromosome 16. Neurology 68, A42.
Cartoni, R., Martinou, J.C., 2009. Role ofmitofusin 2mutations in the physiopathology
of Charcot-Marie-Tooth disease type 2A. Experimental Neurology 218, 268e273.
Casari, G., De Fusco,M., Ciarmatori, S., Zeviani, M., Mora,M., Fernandez, P., et al., 1998.
Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin,
a nuclear-encoded mitochondrial metalloprotease. Cell 93, 973e983.
Chalasani, M.L., Balasubranianian, D., Swarup, G., 2008. Focus on molecules: opti-
neurin. Experimental Eye Research 87, 1e2.
Chalasani, M.L., Radha, V., Gupta, V., Agarwal, N., Balasubramanian, D., Swarup, G.,
2007. A glaucoma-associated mutant of optineurin selectively induces death of
retinal ganglion cells which is inhibited by antioxidants. Investigative
Ophthalmology & Visual Science 48, 1607e1614.
Chalmers, R.M., Harding, A.E., 1996. A case-control study of Leber’s hereditary optic
neuropathy. Brain 119, 1481e1486.
Chalmers, R.M., Robertson, N., Kellarwood, H., Compston, D.A.S., Harding, A.E., 1995.
Sequence of the human homolog of a mitochondrially encoded murine trans-
plantation antigen in patients with multiple-sclerosis. Journal of Neurology 242,
332e334.
Chen, H., Chan, D.C., 2009. Mitochondrial dynamics-fusion, ﬁssion, movement,
and mitophagy-in neurodegenerative diseases. Human Molecular Genetics
18, R169eR176.
Chen, S.F., Chang, Y., Wu, J.C., 2001. The spatial distribution of macular pigment in
humans. Current Eye Research 23, 422e434.
Cheng, J.W., Cai, J.P., Wei, R.L., 2009. Meta-analysis of medical intervention for
normal tension glaucoma. Ophthalmology 116, 1243e1249.
Chevrollier, A., Guillet, V., Loiseau, D., Gueguen, N., de Crescenzo, M.A., Verny, C., et
al., 2008. Hereditary optic neuropathies share a common mitochondrial
coupling defect. Annals of Neurology 63, 794e798.
Chinnery, P.F., 2002. Modulating heteroplasmy. Trends in Genetics 18, 173e176.
Chinnery, P.F., Andrews, R.M., Turnbull, D.M., Howell, N., 2001a. Leber hereditary
optic neuropathy: does heteroplasmy inﬂuence the inheritance and expression
of the G11778A mitochondrial DNA mutation? American Journal of Medical
Genetics 98, 235e243.
Chinnery, P.F., Brown, D.T., Andrews, R.M., Singh-Kler, R., Riordan-Eva, P., Lindley, J.,
et al., 2001b. The mitochondrial ND6 gene is a hot spot for mutations that cause
Leber’s hereditary optic neuropathy. Brain 124, 209e218.
Chinnery, P.F., Majamaa, K., Turnbull, D., Thorburn, D., 2006. Treatment for mito-
chondrial disorders. Cochrane Database of Systematic Reviews.
Chinnery, P.F., Thorburn, D.R., Samuels, D.C., White, S.L., Dahl, H.H.M.,
Turnbull, D.M., et al., 2000. The inheritance of mitochondrial DNA hetero-
plasmy: random drift, selection or both? Trends in Genetics 16, 500e505.
Chinnery, P.F., Zeviani, M., 2008. 155th ENMC workshop: polymerase gamma and
disorders of mitochondrial DNA synthesis, 21e23 September 2007, Naarden,
The Netherlands. Neuromuscul Disord 18, 259e267.
Chinnery, P.F., Zwijnenburg, P.J.G., Walker, M., Howell, N., Taylor, R.W.,
Lightowlers, R.N., et al., 1999. Nonrandom tissue distribution of mutant mtDNA.
American Journal of Medical Genetics 85, 498e501.
Chung, H., Yoon, Y.H., Hwang, J.J., Cho, K.S., Koh, J.Y., Kim, J.G., 2009. Ethambutol-
induced toxicity is mediated by zinc and lysosomal membrane permeabilization
in cultured retinal cells. Toxicology and Applied Pharmacology 235, 163e170.
Ciccosanti, F., Corazzari, M., Soldani, F., Matarrese, P., Pagliarini, V., Iadevaia, V., et al.,
2010. Proteomic analysis identiﬁes prohibitin down-regulation as a crucial
event in the mitochondrial damage observed in HIV-infected patients. Antiviral
Therapy 15, 377e390.
Cipolat, S., Rudka, T., Hartmann, D., Costa, V., Serneels, L., Craessaerts, K., et al., 2006.
Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis
via OPA1-dependent cristae remodeling. Cell 126, 163e175.
Cock, H.R., Cooper, J.M., Schapira, A.H., 1995. The 14484 ND6 mtDNA mutation in
Leber hereditary optic neuropathy does not affect ﬁbroblast complex I activity.
American Journal of Human Genetics 57, 1501e1502 [letter].
Cock, H.R., Cooper, J.M., Schapira, A.H., 1999. Functional consequences of the 3460-
bp mitochondrial DNA mutation associated with Leber’s hereditary optic
neuropathy. Journal of the Neurological Sciences 165, 10e17.
Cock, H.R., Tabrizi, S.J., Cooper, J.M., Schapira, A.H., 1998. The inﬂuence of nuclear
background on the biochemical expression of 3460 Leber’s hereditary optic
neuropathy. Annals of Neurology 44, 187e193.
Cogan, D.G., Truman, J.T., Smith, T.R., 1973. Optic neuropathy, chloramphenicol, and
infantile genetic agranulocytosis. Investigative Ophthalmology 12, 534e537.
Cohn, A.C., Toomes, C., Hewitt, A.W., Kearns, L.S., Inglehearn, C.F., Craig, J.E., et al.,
2008. The natural history of OPA1-related autosomal dominant optic atrophy.
British Journal of Ophthalmology 24, 24.
Cohn, A.C., Toomes, C., Potter, C., Towns, K.V., Hewitt, A.W., Inglehearn, C.F., et al., 2007.
Autosomal dominant optic atrophy: penetrance and expressivity in patients with
OPA1 mutations. American Journal of Ophthalmology 143, 656e662.
Cordeiro, M.F., Guo, L., Luong, V., Harding, G., Wang, W., Jones, H.E., et al., 2004.
Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration.
Proceedings of the National Academy of Sciences of the United States of
America 101, 13352e13356.
Cornille, K., Milea, D., Amati-Bonneau, P., Procaccio, V., Zazoun, L., Guillet, V., et al.,
2008. Reversible optic neuropathy with OPA1 exon 5b mutation. Annals of
Neurology 63, 667e671.
Corral-debrinski, M., Horton, T., Lott, M.T., Shoffner, J.M., Beal, M.F., Wallace, D.C.,
1992. Mitochondrial-DNA deletions in human brain e regional variability and
increase with advanced age. Nature Genetics 2, 324e329.
P. Yu-Wai-Man et al. / Progress in Retinal and Eye Research 30 (2011) 81e114 107Cortelli, P., Montagna, P., Pierangeli, G., Lodi, R., Barboni, P., Liguori, R., et al., 1997.
Clinical and brain bioenergetics improvement with idebenone in a patient with
Leber’s hereditary optic neuropathy: a clinical and 31P-MRS study. Journal of
the Neurological Sciences 148, 25e31.
Costeff, H., Gadoth, N., Apter, N., Prialnic, M., Savir, H., 1989. A familial syndrome of
infantile optic atrophy, movement disorder, and spastic paraplegia. Neurology
39, 595e597.
Cote, H.C.F., Brumme, Z.L., Craib, K.J.P., Alexander, C.S., Wynhoven, B., Ting, L.L., et al.,
2002. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-
infected patients. New England Journal of Medicine 346, 811e820.
Craig, J.E., Hewitt, A.W., Dimasi, D.P., Howell, N., Toomes, C., Cohn, A.C., et al., 2006.
The role of the Met98Lys optineurin variant in inherited optic nerve diseases.
British Journal of Ophthalmology 90, 1420e1424.
Craven, L., Tuppen, H.A., Greggains, G.D., Harbottle, S.J., Murphy, J.L., Cree, L.M., et al.,
2010. Pronuclear transfer in human embryos to prevent transmission of mito-
chondrial DNA disease. Nature 465, 82eU89.
Cree, L.M., Samuels, D.C., Chinnery, P.F., 2009. The inheritance of pathogenic
mitochondrial DNA mutations. Biochimica et Biophysica Acta-Molecular Basis
of Disease 1792, 1097e1102.
Cullom, M.E., Heher, K.L., Miller, N.R., Savino, P.J., Johns, D.R., 1993. Lebers hereditary
optic neuropathy masquerading as tobacco-alcohol amblyopia. Archives of
Ophthalmology 111, 1482e1485.
Das, M., Chiron, S., Verde, F., 2010. Microtubule-dependent spatial organization of
mitochondria in ﬁssion yeast. Methods Cell Biol 97, 203e221.
Daut, P.M., Steinemann, T.L., Westfall, C.T., 2000. Chronic exposure keratopathy
complicating surgical correction of ptosis in patients with chronic progres-
sive external ophthalmoplegia. American Journal of Ophthalmology 130,
519e521.
Davey, K.M., Parboosingh, J.S., McLeod, D.R., Chan, A., Casey, R., Ferreira, P., et al.,
2006. Mutation of DNAJC19, a human homologue of yeast inner mitochon-
drial membrane co-chaperones, causes DCMA syndrome, a novel autosomal
recessive Barth syndrome-like condition. Journal of Medical Genetics 43,
385e393.
Davies, V., Votruba, M., 2006. Focus on molecules: the OPA1 protein. Experimental
Eye Research 83, 1003e1004.
Davies, V.J., Hollins, A.J., Piechota, M.J., Yip, W., Davies, J.R., White, K.E., et al., 2007.
Opa1 deﬁciency in a mouse model of autosomal dominant optic atrophy
impairs mitochondrial morphology, optic nerve structure and visual function.
Human Molecular Genetics 16, 1307e1318.
Davies, V.J., Powell, K.A., White, K.E., Yip, W., Hogan, V., Hollins, A.J., et al., 2008.
A missense mutation in the murine Opa3 gene models human Costeff
syndrome. Brain 131, 368e380.
De Marco, N., Buono, M., Troise, F., Diez-Roux, G., 2006. Optineurin increases cell
survival and translocates to the nucleus in a Rab8-dependent manner upon an
apoptotic stimulus. Journal of Biological Chemistry 281, 16147e16156.
De Marinis, M., 2001. Optic neuropathy after treatment with antituberculous drugs
in a subject with Leber’s hereditary optic neuropathy mutation. Journal of
Neurology 248, 818e819.
De Vries, D.D., Went, L.N., Bruyn, G.W., Scholte, H.R., Hofstra, R.M., Bolhuis, P.A., et al.,
1996. Genetic and biochemical impairment ofmitochondrial complex I activity in
a family with Leber hereditary optic neuropathy and hereditary spastic dystonia.
American Journal of Human Genetics 58, 703e711.
De Vriese, A.S., Van Coster, R., Smet, J., Seneca, S., Lovering, A., Van Haute, L.L., et al.,
2006. Linezolid-induced inhibition of mitochondrial protein synthesis. Clinical
Infectious Diseases 42, 1111e1117.
Decanini-Mancera, A., Harrison, A.R., Lee, M.S., 2009. Another case of Leber
hereditary optic neuropathy in an octogenarian. Journal of Neuro-Ophthal-
mology 29, 159e160.
Degli Esposti, M., Carelli, V., Ghelli, A., Ratta, M., Crimi, M., Sangiorgi, S., et al., 1994.
Functional alterations of the mitochondrially encoded ND4 subunit associated
with Leber’s hereditary optic neuropathy. FEBS Letters 352, 375e379.
Del Bo, R., Bordoni, A., Sciacco, M., Di Fonzo, A., Galbiati, S., Crimi, M., et al., 2003.
Remarkable inﬁdelity of polymerase gamma A associated with mutations in
POLG1 exonuclease domain. Neurology 61, 903e908.
del Toro, D., Alberch, J., Lazaro-Dieguez, F., Martin-Ibanez, R., Xifro, X., Egea, G., et al.,
2009. Mutant huntingtin impairs Post-golgi trafﬁcking to lysosomes by deloc-
alizing optineurin/Rab8 complex from the golgi apparatus. Molecular Biology of
the Cell 20, 1478e1492.
Delettre, C., Lenaers, G., Griffoin, J.M., Gigarel, N., Lorenzo, C., Belenguer, P., et al.,
2000. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is
mutated in dominant optic atrophy. Nature Genetics 26, 207e210.
Di Prospero, N.A., Baker, A., Jeffries, N., Fischbeck, K.H., 2007. Neurological effects of
high-dose idebenone in patients with Friedreich’s ataxia: a randomised,
placebo-controlled trial. Lancet Neurology 6, 878e886.
DiMauro, S., Mancuso, M., 2007. Mitochondrial diseases: therapeutic approaches.
Bioscience Reports 27, 125e137.
DiMauro, S., Rustin, P., 2009. A critical approach to the therapy of mitochondrial
respiratory chain and oxidative phosphorylation diseases. Biochimica et Bio-
physica Acta-Molecular Basis of Disease 1792, 1159e1167.
DiMauro, S., Schon, E.A., 2003. Mechanisms of disease: mitochondrial respiratory-
chain diseases. New England Journal of Medicine 348, 2656e2668.
Dotti, M.T., Plewnia, K., Cardaioli, E., Manneschi, L., Rufa, A., Alema, G., et al.,
1998. A case of ethambutol-induced optic neuropathy harbouring
the primary mitochondrial LHON mutation at nt 11778. Journal of Neurology
245, 302e303.Dudkina, N.V., Eubel, H., Keegstra, W., Boekema, E.J., Braun, H.P., 2005. Structure of
a mitochondrial supercomplex formed by respiratory-chain complexes I and III.
Proceedings of the National Academy of Sciences of the United States of
America 102, 3225e3229.
Dudkina, N.V., Kouril, R., Peters, K., Braun, H.P., Boekema, E.J., 2010. Structure and
function of mitochondrial supercomplexes. Biochimica et Biophysica Acta-
Bioenergetics 1797, 664e670.
Durham, S.E., Samuels, D.C., Cree, L.M., Chinnery, P.F., 2007. Normal levels of wild-
type mitochondrial DNA maintain cytochrome c oxidase activity for two
pathogenic mitochondrial DNA mutations but not for m.3243A->G. American
Journal of Human Genetics 81, 189e195.
Durr, A., Cossee, M., Agid, Y., Campuzano, V., Mignard, C., Penet, C., et al., 1996.
Clinical and genetic abnormalities in patients with Friedreich’s ataxia. New
England Journal of Medicine 335, 1169e1175.
Echaniz-Laguna, A., Chassagne, M., de Seze, J., Mohr, M., Clerc-Renaud, P.,
Tranchant, C., et al., 2010. POLG1 variations presenting as multiple sclerosis.
Archives of Neurology 67, 1140e1143.
Eliott, D., Traboulsi, E.I., Maumenee, I.H., 1993. Visual prognosis in autosomal
dominant optic atrophy (Kjer Type). American Journal of Ophthalmology 115,
360e367.
Elliott, H.R., Samuels, D.C., Eden, J.A., Relton, C.L., Chinnery, P.F., 2008. Pathogenic
mitochondrial DNA mutations are common in the general population. American
Journal of Human Genetics 83, 254e260.
Ellouze, S., Augustin, S., Bouaita, A., Bonnet, C., Simonutti, M., Forster, V., et al., 2008.
Optimized allotopic expression of the human mitochondrial ND4 prevents
blindness in a rat model of mitochondrial dysfunction. American Journal of
Human Genetics 83, 373e387.
Fauser, S., Leo-Kottler, B., Besch, D., Luberichs, J., 2002a. Conﬁrmation of the 14568
mutation in the mitochondrial ND6 gene as causative in Leber’s hereditary optic
neuropathy. Ophthalmic Genetics 23, 191e197.
Fauser, S., Luberichs, J., Besch, D., Leo-Kottler, B., 2002b. Sequence analysis of the
complete mitochondrial genome in patients with Leber’s hereditary optic
neuropathy lacking the three most common pathogenic DNA mutations.
Biochemical and Biophysical Research Communications 295, 342e347.
Ferraris, S., Clark, S., Garelli, E., Davidzon, G., Moore, S.A., Kardon, R.H., et al., 2008.
Progressive external ophthalmoplegia and vision and hearing loss in a patient
with mutations in POLG2 and OPA1. Archives of Neurology 65, 125e131.
Ferre, M., Amati-Bonneau, P., Tourmen, Y., Malthiery, Y., Reynier, P., 2005. eOPA1: An
online database for OPA1 mutations. Human Mutation 25, 423e428.
Ferre, M., Bonneau, D., Milea, D., Chevrollier, A., Verny, C., Dollfus, H., et al., 2009.
Molecular screening of 980 cases of suspected hereditary optic neuropathy with
a report on 77 novel OPA1 mutations. Human Mutation 30, E692eE705.
Figueroa-Martinez, F., Vazquez-Acevedo, M., Cortes-Hernandez, P., Garcia-Trejo, J.J.,
Davidson, E., King, M.P., et al., 2010. What limits the allotopic expression of
nucleus-encoded mitochondrial genes? The case of the chimeric Cox3 and Atp6
genes. Mitochondrion, Epub ahead of print.
Floreani, M., Napoli, E., Martinuzzi, A., Pantano, G., De Riva, V., Trevisan, R., et al.,
2005. Antioxidant defences in cybrids harboring mtDNA mutations associated
with Leber’s hereditary optic neuropathy. FEBS Journal 272, 1124e1135.
Folliot, S., Briot, D., Conrath, H., Provost, N., Cherel, Y., Moullier, P., et al., 2003.
Sustained tetracycline-regulated transgene expression in vivo in rat retinal
ganglion cells using a single type 2 adeno-associated viral vector. Journal of
Gene Medicine 5, 493e501.
Fortuna, F., Barboni, P., Liguori, R., Valentino, M.L., Savini, G., Gellera, C., et al., 2009.
Visual system involvement in patients with Friedreichs ataxia. Brain 132,
116e123.
Fournier, A.V., Damji, K.F., Epstein, D.L., Pollock, S.C., 2001. Disc excavation in
dominant optic atrophy. Ophthalmology 108, 1595e1602.
Fox, C.M., Bensa, S., Bray, I., Zajicek, J.P., 2004. The epidemiology of multiple sclerosis
in Devon: a comparison of the new and old classiﬁcation criteria. Journal of
Neurology, Neurosurgery, and Psychiatry 75, 56e60.
Fraser, J.A., Biousse, V., Newman, N.J., 2010. The neuro-ophthalmology of mito-
chondrial disease. Survey of Ophthalmology 55, 299e334.
Frerichs, F.C.P., Dingemans, K.P., Brinkman, K., 2002. Cardiomyopathy with mito-
chondrial damage associated with nucleoside reverse-transcriptase inhibitors.
New England Journal of Medicine 347, 1895e1896.
Frey, T.G., Mannella, C.A., 2000. The internal structure of mitochondria. Trends in
Biochemical Sciences 25, 319e324.
Frezza, C., Cipolat, S., de Brito, O.M., Micaroni, M., Beznoussenko, G.V., Rudka, T., et
al., 2006. OPA1 controls apoptotic cristae remodeling independently from
mitochondrial fusion. Cell 126, 177e189.
Friedmann, T., 2000. Medical ethics e principles for human gene therapy studies.
Science 287, 2163e2165.
Frohman, E.M., Frohman, T.C., Zee, D.S., McColl, R., Galetta, S., 2005. The neuro-
ophthalmology of multiple sclerosis. Lancet Neurology 4, 111e121.
Frohman, E.M., Fujimoto, J.G., Frohman, T.C., Calabresi, P.A., Cutter, G., Balcer, L.J.,
2008. Optical coherence tomography: a window into the mechanisms of
multiple sclerosis. Nature Clinical Practice Neurology 4, 664e675.
Fuhrmann, N., Alavi, M.V., Bitoun, P., Woernle, S., Auburger, G., Leo-Kottler, B., et al.,
2009. Genomic rearrangements in OPA1 are frequent in patients with auto-
somal dominant optic atrophy. Journal of Medical Genetics 46, 136e144.
Gabaldon, T., Huynen, M.A., 2004. Shaping the mitochondrial proteome. Biochimica
et Biophysica Acta-Bioenergetics 1659, 212e220.
Garcin, R., Raverdy, P., Delthil, S., Man, H.X., Chimenes, H., 1961. On a familial
hereditary disorder comprising cataracts, optic atrophy, extra-pyramidal signs,
P. Yu-Wai-Man et al. / Progress in Retinal and Eye Research 30 (2011) 81e114108and certain stigmata of Friedreich’s ataxia. Revista de Neurologia [Paris] 104,
373e379.
Ghelli, A., Porcelli, A.M., Zanna, C., Martinuzzi, A., Carelli, V., Rugolo, M., 2008.
Protection against oxidant-induced apoptosis by exogenous glutathione in
Leber hereditary optic neuropathy cybrids. Investigative Ophthalmology &
Visual Science 49, 671e676.
Ghelli, A., Porcelli, A.M., Zanna, C., Vidoni, S., Mattioli, S., Barbieri, A., et al., 2009. The
background of mitochondrial DNA haplogroup J increases the sensitivity of Leb-
er’s hereditary optic neuropathy cells to 2,5-hexanedione toxicity. PLoS One, 4.
Ghelli, A., Zanna, C., Porcelli, A.M., Schapira, A.H.V., Martinuzzi, A., Carelli, V., et al.,
2003. Leber’s hereditary optic neuropathy (LHON) pathogenic mutations induce
mitochondrial-dependent apoptotic death in transmitochondrial cells incu-
bated with galactose medium. Journal of Biological Chemistry 278, 4145e4150.
Giordano, C., Montopoli, M., Perli, E., Orlandi, M., Fantin, M., Ross-Cisneros, F.N.,
et al., 2010. Oestrogens ameliorate mitochondrial dysfunction in Leber’s
hereditary optic neuropathy. Brain, Epub ahead of print.
Giraudet, S., Lamirel, C., Amati-Bonneau, P., Reynier, P., Bonneau, D., Milea, D., et al.,
2010. Never too old to harbour a young man’s disease? British Journal of
Ophthalmology 2010, 31.
Godel, V., Nemet, P., Lazar, M., 1980. Chloramphenicol optic neuropathy. Archives of
Ophthalmology 98, 1417e1421.
Gray, D.C., Wolfe, R., Gee, B.P., Scoles, D., Geng, Y., Masella, B.D., et al., 2008. In vivo
imaging of the ﬁne structure of rhodamine-labeled macaque retinal ganglion
cells. Investigative Ophthalmology & Visual Science 49, 467e473.
Gray, M.W., Burger, G., Lang, B.F., 1999. Mitochondrial evolution. Science 283,
1476e1481.
Gronlund, M.A., Honarvar, A.K.S., Andersson, S., Moslemi, A.R., Oldfors, A., Holme, E.,
et al., 2010. Ophthalmological ﬁndings in children and young adults with
genetically veriﬁed mitochondrial disease. British Journal of Ophthalmology
94, 121e127.
Gropman, A., Chen, T.J., Perng, C.L., Krasnewich, D., Chernoff, E., Tifft, C., et al., 2004.
Variable clinical manifestation of homoplasmic G14459A mitochondrial DNA
mutation. American Journal of Medical Genetics: Part A 124, 377e382.
Grzybowski, A., 2007. Tobacco amblyopia: does it really exist? Eye 21, 1448e1449.
Grzybowski, A., Holder, G.E., 2010. Tobacco optic neuropathy (TON) e the historical
and present concept of the disease. Acta Ophthalmologica, Epub ahead of print.
Guillet, V., Chevrollier, A., Cassereau, J., Letournel, F., Gueguen, N., Richard, L., et al.,
2010. Ethambutol-induced optic neuropathy linked to OPA1 mutation and
mitochondrial toxicity. Mitochondrion 10, 115e124.
Guo, L., Cordeiro, M.F., 2008. Assessment of neuroprotection in the retina with
DARC. Glaucoma: an Open Window to Neurodegeneration and Neuroprotection
173, 437e450.
Gvozdjak, J., Gvozdjakova, A., Kucharska, J., Bada, V., 1987. The effect of smoking on
myocardial metabolism. Czechoslovak Medicine 10, 47e53.
Hanein, S., Perrault, I., Roche, O., Gerber, S., Khadom, N., Rio, M., et al., 2009.
TMEM126A, encoding a mitochondrial protein, is mutated in autosomal-
recessive nonsyndromic optic atrophy. American Journal of Human Genetics 84,
493e498.
Harding, A.E., 1983. Classiﬁcation of the hereditary ataxias and paraplegias. Lancet
1, 1151e1155.
Harding, A.E., Riordan-Eva, P., Govan, G.G., 1995a. Mitochondrial DNA diseases:
genotype and phenotype in Leber’s hereditary optic neuropathy. Muscle &
Nerve 3, S82eS84.
Harding, A.E., Sweeney, M.G., Govan, G.G., Riordan-Eva, P., 1995b. Pedigree analysis
in Leber hereditary optic neuropathy families with a pathogenic mtDNA
mutation. American Journal of Human Genetics 57, 77e86.
Harding, A.E., Sweeney, M.G., Miller, D.H., Mumford, C.J., Kellar-Wood, H.,
Menard, D., et al., 1992. Occurrence of a multiple sclerosis-like illness in women
who have a Leber’s hereditary optic neuropathy mitochondrial DNA mutation.
Brain 115, 979e989.
Harris, M.O., Walsh, L.E., Hattab, E.M., Golomb, M.R., 2010. Is it ADEM, POLG, or
both? Archives of Neurology 67, 493e496.
Hauser, M.A., Sena, D.F., Flor, J., Walter, J., Auguste, J., LaRocque-Abramson, K., et al.,
2006. Distribution of optineurin sequence variations in an ethnically diverse
population of low-tension glaucoma patients from the United States. Journal of
Glaucoma 15, 358e363.
Hayreh, S.S., 2009a. Ischemic optic neuropathy. Progress in Retinal and Eye
Research 28, 34e62.
Hayreh, S.S., 2009b. Pathogenesis of nonarteritic anterior ischemic optic neurop-
athy. Archives of Ophthalmology 127, 1082e1083.
He, L.P., Chinnery, P.F., Durham, S.E., Blakely, E.L.,Wardell, T.M., Borthwick, G.M., et al.,
2002. Detection and quantiﬁcation of mitochondrial DNA deletions in individual
cells by real-time PCR. Nucleic Acids Research 30.
Heiduschka, P., Schnichels, S., Fuhrmann, N., Hofmeister, S., Schraermeyer, U.,
Wissinger, B., et al., 2010. Electrophysiological and histologic assessment
of retinal ganglion cell fate in a mouse model for OPA1-associated autosomal
dominant optic atrophy. Investigative Ophthalmology & Visual Science
51, 1424e1431.
Heng, J.E., Vorwerk, C.K., Lessell, E., Zurakowski, D., Levin, L.A., Dreyer, E.B., 1999.
Ethambutol is toxic to retinal ganglion cells via an excitotoxic pathway.
Investigative Ophthalmology & Visual Science 40, 190e196.
Herrnstadt, C., Elson, J.L., Fahy, E., Preston, G., Turnbull, D.M., Anderson, C., et al.,
2002. Reduced-median-network analysis of complete mitochondrial DNA
coding-region sequences for the major African, Asian, and European
haplogroups. American Journal of Human Genetics 70, 1152e1171.Ho, G., Walter, J.H., Christodoulou, J., 2008. Costeff optic atrophy syndrome: new
clinical case and novel molecular ﬁndings. Journal of inherited metabolic
disease 7, 7.
Hofhaus, G., Johns, D.R., Hurko, O., Attardi, G., Chomyn, A., 1996. Respiration and
growth defects in transmitochondrial cell lines carrying the 11778 mutation
associated with Leber’s hereditary optic neuropathy. Journal of Biological
Chemistry 271, 13155e13161.
Horvath, J., Horvath, R., Karcagi, V., Komoly, S., Johns, D.R., 2002. Sequence analysis
of Hungarian LHON patients not carrying the common primary mutations.
Journal of Inherited Metabolic Disease 25, 323e324.
Horvath, R., Gorman, G., Chinnery, P.F., 2008. How can we treat mitochondrial
encephalomyopathies? Approaches to therapy. Neurotherapeutics 5, 558e568.
Horvath, R., Hudson, G., Ferrari, G., Futterer, N., Ahola, S., Lamantea, E., et al., 2006.
Phenotypic spectrum associated with mutations of the mitochondrial poly-
merase gamma gene. Brain 129, 1674e1684.
Howell, N., Bindoff, L.A., McCullough, D.A., Kubacka, I., Poulton, J., Mackey, D., et al.,
1991a. Leber hereditary optic neuropathy: identiﬁcation of the same mito-
chondrial ND1 mutation in six pedigrees. American Journal of Human Genetics
49, 939e950.
Howell, N., Halvorson, S., Burns, J., McCullough, D.A., Paulton, J., 1993. When does
bilateral optic atrophy become Leber hereditary optic neuropathy? American
Journal of Human Genetics 53, 959e963.
Howell, N., Kubacka, I., Xu, M., McCullough, D.A., 1991b. Leber hereditary optic
neuropathy: involvement of the mitochondrial ND1 gene and evidence for an
intragenic suppressor mutation. American Journal of Human Genetics 48,
935e942.
Howell, N., Kubacka, I., Mackey, D.A., 1996. How rapidly does the human mito-
chondrial genome evolve? American Journal of Human Genetics 59, 501e509.
Howell, N., Mackey, D.A., 1998. Low-penetrance branches in matrilineal pedigrees
with leber hereditary optic neuropathy. American Journal of Human Genetics
63, 1220e1224.
Howell, N., Oostra, R.J., Bolhuis, P.A., Spruijt, L., Clarke, L.A., Mackey, D.A., et al., 2003.
Sequence analysis of the mitochondrial genomes from Dutch pedigrees
with Leber hereditary optic neuropathy. American Journal of Human Genetics
72, 1460e1469.
Hoyt, C.S., 1980. Autosomal dominant optic atrophy e a spectrum of disability.
Ophthalmology 87, 245e251.
Huang, T.S., Santarelli, R., Starr, A., 2009. Mutation of OPA1 gene causes deafness by
affecting function of auditory nerve terminals. Brain Research 1300, 97e104.
Hudson, G., Amati-Bonneau, P., Blakely, E.L., Stewart, J.D., He, L.P., Schaefer, A.M., et
al., 2008. Mutation of OPA1 causes dominant optic atrophy with external
ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions:
a novel disorder of mtDNA maintenance. Brain 131, 329e337.
Hudson, G., Carelli, V., Horvath, R., Zeviani, M., Smeets, H.J., Chinnery, P.F., 2007a.
X-Inactivation patterns in females harboring mtDNA mutations that cause
Leber hereditary optic neuropathy. Molecular Vision 13, 2339e2343.
Hudson, G., Carelli, V., Spruijt, L., Gerards, M., Mowbray, C., Achilli, A., et al., 2007b.
Clinical expression of Leber hereditary optic neuropathy is affected by the
mitochondrial DNA-haplogroup background. American Journal of Human
Genetics 81, 228e233.
Hudson, G., Keers, S., Man, P.Y.W., Grifﬁths, P., Huoponen, K., Savontaus, M.L., et al.,
2005. Identiﬁcation of an X-chromosomal locus and haplotype modulating the
phenotype of a mitochondrial DNA disorder. American Journal of Human
Genetics 77, 1086e1091.
Huizing, M., Dorward, H., Ly, L., Klootwijk, E., Kleta, R., Skovby, F., et al., 2010. OPA3,
mutated in 3-methylglutaconic aciduria type III, encodes two transcripts tar-
geted primarily to mitochondria. Molecular Genetics and Metabolism 100,
149e154.
Huoponen, K., Lamminen, T., Juvonen, V., Aula, P., Nikoskelainen, E., Savontaus, M.L.,
1993. The spectrum of mitochondrial DNA mutations in families with Leber
hereditary optic neuroretinopathy. Human Genetics 92, 379e384.
Huoponen, K., Vilkki, J., Aula, P., Nikoskelainen, E.K., Savontaus, M.L., 1991. A new
mtDNA mutation associated with Leber hereditary optic neuroretinopathy.
American Journal of Human Genetics 48, 1147e1153.
Hwang, J.M., Kim, J., Park, S.S., 2003. Leber’s hereditary optic neuropathy mutations
in ethambutol-induced optic neuropathy. Journal of Neurology 250, 87e89.
Ikeda, A., Ikeda, T., Ikeda, N., Kawakami, Y., Mimura, O., 2006. Leber’s hereditary
optic neuropathy precipitated by ethambutol. Japanese Journal of Ophthal-
mology 50, 280e283.
Inglese, M., Rovaris, M., Bianchi, S., La Mantia, L., Mancardi, G.L., Ghezzi, A., et al.,
2001. Magnetic resonance imaging, magnetisation transfer imaging, and
diffusion weighted imaging correlates of optic nerve, brain, and cervical cord
damage in Leber’s hereditary optic neuropathy. Journal of Neurology, Neuro-
surgery, and Psychiatry 70, 444e449.
Ito, Y., Nakamura, M., Yamakoshi, T., Lin, J., Yatsuya, H., Terasaki, H., 2007. Reduction
of inner retinal thickness in patients with autosomal dominant optic atrophy
associated with OPA1 mutations. Investigative Ophthalmology & Visual Science
48, 4079e4086.
Jansen, P.H., van der Knaap, M.S., de Coo, I.F., 1996. Leber’s hereditary optic
neuropathy with the 11 778 mtDNA mutation and white matter disease
resembling multiple sclerosis: clinical, MRI and MRS ﬁndings. Journal of the
Neurological Sciences 135, 176e180.
Jaros, E., Mahad, D.J., Hudson, G., Birchall, D., Sawcer, S.J., Grifﬁths, P.G., et al., 2007.
Primary spinal cord neurodegeneration in leber hereditary optic neuropathy.
Neurology 69, 214e216.
P. Yu-Wai-Man et al. / Progress in Retinal and Eye Research 30 (2011) 81e114 109Javaheri, M., Khurana, R.N., O’Hearn, T.M., Lai, M.M., Sadun, A.A., 2007. Linezolid-
induced optic neuropathy: a mitochondrial disorder? British Journal of
Ophthalmology 91, 111e115.
Jazin, E., Soodyall, H., Jalonen, P., Lindholm, E., Stoneking, M., Gyllensten, U., 1998.
Mitochondrial mutation rate revisited: hot spots and polymorphism. Nature
Genetics 18, 109e110.
Ji, Y.L., Jia, X.Y., Li, S.Q., Xiao, X.S., Guo, X.M., Zhang, Q.J., 2010. Evaluation of the
X-linked modiﬁer loci for Leber hereditary optic neuropathy with the G11778A
mutation in Chinese. Molecular Vision 16, 416e424.
Ji, Y.L., Zhang, A.M., Jia, X.Y., Zhang, Y.P., Xiao, X.S., Li, S.Q., et al., 2008. Mitochondrial
DNA haplogroups M7b1’2 and M8a affect clinical expression of Leber hereditary
optic neuropathy in chinese families with the m.11778G&rarr;A mutation.
American Journal of Human Genetics 83, 760e768.
Johns, D.R., Heher, K.L., Miller, N.R., Smith, K.H., 1993a. Leber’s hereditary optic
neuropathy. Clinical manifestations of the 14484 mutation. Archives of
Ophthalmology 111, 495e498.
Johns, D.R., Neufeld, M.J., 1993. Cytochrome c oxidase mutations in Leber hereditary
optic neuropathy. Biochemical and Biophysical Research Communications 196,
810e815.
Johns, D.R., Neufeld, M.J., Park, R.D., 1992. An ND-6 mitochondrial DNA mutation
associated with Leber hereditary optic neuropathy. Biochemical and Biophysical
Research Communications 187, 1551e1557.
Johns, D.R., Smith, K.H., Miller, N.R., Sulewski, M.E., Bias, W.B., 1993b. Identical twins
who are discordant for Leber’s hereditary optic neuropathy. Archives of
Ophthalmology 111, 1491e1494.
Ju, W.K., Kim, K.Y., Angert, M., Duong-Polk, K.X., Lindsey, J.D., Ellisman, M.H., et al.,
2009a. Memantine blocks mitochondrial OPA1 and cytochrome c release and
subsequent apoptotic cell death in glaucomatous retina. Investigative
Ophthalmology & Visual Science 50, 707e716.
Ju, W.K., Kim, K.Y., Duong-Polk, K.X., Lindsey, J.D., Ellisman, M.H., Weinreb, R.N.,
2010. Increased optic atrophy type 1 expression protects retinal ganglion cells
in a mouse model of glaucoma. Molecular Vision 16, 1331e1342.
Ju, W.K., Kim, K.Y., Lindsey, J.D., Angert, M., Duong-Polk, K.X., Scott, R.T., et al., 2008a.
Intraocular pressure elevation induces mitochondrial ﬁssion and triggers OPA1
release in glaucomatous optic nerve. Investigative Ophthalmology & Visual
Science 49, 4903e4911.
Ju, W.K., Kim, K.Y., Lindsey, J.D., Angert, M., Patel, A., Scott, R.T., et al., 2009b.
Elevated hydrostatic pressure triggers release of OPA1 and cytochrome C, and
induces apoptotic cell death in differentiated RGC-5 cells. Molecular Vision 15,
120e134.
Ju, W.K., Lindsey, J.D., Angert, M., Patel, A., Weinreb, R.N., 2008b. Glutamate receptor
activation triggers OPA1 release and induces apoptotic cell death in ischemic rat
retina. Molecular Vision 14, 2629e2638.
Jun, A.S., Brown, M.D., Wallace, D.C., 1994. A mitochondrial DNA mutation at
nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated
with maternally inherited Leber hereditary optic neuropathy and dystonia.
Proceedings of the National Academy of Sciences of the United States of
America 91, 6206e6210.
Kamei, S., Chen-Kuo-Chang, M., Cazevieille, C., Lenaers, G., Olichon, A.,
Belenguer, P., et al., 2005. Expression of the Opa1 mitochondrial protein in
retinal ganglion cells: its downregulation causes aggregation of the mito-
chondrial network. Investigative Ophthalmology & Visual Science 46,
4288e4294.
Katz, B.J., Zhao, Y., Warner, J.E.A., Tong, Z.Z., Yang, Z.L., Zhang, K., 2006. A family with
X-linked optic atrophy linked to the OPA2 locus Xp11.4-Xp11.2. American
Journal of Medical Genetics: Part A 140A, 2207e2211.
Kaukonen, J., Juselius, J.K., Tiranti, V., Kyttala, A., Zeviani, M., Comi, G.P., et al., 2000.
Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 289,
782e785.
Kawasaki, A., Herbst, K., Sander, B., Milea, D., 2010. Selective wavelength pupill-
ometry in Leber hereditary optic neuropathy. Clinical and Experimental
Ophthalmology 38, 322e324.
Kellar-Wood, H., Robertson, N., Govan, G.G., Compston, D.A., Harding, A.E., 1994.
Leber’s hereditary optic neuropathy mitochondrial DNA mutations in multiple
sclerosis. Annals of Neurology 36, 109e112.
Kerrison, J.B., Arnould, V.J., Sallum, J.M.F., Vageﬁ, M.R., Barmada, M.M., Li, Y.Y., et al.,
1999. Genetic heterogeneity of dominant optic atrophy, Kjer type e identiﬁ-
cation of a second locus on chromosome 18q12.2-12.3. Archives of Ophthal-
mology 117, 805e810.
Kerrison, J.B., Miller, N.R., Hsu, F., Beaty, T.H., Maumenee, I.H., Smith, K.H., et al., 2000.
A case-control study of tobacco and alcohol consumption in Leber hereditary
optic neuropathy. American Journal of Ophthalmology 130, 803e812.
Khrapko, K., 2008. Two ways to make an mtDNA bottleneck. Nature Genetics
40, 134e135.
Kim, J.Y., Hwang, J.M., Park, S.S., 2002. Mitochondrial DNA C4171A/ND1 is a novel
primary causative mutation of Leber’s hereditary optic neuropathy with a good
prognosis. Annals of Neurology 51, 630e634.
Kim, T.W., Hwang, J.M., 2007. Stratus OCT in dominant optic atrophy: features
differentiating it from glaucoma. Journal of Glaucoma 16, 655e658.
Kim, U., Hwang, J.M., 2009. Early stage ethambutol optic neuropathy: retinal nerve
ﬁber layer and optical coherence tomography. European Journal of Ophthal-
mology 19, 466e469.
Kirkman, M.A., Korsten, A., Leonhardt, M., Dimitriadis, K., De Coo, I.F., Klopstock, T.,
et al., 2009a. Quality of life in patients with leber hereditary optic neuropathy.
Investigative Ophthalmology & Visual Science 50, 3112e3115.Kirkman,M.A., Yu-Wai-Man, P., Korsten, A., Leonhardt,M., Dimitriadis, K., De Coo, I.F.,
et al., 2009b. Gene-environment interactions in Leber hereditary optic neurop-
athy. Brain 132, 2317e2326.
Kjer, B., 1956. Infantile optic atrophy with dominant transmission. Danish Medical
Bulletin 3, 135e141.
Kjer, B., Eiberg, H., Kjer, P., Rosenberg, T., 1996. Dominant optic atrophy mapped to
chromosome 3q region. II. Clinical and epidemiological aspects. Acta Oph-
thalmologica Scandinavica 74, 3e7.
Kjer, P., 1959. Infantile optic atrophy with dominant mode of inheritance: a clinical
and genetic study of 19 Danish families. Acta Ophthalmologica, 1e146.
Kline, L.B., Glaser, J.S., 1979. Dominant optic atrophy e clinical proﬁle. Archives of
Ophthalmology 97, 1680e1686.
Klivenyi, P., Karg, E., Rozsa, C., Horvath, R., Komoly, S., Nemeth, I., et al., 2001. alpha-
tocopherol/lipid ratio in blood is decreased in patients with Leber’s hereditary
optic neuropathy and asymptomatic carriers of the 11778 mtDNA mutation.
Journal of Neurology, Neurosurgery, and Psychiatry 70, 359e362.
Kobbert, C., Apps, R., Bechmann, I., Lanciego, J.L., Mey, J., Thanos, S., 2000. Current
concepts in neuroanatomical tracing. Progress in Neurobiology 62, 327e351.
Koch-Henriksen, N., Sorensen, P.S., 2010. The changing demographic pattern of
multiple sclerosis epidemiology. Lancet Neurology 9, 520e532.
Kovacs, G.G., Hoftberger, R., Horvath, R., Barsi, P., Komoly, S., Lassmann, H., et al.,
2005. Neuropathology of white matter disease in Leber’s hereditary optic
neuropathy. Brain 128, 35e41.
Kumaramanickavel, G., Aung, T., Sripriya, S., Waseem, N., Okada, K., Seah, S.K.L., et al.,
2005. Lack of association of IVS8þ4 C/T and IVS8þ32 T/C polymorphisms in the
OPA1 gene with normal tension glaucoma in patients from Singapore, India and
Japan. Investigative Ophthalmology & Visual Science 46, 3811.
Kyriakouli, D.S., Boesch, P., Taylor, R.W., Lightowlers, R.N., 2008. Progress
and prospects: gene therapy for mitochondrial DNA disease. Gene Therapy
15, 1017e1023.
La Morgia, C., Achilli, A., Iommarini, L., Barboni, P., Pala, M., Olivieri, A., et al., 2008.
Rare mtDNA variants in Leber hereditary optic neuropathy families with
recurrence of myoclonus. Neurology 70, 762e770.
La Morgia, C., Ross-Cisneros, F.N., Sadun, A.A., Hannibal, J., Munarini, A.,
Mantovani, V., et al., 2010. Melanopsin retinal ganglion cells are resistant to
neurodegeneration in mitochondrial optic neuropathies. Brain 133,
2426e2438.
Lamminen, T., Majander, A., Juvonen, V., Wikstrom, M., Aula, P., Nikoskelainen, E.,
et al., 1995. A mitochondrial mutation at nt 9101 in the ATP synthase 6 gene
associated with deﬁcient oxidative phosphorylation in a family with Leber
hereditary optic neuroretinopathy. American Journal of Human Genetics 56,
1238e1240 [letter].
Landrum, J.T., Bone, R.A., 2001. Lutein, zeaxanthin, and the macular pigment.
Archives of Biochemistry and Biophysics 385, 28e40.
Larsson, N.G., Andersen, O., Holme, E., Oldfors, A., Wahlstrom, J., 1991. Leber’s
hereditary optic neuropathy and complex I deﬁciency in muscle. Annals of
Neurology 30, 701e708.
Lascaratos, G., Ji, D., Wood, J.P.M., Osborne, N.N., 2007. Visible light affects mito-
chondrial function and induces neuronal death in retinal cell cultures. Vision
Research 47, 1191e1201.
Lee, E.J., Kim, S.J., Choung, H.K., Kim, J.H., Yu, Y.S., 2008. Incidence and clinical
features of ethambutol-induced optic neuropathy in Korea. Journal of Neuro-
Ophthalmology 28, 269e277.
Lenaers, G., Reynier, P., ElAchouri, G., Soukkarieh, C., Olichon, A., Belenguer, P., et al.,
2009. OPA1 functions in mitochondria and dysfunctions in optic nerve. Inter-
national Journal of Biochemistry & Cell Biology 41, 1866e1874.
Leo-Kottler, B., Luberichs, J., Besch, D., Christ-Adler, M., Fauser, S., 2002. Leber’s
hereditary optic neuropathy: clinical and molecular genetic results in a patient
with a point mutation at np T11253C (isoleucine to threonine) in the ND4 gene
and spontaneous recovery. Graefes Archive for Clinical & Experimental
Ophthalmology 240, 758e764.
Lessell, S.,1998. Nutritional amblyopia. Journal of Neuro-Ophthalmology 18,106e111.
Leung, C.K.S., Weinreb, R.N., 2009. Experimental detection of retinal ganglion cell
damage in vivo. Experimental Eye Research 88, 831e836.
Li, C.H., Cheng, Y.W., Liao, P.L., Yang, Y.T., Kang, J.J., 2010. Chloramphenicol causes
mitochondrial stress, decreases ATP biosynthesis, induces matrix metal-
loproteinase-13 expression, and solid-tumor cell invasion. Toxicological
Sciences 116, 140e150.
Libby, R.T., Gould, D.B., Anderson, M.G., John, S.W.M., 2005. Complex genetics of
glaucoma susceptibility. Annual Review of Genomics and Human Genetics 6,
15e44.
Lightowlers, R.N., Chinnery, P.F., Turnbull, D.M., Howell, N., 1997. Mammalian
mitochondrial genetics: heredity, heteroplasmy and disease. Trends in Genetics
13, 450e455.
Liguori, M., 2008. A phenotypic variation of dominant optic atrophy and deafness
(ADOAD) due to a novel OPA1 mutation. Journal of Neurology 255, 127e129.
Lodi, R., Carelli, V., Cortelli, P., Iotti, S., Valentino, M.L., Barboni, P., et al., 2002.
Phosphorus MR spectroscopy shows a tissue speciﬁc in vivo distribution of
biochemical expression of the G3460A mutation in Leber’s hereditary optic
neuropathy. Journal of Neurology, Neurosurgery, and Psychiatry 72, 805e807.
Lodi, R., Montagna, P., Cortelli, P., Iotti, S., Cevoli, S., Carelli, V., et al., 2000.
’Secondary’ 4216/ND1 and 13708/ND5 Leber’s hereditary optic neuropathy
mitochondrial DNA mutations do not further impair in vivo mitochondrial
oxidative metabolism when associated with the 11778/ND4 mitochondrial DNA
mutation. Brain 123, 1896e1902.
P. Yu-Wai-Man et al. / Progress in Retinal and Eye Research 30 (2011) 81e114110Lodi, R., Taylor, D.J., Tabrizi, S.J., Kumar, S., Sweeney, M., Wood, N.W., et al., 1997. In
vivo skeletal muscle mitochondrial function in Leber’s hereditary optic
neuropathy assessed by P-31 magnetic resonance spectroscopy. Annals of
Neurology 42, 573e579.
Lodi, R., Tonon, C., Valentino, M.L., Iotti, S., Clementi, V., Malucelli, E., et al., 2004.
Deﬁcit of in vivo mitochondrial ATP production in OPA1-related dominant optic
atrophy. Annals of Neurology 56, 719e723.
Loiseau,D., Chevrollier, A., Verny, C.,Guillet,V.,Gueguen,N., deCrescenzo,M.A.P., et al.,
2007. Mitochondrial coupling defect in Charcot-Marie-Tooth type 2A disease.
Annals of Neurology 61, 315e323.
Longley, M.J., Clark, S., Man, C.Y.W., Hudson, G., Durham, S.E., Taylor, R.W., et al.,
2006. Mutant POLG2 disrupts DNA polymerase gamma subunits and causes
progressive external ophthalmoplegia. American Journal of Human Genetics
78, 1026e1034.
Loveland, B., Wang, C.R., Yonekawa, H., Hermel, E., Lindahl, K.F., 1990. Maternally
transmitted histocompatibility antigen of mice e a hydrophobic peptide of
a mitochondrially encoded protein. Cell 60, 971e980.
Luca, C.C., Lam,B.L.,Moraes, C.T., 2004. Erythromycinasapotential precipitatingagent
in the onset of Leber’s hereditary optic neuropathy. Mitochondrion 4, 31e36.
Maagaard, A., Holberg-Petersen, M., Kvittingen, E.A., Sandvik, L., Bruun, J.N., 2006.
Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear
cells in HIV-1-infected treatment-naive patients. HIV Medicine 7, 53e58.
Mabuchi, F., Tang, S., Kashiwagi, K., Yamagata, Z., Iijima, H., Tsukahara, S., 2007. The
OPA1 gene polymorphism is associated with normal tension and high tension
glaucoma. American Journal of Ophthalmology 143, 125e130.
MacKenzie, J.A., Payne, R.M., 2007. Mitochondrial protein import and human health
and disease. Biochimica et Biophysica Acta-Molecular Basis of Disease 1772,
509e523.
Mackey, D., Howell, N., 1992. A variant of Leber hereditary optic neuropathy char-
acterized by recovery of vision and by an unusual mitochondrial genetic
etiology. American Journal of Human Genetics 51, 1218e1228.
Mackey, D.A., Buttery, R.G., 1992. Leber hereditary optic neuropathy in Australia.
Australian and New Zealand Journal of Ophthalmology 20, 177e184.
Mackey, D.A., Fingert, J.H., Luzhansky, J.Z.,McCluskey, P.J., Howell, N., Hall, A.J.H., et al.,
2003. Leber’s hereditary optic neuropathy triggered by antiretroviral therapy for
human immunodeﬁciency virus. Eye 17, 312e317.
Mackey, D.A., Oostra, R.J., Rosenberg, T., Nikoskelainen, E., Bronte-Stewart, J.,
Poulton, J., et al., 1996. Primary pathogenic mtDNA mutations in multi-
generation pedigrees with Leber hereditary optic neuropathy. American Journal
of Human Genetics 59, 481e485.
Mackey, D.A., Trounce, I., 2010. Genetics: optic nerve genetics-more than meets the
eye. Nature Reviews Neurology 6, 357e358.
Mahad, D.J., Ziabreva, I., Campbell, G., Lax, N., White, K., Hanson, P.S., et al., 2009.
Mitochondrial changes within axons in multiple sclerosis. Brain 132, 1161e1174.
Mahad, D.J., Ziabreva, I., Lassmann, H., Turnbull, D.M., 2007. Mitochondria and
primary oligodendrocyte dysfunction in multiple sclerosis. Journal of
Neurology, Neurosurgery, and Psychiatry 78, 101.
Majander, A., Finel, M., Savontaus, M.L., Nikoskelainen, E., Wikstrom, M., 1996.
Catalytic activity of complex I in cell lines that possess replacement mutations
in the ND genes in Leber’s hereditary optic neuropathy. European Journal of
Biochemistry 239, 201e207.
Majander, A., Huoponen, K., Savontaus, M.L., Nikoskelainen, E., Wikstrom, M., 1991.
Electron transfer properties of NADH:ubiquinone reductase in the ND1/3460
and the ND4/11778 mutations of the Leber hereditary optic neuroretinopathy
(LHON). FEBS Letters 292, 289e292.
Man, P.Y., Grifﬁths, P.G., Brown, D.T., Howell, N., Turnbull, D.M., Chinnery, P.F., 2003.
The epidemiology of Leber hereditary optic neuropathy in the North East of
England. American Journal of Human Genetics 72, 333e339.
Manfredi, G., Fu, J., Ojaimi, J., Sadlock, J.E., Kwong, J.Q., Guy, J., et al., 2002. Rescue of
a deﬁciency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-
encoded gene, to the nucleus. Nature Genetics 30, 394e399.
Mao, P.Z., Reddy, P.H., 2010. Is multiple sclerosis a mitochondrial disease? Bio-
chimica et Biophysica Acta-Molecular Basis of Disease 1802, 66e79.
Marchbank, N.J., Craig, J.E., Leek, J.P., Toohey, M., Churchill, A.J., Markham, A.F., et al.,
2002. Deletion of theOPA1 gene in a dominant optic atrophy family: evidence that
haploinsufﬁciency is the cause of disease. Journal of Medical Genetics 39, e47.
Marella, M., Seo, B.B., Thomas, B.B., Matsuno-Yagi, A., Yagi, T., 2010. Successful
amelioration of mitochondrial optic neuropathy using the yeast NDI1 gene in
a rat animal model. PLoS One, 5, e11472.
Margulis, L., 1971. Symbiosis and evolution. Scientiﬁc American 225, 48e57.
Martin, W., Muller, M., 1998. The hydrogen hypothesis for the ﬁrst eukaryote.
Nature 392, 37e41.
Martinelli, P., Rugarli, E.I., 2010. Emerging roles of mitochondrial proteases in
neurodegeneration. Biochimica et Biophysica Acta-Bioenergetics 1797, 1e10.
Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y., et al., 2010.
Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465,
223e226.
Mashima, Y., Kigasawa, K., Hasegawa, H., Tani, M., Oguchi, Y., 1996. High incidence of
pre-excitation syndrome in Japanese families with Leber’s hereditary optic
neuropathy. Clinical Genetics 50, 535e537.
Mashima, Y., Kigasawa, K., Wakakura, M., Oguchi, Y., 2000. Do idebenone and
vitamin therapy shorten the time to achieve visual recovery in Leber hereditary
optic neuropathy? Journal of Neuro-Ophthalmology 20, 166e170.
Mashima, Y., Yamada, K., Wakakura, M., Kigasawa, K., Kudoh, J., Shimizu, N., et al.,
1998. Spectrum of pathogenic mitochondrial DNA mutations and clinicalfeatures in Japanese families with Leber’s hereditary optic neuropathy. Current
Eye Research 17, 403e408.
Mayorov, V., Biousse, V., Newman, N.J., Brown, M.D., 2005. The role of the ND5 gene
in LHON: characterization of a new, heteroplasmic LHON mutation. Annals of
Neurology 58, 807e811.
McFarland, R., Chinnery, P.F., Blakely, E.L., Schaefer, A.M., Morris, A.A.M., Foster, S.M.,
et al., 2007. Homoplasmy, heteroplasmy, and mitochondrial dystonia.
Neurology 69, 911e916.
McKinley, S.H., Foroozan, R., 2005. Optic neuropathy associated with linezolid
treatment. Journal of Neuro-Ophthalmology 25, 18e21.
Meire, F., Delaey, J.J., Debie, S., Vanstaey, M., Matton, M.T., 1985. Dominant optic-
nerve atrophy with progressive hearing-loss and chronic progressive external
ophthalmoplegia (Cpeo). Ophthalmic Paediatrics and Genetics 5, 91e97.
Meire, F.M., Van Coster, R., Cochaux, P., Obermaier-Kusser, B., Candaele, C.,
Martin, J.J., 1995. Neurological disorders in members of families with Leber’s
hereditary optic neuropathy (LHON) caused by different mitochondrial muta-
tions. Ophthalmic Genetics 16, 119e126.
Melamud, A., Kosmorsky, G.S., Lee, M.S., 2003. Ocular ethambutol toxicity. Mayo
Clinic Proceedings 78, 1409e1411.
Meyer, E., Michaelides, M., Tee, L.J., Robson, A.G., Rahman, F., Pasha, S., et al., 2010.
Nonsense mutation in TMEM126A causing autosomal recessive optic atrophy
and auditory neuropathy. Molecular Vision 16, 650e664.
Milea, D., Sander, B., Wegener, M., Jensen, H., Kjer, B., Jorgensen, T.M., et al., 2010.
Axonal loss occurs early in dominant optic atrophy. Acta Ophthalmologica
88, 342e346.
Miller, J.W., 2008. Preliminary results of gene therapy for retinal degeneration. New
England Journal of Medicine 358, 2282e2284.
Mokranjac, D., Bourenkov, G., Hell, K., Neupert, W., Groll, M., 2006. Structure and
function of Tim14 and Tim16, the J and J-like components of the mitochondrial
protein import motor. EMBO Journal 25, 4675e4685.
Montagna, P., Plazzi, G., Cortelli, P., Carelli, V., Lugaresi, E., Barboni, P., et al., 1995.
Abnormal lactate after effort in healthy carriers of Leber’s hereditary optic
neuropathy. Journal of Neurology, Neurosurgery, and Psychiatry 58, 640e641
[letter].
Moore, B.A., Gonzalez Aviles, G.D., Larkins, C.E., Hillman, M.J., Caspary, T., 2010.
Mitochondrial retention of Opa1 is required for mouse embryogenesis.
Mammalian Genome 21, 350e360.
Morﬁni, G.A., Burns, M., Binder, L.I., Kanaan, N.M., LaPointe, N., Bosco, D.A., et al.,
2009. Axonal transport defects in neurodegenerative diseases. Journal of
Neuroscience 29, 12776e12786.
Morgan, J.E., 2004. Circulation and axonal transport in the optic nerve. Eye
18, 1089e1095.
Nekhaeva, E., Bodyak, N.D., Kraytsberg, Y., McGrath, S.B., Van Orsouw, N.J.,
Pluzhnikov, A., et al., 2002. Clonally expanded mtDNA point mutations are
abundant in individual cells of human tissues. Proceedings of the National
Academy of Sciences of the United States of America 99, 5521e5526.
Newman, N.J., 2009. Leber hereditary optic neuropathy: bad habits, bad vision.
Brain 132, 2306e2308.
Newman, N.J., Biousse, V., 2004. Hereditary optic neuropathies. Eye 18, 1144e1160.
Newman, N.J., Biousse, V., David, R., Bhatti, M.T., Hamilton, S.R., Farris, B.K., et al.,
2005. Prophylaxis for second eye involvement in leber hereditary optic
neuropathy: an open-labeled, nonrandomized multicenter trial of topical bri-
monidine purite. American Journal of Ophthalmology 140, 407e415.
Newman, N.J., Torroni, A., Brown, M.D., Lott, M.T., Fernandez, M.M., Wallace, D.C.,
1994. Epidemic neuropathy in Cuba not associated with mitochondrial-DNA
mutations found in Lebers hereditary optic neuropathy patients. American
Journal of Ophthalmology 118, 158e168.
Nijtmans, L.G.J., Ugalde, C., van den Heuvel, L.P., Smeitink, J.A.M., 2004. Function and
dysfunction of the oxidative phosphorylation system. Mitochondrial Function
and Biogenesis 8, 149e176.
Nikoskelainen, E., Sogg, R.L., Rosenthal, A.R., Friberg, T.R., Dorfman, L.J.,1977. The early
phase in Leberhereditaryoptic atrophy. ArchivesofOphthalmology95, 969e978.
Nikoskelainen, E.K., 1994. Clinical picture of LHON. Clinical Neuroscience 2, 115e120.
Nikoskelainen, E.K., Huoponen, K., Juvonen, V., Lamminen, T., Nummelin, K.,
Savontaus, M.L., 1996. Ophthalmologic ﬁndings in Leber hereditary optic
neuropathy, with special reference to mtDNA mutations. Ophthalmology
103, 504e514.
Nikoskelainen, E.K., Marttila, R.J., Huoponen, K., Juvonen, V., Lamminen, T.,
Sonninen, P., et al., 1995. Leber’s “plus”: neurological abnormalities in patients
with Leber’s hereditary optic neuropathy. Journal of Neurology, Neurosurgery,
and Psychiatry 59, 160e164.
Nikoskelainen, E.K., Savontaus, M.L., Huoponen, K., Antila, K., Hartiala, J., 1994. Pre-
excitation syndrome in Leber’s hereditary optic neuropathy. Lancet
344, 857e858.
Nishigaki, Y., Marti, R., Copeland, W.C., Hirano, M., 2003. Site-speciﬂic somatic
mitochondrial DNA point mutations in patients with thymidine phosphorylase
deﬁciency. Journal of Clinical Investigation 111, 1913e1921.
Nishino, I., Spinazzola, A., Hirano, M., 1999. Thymidine phosphorylase gene muta-
tions in MNGIE, a human mitochondrial disorder. Science 283, 689e692.
Nochez, Y., Arsene, S., Gueguen, N., Chevrollier, A., Ferre, M., Guillet, V., et al., 2009.
Acute and late-onset optic atrophy due to a novel OPA1 mutation leading to
a mitochondrial coupling defect. Molecular Vision 15, 598e608.
Nolan, D., Mallal, S., 2004. Complications associated with NRTI therapy: update on
clinical features, and possible pathogenic mechanisms. Antiviral Therapy
9, 849e863.
P. Yu-Wai-Man et al. / Progress in Retinal and Eye Research 30 (2011) 81e114 111Olichon,A.,Guillou,E.,Delettre,C., Landes, T.,Arnaune-Pelloquin, L., Emorine, L.J., et al.,
2006. Mitochondrial dynamics and disease, OPA1. Biochimica et Biophysica Acta-
Molecular Cell Research 1763, 500e509.
Olichon, A., Landes, T., Arnaune-Pelloquin, L., Emorine, L.J., Mils, V., Guichet, A., et al.,
2007. Effects of OPA1 mutations on mitochondrial morphology and apoptosis:
relevance to ADOA pathogenesis. Journal of Cellular Physiology 211, 423e430.
Oostra, R.J., Kemp, S., Bolhuis, P.A., Bleeker-Wagemakers, E.M., 1996. No evidence for
’skewed’ inactivation of the X-chromosome as cause of Leber’s hereditary optic
neuropathy in female carriers. Human Genetics 97, 500e505.
Oostra, R.J., Van Galen, M.J., Bolhuis, P.A., Bleeker-Wagemakers, E.M., Van den
Bogert, C., 1995. The mitochondrial DNA mutation ND6*14,484C associated
with leber hereditary optic neuropathy, leads to deﬁciency of complex I of the
respiratory chain. Biochemical and Biophysical Research Communications 215,
1001e1005.
Osborne, N.N., Li, G.Y., Ji, D., Mortiboys, H.J., Jackson, S., 2008. Light affects mito-
chondria to cause apoptosis to cultured cells: possible relevance to ganglion cell
death in certain optic neuropathies. Journal of Neurochemistry 105,
2013e2028.
Ostojic, J., Jancic, J., Kozic, D., Semnic, R., Koprivsek, K., Prvulovic, M., et al., 2009.
Brain white matter 1 H MRS in Leber optic neuropathy mutation carriers. Acta
Neurologica Belgica 109, 305e309.
Palace, J., 2009. Multiple sclerosis associated with Leber’s hereditary optic
neuropathy. Journal of the Neurological Sciences 286, 24e27.
Pareyson, D., Marchesi, C., 2009. Diagnosis, natural history, and management of
Charcot-Marie-Tooth disease. Lancet Neurology 8, 654e667.
Parker Jr., W.D., Oley, C.A., Parks, J.K., 1989. A defect in mitochondrial electron-
transport activity (NADH-coenzyme Q oxidoreductase) in Leber’s hereditary
optic neuropathy. New England Journal of Medicine 320, 1331e1333.
Parsons, T.J., Muniec, D.S., Sullivan, K., Woodyatt, N., AllistonGreiner, R.,
Wilson, M.R., et al., 1997. A high observed substitution rate in the human
mitochondrial DNA control region. Nature Genetics 15, 363e368.
Payne, M., Yang, Z.L., Katz, B.J., Warner, J.E.A., Weight, C.J., Zhao, Y., et al., 2004.
Dominant optic atrophy, sensorineural hearing loss, ptosis, and oph-
thalmoplegia: a syndrome caused by a missense mutation in OPA1. American
Journal of Ophthalmology 138, 749e755.
Pegoraro, E., Carelli, V., Zeviani, M., Cortelli, P., Montagna, P., Barboni, P., et al., 1996.
X-inactivation patterns in female Leber’s hereditary optic neuropathy patients
do not support a strong X-linked determinant. American Journal of Medical
Genetics 61, 356e362.
Pei, W.H., Kratz, L.E., Bernardini, I., Sood, R., Yokogawa, T., Dorward, H., et al., 2010.
A model of Costeff Syndrome reveals metabolic and protective functions of
mitochondrial OPA3. Development 137, 2587e2596.
Pellegrini, L., Scorrano, L., 2007. A cut short to death: Parl and Opa1 in the regulation
of mitochondrial morphology and apoptosis. Cell Death and Differentiation
14, 1275e1284.
Pello, R., Martin, M.A., Carelli, V., Nijtmans, L.G., Achilli, A., Pala, M., et al., 2008.
Mitochondrial DNA background modulates the assembly kinetics of OXPHOS
complexes in a cellular model of mitochondrial disease. Human Molecular
Genetics 17, 4001e4011.
Perales-Clemente, E., Fernandez-Silva, P., Acin-Perez, R., Perez-Martos, A., Enriquez,
J.A., 2010. Allotopic expression of mitochondrial-encoded genes in mammals:
achieved goal, undemonstrated mechanism or impossible task? Nucleic Acids
Research, Epub ahead of print.
Perkins, G., Renken, C., Martone, M.E., Young, S.J., Ellisman, M., 1997. Electron tomog-
raphy of neuronalmitochondria: three-dimensional structure andorganization of
cristae and membrane contacts. Journal of Structural Biology 119, 260e272.
Pesch, U.E.A., Fries, J.E., Bette, S., Kalbacher, H., Wissinger, B., Alexander, C., et al.,
2004. OPA1, the disease gene for autosomal dominant optic atrophy, is specif-
ically expressed in ganglion cells and intrinsic neurons of the retina. Investi-
gative Ophthalmology & Visual Science 45, 4217e4225.
Pesch,U.E.A., Leo-Kottler, B.,Mayor, S., Jurklies, B., Kellner,U., Apfelstedt-Sylla, E., et al.,
2001. OPA1 mutations in patients with autosomal dominant optic atrophy and
evidence for semi-dominant inheritance. Human Molecular Genetics 10,
1359e1368.
Pfeffer, G., Cote, H.C.F., Montaner, J.S., Li, C.C., Jitratkosol, M., Mezei, M.M., 2009.
Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV
therapy. Neurology 73, 71e72.
Phasukkijwatana, N., Kunhapan, B., Stankovich, J., Chuenkongkaew, W.L.,
Thomson, R., Thornton, T., et al., 2010. Genome-wide linkage scan and associ-
ation study of PARL to the expression of LHON families in Thailand. Human
Genetics 128, 39e49.
Pich, S., Bach, D., Briones, P., Liesa, M., Camps, M., Testar, X., et al., 2005. The Charcot-
Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through
expression of OXPHOS system. Human Molecular Genetics 14, 1405e1415.
Pommer, R., Schoeler, S., Mawrin, C., Szibor, R., Kirches, E., 2008. The G11778A LHON
mutation does not enhance ethambutol cytotoxicity in a cybrid model. Clinical
Neuropathology 27, 414e423.
Ponjavic, V., Andreasson, S., Tranebjaerg, L., Lubs, H.A., 1996. Full-ﬁeld electro-
retinograms in a family with MohreTranebjaerg syndrome. Acta Oph-
thalmologica Scandinavica 74, 632e635.
Powell, B., Toomes, C., Scott, S., Yeung, A., Marchbank, N., Spry, P., et al., 2003.
Polymorphisms in OPA1 are associated with normal tension glaucoma.
Molecular Vision 9, 460e464.
Pradhan, M., Sharp, D., Best, S., Vincent, A., Vaphiades, M., 2010. Drug-induced optic
neuropathy-TB or Not TB. Survey of Ophthalmology 55, 378e385.Puomila, A., Hamalainen, P., Kivioja, S., Savontaus, M.L., Koivumaki, S., Huoponen, K.,
et al., 2007. Epidemiology and penetrance of Leber hereditary optic neuropathy
in Finland. European Journal of Human Genetics 15, 1079e1089.
Puomila, A., Huoponen, K., Mantyjarvi, M., Hamalainen, P., Paananen, R., Sankila, E.M.,
et al., 2005. Dominant optic atrophy: correlation between clinical and molecular
genetic studies. Acta Ophthalmologica Scandinavica 83, 337e346.
Purohit, S.S., Tomsak, R.L., 1997. Nutritional deﬁciency amblyopia or Leber’s
hereditary optic neuropathy? Neuro-Ophthalmology 18, 111e116.
Qi, X.P., Lewin, A.S., Hauswirth, W.W., Guy, J., 2003. Suppression of complex I gene
expression induces optic neuropathy. Annals of Neurology 53, 198e205.
Qi, X.P., Lewin, A.S., Sun, L., Hauswirth, W.W., Guy, J., 2004. SOD2 gene transfer
protects against optic neuropathy induced by deﬁciency of complex I. Annals of
Neurology 56, 182e191.
Qi, X.P., Sun, L., Hauswirth, W.W., Lewin, A.S., Guy, J., 2007a. Use of mitochondrial
antioxidant defenses for rescue of cells with a Leber hereditary optic neurop-
athy-causing mutation. Archives of Ophthalmology 125, 268e272.
Qi, X.P., Sun, L., Lewin, A.S., Hauswirth, W.W., Guy, J., 2007b. The mutant human
ND4 subunit of complex I induces optic neuropathy in the mouse. Investigative
Ophthalmology & Visual Science 48, 1e10.
Quigley, H.A., Broman, A.T., 2006. The number of people with glaucoma worldwide
in 2010 and 2020. British Journal of Ophthalmology 90, 262e267.
Quiros, P.A., Torres, R.J., Salomao, S., Berezovsky, A., Carelli, V., Sherman, J., et al.,
2006. Colour vision defects in asymptomatic carriers of the Leber’s heredi-
tary optic neuropathy (LHON) mtDNA 11778 mutation from a large Brazilian
LHON pedigree: a case-control study. British Journal of Ophthalmology
90, 150e153.
Raha, S., Robinson, B.H., 2000. Mitochondria, oxygen free radicals, disease and
ageing. Trends in Biochemical Sciences 25, 502e508.
Ramos, CdVF, Bellusci, C., Savini, G., Carbonelli, M., Berezovsky, A., Tamaki, C., et al.,
2009. Association of optic disc size with development and prognosis of Leber’s
hereditary optic neuropathy. Investigative Ophthalmology & Visual Science
50, 1666e1674.
Ray, K., Mookherjee, S., 2009. Molecular complexity of primary open angle glau-
coma: current concepts. Journal of Genetics 88, 451e467.
Reid, E., 2003. Science in motion: common molecular pathological themes emerge
in the hereditary spastic paraplegias. Journal of Medical Genetics 40, 81e86.
Reynier, P., Amati-Bonneau, P., Verny, C., Olichon, A., Simard, G., Guichet, A., et al.,
2004. OPA3 gene mutations responsible for autosomal dominant optic atrophy
and cataract. Journal of Medical Genetics, 41.
Rezaie, T., Child, A., Hitchings, R., Brice, G., Miller, L., Coca-Prados, M., et al., 2002.
Adult-onset primary open-angle glaucoma caused by mutations in optineurin.
Science 295, 1077e1079.
Richardson, C., Smith, T., Schaefer, A., Turnbull, D., Grifﬁths, P., 2005. Ocular motility
ﬁndings in chronic progressive external ophthalmoplegia. Eye 19, 258e263.
Rizzo, J.F., Lessell, S., 1993. Tobacco amblyopia. American Journal of Ophthalmology
116, 84e87.
Rodriguez, M.C., MacDonald, J.R., Mahoney, D.J., Parise, G., Beal, M.F.,
Tarnopolsky, M.A., 2007. Beneﬁcial effects of creatine, CoQ(10), and lipoic acid
in mitochondrial disorders. Muscle & Nerve 35, 235e242.
Rotig, A., de Lonlay, P., Chretien, D., Foury, F., Koenig, M., Sidi, D., et al., 1998.
Frataxin gene expansion causes aconitase and mitochondrial iron-sulphur
protein deﬁciency in Friedreich ataxia. European Journal of Human Genetics
6, C304.
Rotig, A., deLonlay, P., Chretien, D., Foury, F., Koenig, M., Sidi, D., et al., 1997. Aco-
nitase and mitochondrial ironesulphur protein deﬁciency in Friedreich ataxia.
Nature Genetics 17, 215e217.
Rotig, A., Sidi, D., Munnich, A., Rustin, P., 2002. Molecular insights into Friedreich’s
ataxia andantioxidant-based therapies. Trends inMolecularMedicine8, 221e224.
Rouault, T.A., Tong, W.H., 2005. Iron-sulphur cluster biogenesis and mitochondrial
iron homeostasis. Nature Reviews Molecular Cell Biology 6, 345e351.
Rucker, J.C., Hamilton, S.R., Bardenstein, D., Isada, C.M., Lee, M.S., 2006. Linezolid-
associated toxic optic neuropathy. Neurology 66, 595e598.
Rustin, P., Bonnet, D., Rotig, A., Munnich, A., Sidi, D., 2004. Idebenone treatment in
Friedreich patients: one-year-long randomized placebo-controlled trial.
Neurology 62, 524e525.
Rustin, P., von Kleist-Retzow, J.C., Chantrel-Groussard, K., Sidi, D., Munnich, A.,
Rotig, A., 1999. Effect of idebenone on cardiomyopathy in Friedreich’s ataxia:
a preliminary study. Lancet 354, 477e479.
Ryu, S.W., Jeong, H.J., Choi, M., Karbowski, M., Choi, C., 2010. Optic atrophy 3 as
a protein of the mitochondrial outer membrane induces mitochondrial frag-
mentation. Cellular and Molecular Life Sciences 67, 2839e2850.
Sacai, P.Y., Salomao, S.R., Carelli, V., Pereira, J.M., Belfort Jr., R., Sadun, A.A., et al.,
2010. Visual evoked potentials ﬁndings in non-affected subjects from a large
Brazilian pedigree of 11778 Leber’s hereditary optic neuropathy. Documenta
Ophthalmologica 121, 147e154.
Sacconi, S., Trevisson, E., Salviati, L., Ayme, S., Rigal, O., Redondo, A.G., et al., 2010.
Coenzyme Q(10) is frequently reduced in muscle of patients with mitochondrial
myopathy. Neuromuscular Disorders 20, 44e48.
Sadun, A.A., Carelli, V., Salomao, S.R., Berezovsky, A., Quiros, P.A., Sadun, F., et al.,
2003. Extensive investigation of a large Brazilian pedigree of 11778/haplogroup
J Leber hereditary optic neuropathy. American Journal of Ophthalmology 136,
231e238.
Sadun, A.A., Martone, J.F., Mucimendoza, R., Reyes, L., Dubois, L., Silva, J.C., et al.,
1994. Epidemic optic neuropathy in Cuba e eye ﬁndings. Archives of
Ophthalmology 112, 691e699.
P. Yu-Wai-Man et al. / Progress in Retinal and Eye Research 30 (2011) 81e114112Sadun, A.A., Salomao, S.R., Berezovsky, A., Sadun, F., Denegri, A.M., Quiros, P.A., et al.,
2006. Subclinical carriers and conversions in Leber hereditary optic neurop-
athy: a prospective psychophysical study. Transactions of American Ophthal-
mological Society 104, 51e61.
Sadun, A.A., Win, P.H., Ross-Cisneros, F.N., Walker, S.O., Carelli, V., 2000. Leber’s
hereditary optic neuropathy differentially affects smaller axons in the optic
nerve. Trans Am Ophthalmol Soc 98, 223e232. discussion 232e5.
Saijo, T., Hayashi, K., Yamada, H., Wakakura, M., 2005. Linezolid-induced optic
neuropathy. American Journal of Ophthalmology 139, 1114e1116.
Sala, G., Trombin, F., Beretta, S., Tremolizzo, L., Presutto, P., Montopoli, M., et al.,
2008. Antioxidants partially restore glutamate transport defect in Leber
hereditary optic neuropathy cybrids. Journal of Neuroscience Research 86,
3331e3337.
Salinas, S., Proukakis, C., Crosby, A., Warner, T.T., 2008. Hereditary spastic paraplegia:
clinical features and pathogenetic mechanisms. Lancet Neurology 7, 1127e1138.
Salomao, S.R., Berezovsky, A., Andrade, R.E., Belfort, R., Carelli, V., Sadun, A.A., 2004.
Visual electrophysiologic ﬁndings in patients from an extensive Brazilian family
with Leber’s hereditary optic neuropathy e visual electrophysiology in LHON.
Documenta Ophthalmologica 108, 147e155.
Samuels, D.C., 2006. Mitochondrial AZT metabolism. IUBMB Life 58, 403e408.
Sanchez, R.N., Smith, A.J., Carelli, V., Sadun, A.A., Keltner, J.L., 2006. Leber hereditary
optic neuropathy possibly triggered by exposure to tire ﬁre. Journal of Neuro-
Ophthalmology 26, 268e272.
Sapey, E., Burdon, M.A., Nightingale, S., 2001. Evidence of active demyelination in
a man with Leber’s hereditary optic neuropathy mtDNA 14484 genotype.
Neuro-Ophthalmology 26, 119e126.
Sato, M., Kawase, K., Yamamoto, T., Dubo, S., Shink, E.E., Si, E., et al., 2003. Lack of
association between normal-tension glaucoma and intron 8 polymorphisms in
the gene causing autosomal dominant optic atrophy, OPA1, in Japan. Investi-
gative Ophthalmology & Visual Science 44, 1124.
Savini, G., Barboni, P., Valentino, M.L., Montagna, P., Cortelli, P., De Negri, A.M., et al.,
2005. Retinal nerve ﬁber layer evaluation by optical coherence tomography in
unaffected carriers with Leber’s hereditary optic neuropathy mutations.
Ophthalmology 112, 127e131.
Schaefer, A.M.,McFarland,R., Blakely, E.L.,He, L.,Whittaker, R.G., Taylor, R.W., et al., 2008.
Prevalence ofmitochondrial DNA disease in adults. Annals of Neurology 63, 35e39.
Schimpf, S., Schaich, S., Wissinger, B., 2006. Activation of cryptic splice sites is
a frequent splicing defect mechanism caused by mutations in exon and intron
sequences of the OPA1 gene. Human Genetics 118, 767e771.
Schmucker, S., Puccio, H., 2010. Understanding the molecular mechanisms of Frie-
dreich’s ataxia to develop therapeutic approaches. Human Molecular Genetics
19, R103eR110.
Schon, E.A., DiMauro, S., Hirano, M., Gilkerson, R.W., 2010. Therapeutic prospects for
mitochondrial disease. Trends in Molecular Medicine 16, 268e276.
Schulzer, M., Alward, W.L., Feldman, F., Cashwell, L.F., Wilensky, J., Geijssen, H.C., et
al., 1998. Comparison of glaucomatous progression between untreated patients
with normal-tension glaucoma and patients with therapeutically reduced
intraocular pressures. American Journal of Ophthalmology 126, 487e497.
Scruggs, E.R., Naylor, A.J.D., 2008. Mechanisms of zidovudine-induced mitochon-
drial toxicity and myopathy. Pharmacology 82, 83e88.
Seo, J.H., Hwang, J.M., Park, S.S., 2009. Comparison of retinal nerve ﬁbre layers
between 11778 and 14484 mutations in Leber’s hereditary optic neuropathy.
Eye (London).
Seo, J.H., Hwang, J.M., Park, S.S., 2010. Antituberculosis medication as a possible
epigenetic factor of Leber’s hereditary optic neuropathy. Clinical and Experi-
mental Ophthalmology 38, 363e366.
Shah, V.A., Randhawa, S., Mizen, T., Lee, A.G., Foroozan, R., 2008. You’re too old for
that. Survey of Ophthalmology 53, 403e410.
Shahrestani, P., Leung, H.T., Le, P.K., Pak, W.L., Tse, S., Ocorr, K., et al., 2009. Hetero-
zygous mutation of Drosophila Opa1 causes the development of multiple organ
abnormalities in an age-dependent and organ-speciﬁc manner. Plos One 4.
Shaikh, S., Ta, C., Basham, A.A., Mansour, S., 2001. Leber hereditary optic neuropathy
associated with antiretroviral therapy for human immunodeﬁciency virus
infection. American Journal of Ophthalmology 131, 143e145.
Shankar, S.P., Fingert, J.H., Carelli, V., Valentino, M.L., King, T.M., Daiger, S.P., et al.,
2008. Evidence for a novel x-linked modiﬁer locus for leber hereditary optic
neuropathy. Ophthalmic Genetics 29, 17e24.
Shi, P., Gal, J., Kwinter, D.M., Liu, X.Y., Zhu, H.N., 2010. Mitochondrial dysfunction in
amyotrophic lateral sclerosis. Biochimica et Biophysica Acta-Molecular Basis of
Disease 1802, 45e51.
Shimizu, S., Mori, N., Kishi, M., Sugata, H., Tsuda, A., Kubota, N., 2003. A novel
mutation in the OPA1 gene in a Japanese patient with optic atrophy. American
Journal of Ophthalmology 135, 256e257.
Shindler, K.S., Ventura, E., Rex, T.S., Elliott, P., Rostami, A., 2007. SIRT1 activation
confers neuroprotection in experimental optic neuritis. Investigative Ophthal-
mology & Visual Science 48, 3602e3609.
Shorr, N., Christenbury, J.D., Goldberg, R.A., 1987. Management of ptosis in chronic
progressive external ophthalmoplegia. Ophthal Plast Reconstr Surg 3, 141e145.
Shoubridge, E.A., Karpati, G., Hastings, K.E.M., 1990. Deletion mutants are func-
tionally dominant over wild-type mitochondrial genomes in skeletal-muscle
ﬁber segments in mitochondrial disease. Cell 62, 43e49.
Shy, M.E., Garbern, J.Y., Kamholz, J., 2002. Hereditary motor and sensory neuropa-
thies: a biological perspective. Lancet Neurology 1, 110e118.
Sigal, I.A., Ethier, C.R., 2009. Biomechanics of the optic nerve head. Experimental
Eye Research 88, 799e807.Sigal, I.A., Flanagan, J.G., Tertinegg, I., Ethier, C.R., 2010. 3D morphometry of the
human optic nerve head. Experimental Eye Research 90, 70e80.
Siguroardottir, S., Helgason, A., Gulcher, J.R., Stefansson, K., Donnelly, P., 2000. The
mutation rate in the human mtDNA control region. American Journal of Human
Genetics 66, 1599e1609.
Skinnider, L.F., Ghadially, F.N., 1976. Chloramphenicol-induced mitochondrial and
ultrastructural changes in hematopoietic cells. Archives of Pathology & Labo-
ratory Medicine 100, 601e605.
Smith, K.H., Johns, D.R., Heher, K.L., Miller, N.R., 1993. Heteroplasmy in Leber’s
hereditary optic neuropathy. Archives of Ophthalmology 111, 1486e1490.
Smith, P.R., Cooper, J.M., Govan, G.G., Harding, A.E., Schapira, A.H., 1994. Platelet
mitochondrial function in Leber’s hereditary optic neuropathy. Journal of the
Neurological Sciences 122, 80e83.
Smith, U., Smith, D.S., Yunis, A.A., 1970. Chloramphenicol-related changes in mito-
chondrial ultrastructure. Journal of Cell Science 7, 501e521.
Spelbrink, J.N., Li, F.Y., Tiranti, V., Nikali, K., Yuan, Q.P., Tariq, M., et al., 2001. Human
mitochondrial DNA deletions associated with mutations in the gene encoding
Twinkle, a phage T7 gene LF-like protein localized in mitochondria. Nature
Genetics 28, 223e231.
Spinazzi, M., Cazzola, S., Bortolozzi, M., Baracca, A., Loro, E., Casarin, A., et al., 2008.
A novel deletion in the GTPase domain of OPA1 causes defects in mitochondrial
morphology and distribution, but not in function. Human Molecular Genetics
17, 3291e3302.
Spinazzola, A., Invernizzi, F., Carrara, F., Lamantea, E., Donati, A., DiRocco, M., et al.,
2009. Clinical and molecular features of mitochondrial DNA depletion
syndromes. Journal of Inherited Metabolic Disease 32, 143e158.
Spinazzola, A., Zeviani, M., 2009. Mitochondrial diseases: a cross-talk between
mitochondrial and nuclear genomes. In: Espinos, C.F.V.P.F. (Ed.), Inherited
Neuromuscular Diseases: Translation from Pathomechanisms to Therapies
, vol. 652, pp. 69e84.
Spruijt, L., Kolbach, D.N., de Coo, R.F., Plomp, A.S., Bauer, N.J., Smeets, H.J., et al.,
2006. Inﬂuence of mutation type on clinical expression of Leber hereditary
optic neuropathy. American Journal of Ophthalmology 141, 676e682.
Spruijt, L., Smeets, H.J., Hendrickx, A., Bettink-Remeijer, M.W., Maat-Kievit, A.,
Schoonderwoerd, K.C., et al., 2007. A MELAS-associated ND1 mutation causing
Leber hereditary optic neuropathy and spastic dystonia. Archives of Neurology
64, 890e893.
Sripriya, S., Nirmaladevi, J., George, R., Hemamalini, A., Baskaran, M., Prema, R., et al.,
2006. OPTN gene: proﬁle of patients with glaucoma from India. Molecular Vision
12, 816e820.
Stemmler, T.L., Lesuisse, E., Pain, D., Dancis, A., 2010. Frataxin and mitochon-
drial FeS cluster biogenesis. Journal of Biological Chemistry 285,
26737e26743.
Stewart, J.D., Hudson, G., Yu-Wai-Man, P., Blakeley, E.L., He, L., Horvath, R., et al.,
2008. Opa1 in multiple mitochondrial DNA deletion disorders. Neurology 71,
1829e1831.
Stone, E.M., Newman, N.J., Miller, N.R., Johns, D.R., Lott, M.T., Wallace, D.C., 1992.
Visual recovery in patients with Leber’s hereditary optic neuropathy and the
11778 mutation. Journal of Clinical Neuro-Ophthalmology 12, 10e14.
Suen, D.F., Norris, K.L., Youle, R.J., 2008. Mitochondrial dynamics and apoptosis.
Genes & Development 22, 1577e1590.
Sugisaka, E., Ohde, H., Shinoda, K., Mashima, Y., 2007. Woman with atypical
unilateral Leber’s hereditary optic neuropathy with visual improvement. Clin-
ical & Experimental Ophthalmology 35, 868e870.
Tachibana, M., Sparman, M., Sritanaudomchai, H., Ma, H., Clepper, L., Woodward, J.,
et al., 2009. Mitochondrial gene replacement in primate offspring and embry-
onic stem cells. Nature 461, 367e372.
Talman, L.S., Bisker, E.R., Sackel, D.J., Long Jr., D.A., Galetta, K.M., Ratchford, J.N., et al.,
2010. Longitudinal study of vision and retinal nerve ﬁber layer thickness in
multiple sclerosis. Annals of Neurology 67, 749e760.
Tang, S., Le, P.K., Tse, S., Wallace, D.C., Huang, T.S., 2009. Heterozygous mutation of
Opa1 in Drosophila shortens lifespan mediated through increased reactive
oxygen species production. Plos One 4.
Tarnopolsky, M.A., 2008. The mitochondrial cocktail: rationale for combined
nutraceutical therapy in mitochondrial cytopathies. Advanced Drug Delivery
Reviews 60, 1561e1567.
Tarnopolsky, M.A., Baker, S.K., Myint, T., Maxner, C.E., Robitaille, J., Robinson, B.H.,
2004. Clinical variability in maternally inherited leber hereditary optic
neuropathy with the G14459A mutation. American Journal of Medical Genetics:
Part A 124, 372e376.
Taylor, R.W., Jobling, M.S., Turnbull, D.M., Chinnery, P.F., 2003. Frequency of rare
mitochondrial DNA mutations in patients with suspected Leber’s hereditary
optic neuropathy. Journal of Medical Genetics, 40.
Taylor, R.W., Schaefer, A.M., Barron, M.J., McFarland, R., Turnbull, D.M., 2004. The
diagnosis of mitochondrial muscle disease. Neuromuscular Disorders 14,
237e245.
Taylor, R.W., Turnbull, D.M., 2005. Mitochondrial DNA mutations in human disease.
Nature Reviews Genetics 6, 389e402.
Tharaphan, P., Chuenkongkaew, W.L., Luangtrakool, K., Sanpachudayan, T.,
Suktitipat, B., Suphavilai, R., et al., 2006. Mitochondrial DNA haplogroup
distribution in pedigrees of Southeast Asian G11778A Leber hereditary optic
neuropathy. Journal of Neuro-Ophthalmology 26, 264e267.
Thomas, D.Y., Wilkie, D., 1968. Inhibition of mitochondrial synthesis in yeast by
erythromycin e cytoplasmic and nuclear factors controlling resistance. Genet-
ical Research 11, 33e41.
P. Yu-Wai-Man et al. / Progress in Retinal and Eye Research 30 (2011) 81e114 113Tok, J.B.H., Bi, L.R., 2003. Aminoglycoside and its derivatives as ligands to target the
ribosome. Current Topics in Medicinal Chemistry 3, 1001e1019.
Tonon, C., Lodi, R., 2008. Idebenone in Friedreich’s ataxia. Expert Opinion on
Pharmacotherapy 9, 2327e2337.
Tonska, K., Kodron, A., Bartnik, E., 2010. Genotype-phenotype correlations in Leber
hereditary optic neuropathy. Biochimica et Biophysica Acta-Bioenergetics 1797,
1119e1123.
Toomes, C., Marchbank, N.J., Mackey, D.A., Craig, J.E., Newbury-Ecob, R.A.,
Bennett, C.P., et al., 2001. Spectrum, frequency and penetrance of OPA1
mutations in dominant optic atrophy. Human Molecular Genetics 10,
1369e1378.
Torroni, A., Wallace, D.C., 1994. Mitochondrial DNA variation in human populations
and implications for detection of mitochondrial DNA mutations of pathological
signiﬁcance. Journal of Bioenergetics and Biomembranes 26, 261e271.
Touitou, V., Johnson, M.A., Miller, N.R., Guo, Y., Bernstein, D.A., Bernstein, S.L., 2010.
Sustained neuroprotection after a single intravitreal injection of PGJ2 in
a rodent model of NAION. Neuro-Ophthalmology 34, 271e272.
Tranebjaerg, L., 2003. Deafness-dystonia-optic neuronopathy syndrome. In:
Pagon, R.A., Bird, T.C., Dolan, C.R., Stephens, K. (Eds.), GeneReviews. University
of Washington, Seattle, Seattle (WA).
Tranebjaerg, L., Jensen, P.K., Van Ghelue, M., Vnencak-Jones, C.L., Sund, S., Elgjo, K.,
et al., 2001. Neuronal cell death in the visual cortex is a prominent feature of the
X-linked recessive mitochondrial deafness-dystonia syndrome caused by
mutations in the TIMM8a gene. Ophthalmic Genetics 22, 207e223.
Tranebjaerg, L., Schwartz, C., Eriksen, H., Andreasson, S., Ponjavic, V., Dahl, A., et al.,
1995. A new X-linked recessive deafness syndrome with blindness, dystonia,
fractures, and mental deﬁciency is linked to Xq22. Journal of Medical Genetics
32, 257e263.
Tranebjaerg, L., vanGhelue,M.,Nilssen,O.,Hodes,M.E., Dlouhy, S.R., Farlow,M.R., et al.,
1997. Jensen syndrome is allelic to MohreTranebjaerg syndrome and both are
caused by stop mutations in the DDP gene. American Journal of Human Genetics
61, 2043.
Trobe, J.D., Glaser, J.S., Cassady, J., Herschler, J., Anderson, D.R.,1980. Nonglaucomatous
excavation of the optic disk. Archives of Ophthalmology 98, 1046e1050.
Tsao, K., Aitken, P.A., Johns, D.R., 1999. Smoking as an aetiological factor in a pedi-
gree with Leber’s hereditary optic neuropathy. British Journal of Ophthalmology
83, 577e581.
Tzoulis, C., Engelsen, B.A., Telstad, W., Aasly, J., Zeviani, M., Winterthun, S., et al.,
2006. The spectrum of clinical disease caused by the A467T and W748SPOLG
mutations: a study of 26 cases. Brain 129, 1685e1692.
Ujike, H., Tanabe, Y., Takehisa, Y., Hayabara, T., Kuroda, S., 2001. A family with
X-linked dystonia-deafness syndrome with a novel mutation of the DDP gene.
Archives of Neurology 58, 1004e1007.
Valentino, M.L., Avoni, P., Barboni, P., Pallotti, F., Rengo, C., Torroni, A., et al., 2002.
Mitochondrial DNA nucleotide changes C14482G and C14482A in the ND6 gene
are pathogenic for Leber’s hereditary optic neuropathy. Annals of Neurology
51, 774e778.
Valentino, M.L., Barboni, P., Ghelli, A., Bucchi, L., Rengo, C., Achilli, A., et al., 2004.
The ND1 gene of complex I is a mutational hot spot for Leber’s hereditary optic
neuropathy. Annals of Neurology 56, 631e641.
Van Goethem, G., Dermaut, B., Lofgren, A., Martin, J.J., Van Broeckhoven, C., 2001.
Mutation of POLG is associated with progressive external ophthalmoplegia
characterized by mtDNA deletions. Nature Genetics 28, 211e212.
Vanjaarsveld, H., Kuyl, J.M., Alberts, D.W., 1992. Exposure of rats to low concen-
tration of cigarette-smoke increases myocardial sensitivity to ischemia reper-
fusion. Basic Research in Cardiology 87, 393e399.
Vanopdenbosch, L., Dubois, B., D’Hooghe, M.B., Meire, F., Carton, H., 2000. Mito-
chondrial mutations of Leber’s hereditary optic neuropathy: a risk factor for
multiple sclerosis. Journal of Neurology 247, 535e543.
Venegas-Francke, P., Fruns-Quintana, M., Oporto-Caroca, M., 2000. Bilateral optic
neuritis due to chloramphenicol. Revista De Neurologia 31, 699e700.
Vergani, L., Martinuzzi, A., Carelli, V., Cortelli, P., Montagna, P., Schievano, G., et al.,
1995. MtDNA mutations associated with Leber’s hereditary optic neuropathy:
studies on cytoplasmic hybrid (cybrid) cells. Biochemical and Biophysical
Research Communications 210, 880e888.
Verny, C., Loiseau, D., Scherer, C., Lejeune, P., Chevrollier, A., Gueguen, N., et al.,
2008. Multiple sclerosis-like disorder in OPA1-related autosomal dominant
optic atrophy. Neurology 70, 1152e1153.
Votruba, M., Fitzke, F.W., Holder, G.E., Carter, A., Bhattacharya, S.S., Moore, A.T.,
1998a. Clinical features in affected individuals from 21 pedigrees with domi-
nant optic atrophy. Archives of Ophthalmology 116, 351e358.
Votruba, M., Moore, A.T., Bhattacharya, S.S., 1998b. Clinical features, molecular
genetics, and pathophysiology of dominant optic atrophy. Journal of Medical
Genetics 35, 793e800.
Votruba, M., Thiselton, D., Bhattacharya, S.S., 2003. Optic disc morphology of
patients with OPA1 autosomal dominant optic atrophy. British Journal of
Ophthalmology 87, 48e53.
Wakakura, M., Yokoe, J., 1995. Evidence for preserved direct pupillary light response
in Lebers hereditary optic neuropathy. British Journal of Ophthalmology
79, 442e446.
Wallace, D.C., Singh, G., Lott, M.T., Hodge, J.A., Schurr, T.G., Lezza, A.M., et al., 1988.
Mitochondrial DNA mutation associated with Leber’s hereditary optic neurop-
athy. Science 242, 1427e1430.
Walsh,M.K.,Quigley,H.A., 2008. Invivo time-lapseﬂuorescence imagingof individual
retinal ganglion cells in mice. Journal of Neuroscience Methods 169, 214e221.Wang, Y., Michikawa, Y., Mallidis, C., Bai, Y., Woodhouse, L., Yarasheski, K.E., et al.,
2001. Muscle-speciﬁc mutations accumulate with aging in critical human
mtDNA control sites for replication. Proceedings of the National Academy of
Sciences of the United States of America 98, 4022e4027.
Wanrooij, S., Luoma, P., van Goethem, G., van Broeckhoven, C., Suomalainen, A.,
Spelbrink, J.N., 2004. Twinkle and POLG defects enhance age-dependent
accumulation of mutations in the control region of mtDNA. Nucleic Acids
Research 32, 3053e3064.
Waterham, H.R., Koster, J., van Roermund, C.W.T., Mooyer, P.A.W., Wanders, R.J.A.,
Leonard, J.V., 2007. A lethal defect of mitochondrial and peroxisomal ﬁssion.
New England Journal of Medicine 356, 1736e1741.
Weisschuh, N., Neumann, D., Wolf, C., Wissinger, B., Gramer, E., 2005. Prevalence of
myocilin and optineurin sequence variants in German normal tension glaucoma
patients. Molecular Vision 11, 284e287.
Wheeler, L., WoldeMussie, E., Lai, R., 2003. Role of alpha-2 agonists in neuro-
protection. Survey of Ophthalmology 48, S47eS51.
White, K.E., Davies, V.J., Hogan, V.E., Piechota, M.J., Nichols, P.P., Turnbull, D.M., et al.,
2009. OPA1 deﬁciency associated with increased autophagy in retinal ganglion
cells in a murine model of dominant optic atrophy. Investigative Ophthal-
mology & Visual Science 50, 2567e2571.
Wiggs, J.L., 2007.Genetic etiologiesofglaucoma.ArchivesofOphthalmology125, 30e37.
Wilkinson, P.A., Crosby, A.H., Turner, C., Bradley, L.J., Ginsberg, L., Wood, N.W., et al.,
2004. A clinical, genetic and biochemical study of SPG7 mutations in hereditary
spastic paraplegia. Brain 127, 973e980.
Williams, P.A., Morgan, J.E., Votruba, M., 2010. Opa1 deﬁciency in a mouse model of
dominant optic atrophy leads to retinal. Brain 133, 2942e2951.
Wissinger, B., Besch, D., Baumann, B., Fauser, S., Christ-Adler, M., Jurklies, B., et al.,1997.
Mutation analysis of the ND6 gene in patients with Lebers hereditary optic
neuropathy. Biochemical andBiophysical ResearchCommunications234, 511e515.
Wolf, C., Gramer, E., Muller-Myhsok, B., Pasutto, F., Reinthal, E., Wissinger, B., et al.,
2009. Evaluation of nine candidate genes in patients with normal tension
glaucoma: a case control study. BMC Medical Genetics, 10.
Wong, A., Cavelier, L., Collins-Schramm, H.E., Seldin, M.F., McGrogan, M.,
Savontaus, M.L., et al., 2002. Differentiation-speciﬁc effects of LHON mutations
introduced into neuronal NT2 cells. Human Molecular Genetics 11, 431e438.
Woo, S.J., Kim, D.M., Kim, J.Y., Park, S.S., Ko, H.S., Yoo, T., 2004. Investigation of the
association between OPA1 polymorphisms and normal-tension glaucoma in
Korea. Journal of Glaucoma 13, 492e495.
Yaffe, M.P., Stuurman, N., Vale, R.D., 2003. Mitochondrial positioning in ﬁssion yeast
is driven by association with dynamic microtubules and mitotic spindle poles.
Proceedings of the National Academy of Sciences of the United States of
America 100, 11424e11428.
Yang, Z., Harrison, C.A., Chuang, G.C., Ballinger, S.W., 2007. The role of tobacco
smoke induced mitochondrial damage in vascular dysfunction and athero-
sclerosis. Mutation Research-Fundamental and Molecular Mechanisms of
Mutagenesis 621, 61e74.
Yao, W.L., Jiao, X.D., Hejtmancik, J., Leske, M., Hennis, A., Nemesure, B., 2006.
Evaluation of the association between OPA1 polymorphisms and primary open-
angle glaucoma in Barbados families. Molecular Vision 12, 649e654.
Yarosh, W., Monserrate, J., Tong, J.J., Tse, S., Le, P.K., Nguyen, K., et al., 2008. The
molecular mechanisms of OPA1-mediated optic atrophy in Drosophila model
and prospects for antioxidant treatment. Plos Genetics 4.
Yen, M.Y., Kao, S.H., Wang, A.G., Wei, Y.H., 2004. Increased 8-hydroxy-20-deoxy-
guanosine in leukocyte DNA in Leber’s hereditary optic neuropathy. Investiga-
tive Ophthalmology & Visual Science 45, 1688e1691.
Yen, M.Y., Wang, A.G., Chang, W.L., Hsu, W.M., Liu, J.H., Wei, Y.H., 2002. Leber’s
hereditary optic neuropathy-the spectrum of mitochondrial DNA mutations in
Chinese patients. Japanese Journal of Ophthalmology 46, 45e51.
Yoshida, M., Muneyuki, E., Hisabori, T., 2001. ATP synthase e a marvellous rotary
engine of the cell. Nature Reviews Molecular Cell Biology 2, 669e677.
Yu-Wai-Man, P., Bateman, D.E., Hudson, G., Grifﬁths, P.G., Chinnery, P.F., 2008. Leber
hereditary optic neuropathy presenting in a 75-year-old man. Journal of Neu-
roophthalmology 28, 155.
Yu-Wai-Man, P., Davies, V.J., Piechota, M.J., Cree, L.M., Votruba, M., Chinnery, P.F.,
2009a. Secondary mtDNA defects do not cause optic nerve dysfunction in
a mouse model of dominant optic atrophy. Investigative Ophthalmology &
Visual Science 50, 4561e4566.
Yu-Wai-Man, P., Grifﬁths, P.G., Hudson, G., Chinnery, P.F., 2009b. Inherited mito-
chondrial optic neuropathies. Journal of Medical Genetics 46, 145e158.
Yu-Wai-Man, P., Grifﬁths, P.G., Burke, A., Sellar, P.W., Clarke, M.P., Gnanaraj, L., et al.,
2010a. The prevalence and natural history of dominant optic atrophy due to
OPA1 mutations. Ophthalmology 117, 1538.
Yu-Wai-Man, P., Grifﬁths, P.G., Gorman, G.S., Lourenco, C.M., Wright, A.F., Auer-
Grumbach, M., et al., 2010b. Multi-system neurological disease is common in
patients with OPA1 mutations. Brain 133, 771e786.
Yu-Wai-Man, P., Shankar, S.P., Biousse, V., Miller, N.R., Bean, L.J.H., Coffee, B., et al.,
2010c. Genetic screening for OPA1 and OPA3 mutations in patients with sus-
pected inherited optic neuropathies. Ophthalmology, Epub ahead of print.
Yu-Wai-Man, P., Sitarz, K.S., Samuels, D.C., Grifﬁths, P.G., Reeve, A.K., Bindoff, L.A.,
et al., 2010d. OPA1 mutations cause cytochrome c oxidase deﬁciency due to
loss of wild-type mtDNA molecules. Human Molecular Genetics 19,
3043e3052.
Yu-Wai-Man, P., Stewart, J.D., Hudson, G., Andrews, R.M., Grifﬁths, P.G., Birch, M.K.,
et al., 2010e. OPA1 increases the risk of normal but not high tension glaucoma.
Journal of Medical Genetics 47, 120e125.
P. Yu-Wai-Man et al. / Progress in Retinal and Eye Research 30 (2011) 81e114114Yu-Wai-Man, P., Trenell, M.I., Hollingsworth, K.G., Grifﬁths, P.G., Chinnery, P.F.,
2010f. OPA1 mutations impair mitochondrial function in both pure and
complicated dominant optic atrophy. Brain, Epub ahead of print.
Yunis, A.A., 1989. Chloramphenicol toxicity e 25 years of research. American Journal
of Medicine 87, N44eN48.
Yunis, A.A., Smith, U.S., 1970. Reversible bone marrow suppression from chloram-
phenicol e a consequence of mitochondrial injury. Archives of Internal Medi-
cine 126, 272e275.
Zanna, C., Ghelli, A., Porcelli, A.M., Carelli, V., Martinuzzi, A., Rugolo, M., 2003.
Apoptotic cell death of cybrid cells bearing Leber’s hereditary optic neuropathy
mutations is caspase independent. Apoptosis: From Signaling Pathways to
Therapeutic Tools 1010, 213e217.
Zanna, C., Ghelli, A., Porcelli, A.M., Karbowski, M., Youle, R.J., Schimpf, S., et al., 2008.
OPA1 mutations associated with dominant optic atrophy impair oxidative
phosphorylation and mitochondrial fusion. Brain 131, 352e367.
Zaveri, M.S., Conger, A., Salter, A., Frohman, T.C., Galetta, S.L., Markowitz, C.E., et al.,
2008. Retinal imaging by laser polarimetry and optical coherence tomography
evidence of axonal degeneration in multiple sclerosis. Archives of Neurology
65, 924e928.
Zeviani, M., 2008. OPA1 mutations and mitochondrial DNA damage: keeping the
magic circle in shape. Brain 131, 314e317.Zhadanov, S.I., Atamanov, V.V., Zhadanov, N.I., Oleinikov, O.V., Osipova, L.P.,
Schurr, T.G., 2005. A novel mtDNA ND6 gene mutation associated with LHON in
a Caucasian family. Biochemical and Biophysical Research Communications 332,
1115e1121.
Zhang, A.M., Jia, X., Zhang, Q., Yao, Y.G., 2010. No association between the SNPs
(rs3749446 and rs1402000) in the PARL gene and LHON in Chinese patients
with m.11778G>A. Human Genetics 128, 465e468.
Zhang, X., Jones, D., Gonzalez-Lima, F., 2002. Mousemodel of optic neuropathy caused
by mitochondrial complex I dysfunction. Neuroscience Letters 326, 97e100.
Zhu, G., Wu, C.J., Zhao, Y., Ashwell, J.D., 2007. Optineurin negatively regulates TNF
alpha-induced NF-kappa B activation by competing with NEMO for ubiquiti-
nated RIP. Current Biology 17, 1438e1443.
Zuchner, S., De Jonghe, P., Jordanova, A., Claeys, K.G., Guergueltcheva, V.,
Cherninkova, S., et al., 2006. Axonal neuropathy with optic atrophy is caused by
mutations in mitofusin 2. Annals of Neurology 59, 276e281.
Zuchner, S., Mersiyanova, I.V., Muglia,M., Bissar-Tadmouri, N., Rochelle, J., Dadali, E.L.,
et al., 2004. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-
Marie-Tooth neuropathy type 2A. Nature Genetics 36, 449e451.
Zuchner, S., Vance, J.M., 2006. Mechanisms of disease: a molecular genetic update
on hereditary axonal neuropathies. Nature Clinical Practice Neurology
2, 45e53.
